



CURRICULUM VITAE

Aman U. Buzdar, M.D., F.A.C.P.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor of Medicine and Internist (tenured), Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Vice President, Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A



OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
Vice President for Clinical Research
1515 Holcombe Boulevard
Unit Number: 1435
Houston, TX 77030
Room Number: FCT 8.5016
Phone: (713)745-7139
Fax: (713)563-9586
Email: abuzdar@mdanderson.org

EDUCATION

Degree-Granting Education

Government Emerson College, Multan, Pakistan, FSc, 1962

Nishtar Medical College, Multan, Pakistan, MB,BS, 1967

Postgraduate Training

Rotating Intern, Kaukini Hospital, Honolulu, HI, 1968–1969

First Year Resident, General Practice, Maryview Hospital, Portsmouth, VA, 1969–1970

First Year Resident, Medicine, Lakewood Hospital, Lakewood, OH, 1970–1971

Second Year Resident in Medicine, Lutheran Hospital, Cleveland, OH, 1971–1972

Senior Resident in Medicine, Norwalk Hospital, Norwalk, CT, 1972–1973

First Year Fellow in Hematology-Oncology, Norwalk Hospital, Norwalk, CT, 1973–1974

Second Year Fellow in Medicine (Oncology), The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, TX, 1974–1975

CREDENTIALS

Board Certification

American Board of Internal Medicine, Diplomate, 1/1975

American Board of Medical Oncology, Diplomate, 1/1979

Licensures

Active

Texas, TX, (b) (6) 1975

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Faculty Associate in Medicine (Medical Breast Service), Department of Medicine, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, TX, 1975–1976

Assistant Internist and Instructor of Medicine - Medical Breast Service (non-tenured track research appointment), Department of Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1976–1977

Instructor in Medicine (non-tenured track research appointment), University of Texas Medical School, Houston, TX, 1977–1978

Assistant Internist and Assistant Professor of Medicine (tenure track), Department of Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1978–1979

Associate Internist and Assistant Professor of Medicine (tenure track), Department of Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1979–1980

Associate Internist and Associate Professor of Medicine (tenured), Department of Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1980–1983

Associate Professor of Medicine and Internist (tenured), Department of Breast Medical Oncology, UT M.D. Anderson Cancer Center, Houston, TX, 1983–1986

Professor of Medicine and Internist (tenured), Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1986–present

Administrative Appointments/Responsibilities

Alternate Section Chief, Department of Breast Medical Oncology, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1/1985–1/1993

Deputy Department Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, UT M. D. Anderson Cancer Center, Houston, TX, 1/1993–10/2008

Ad Interim Vice President, Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2010–5/2012

Vice President, Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2012–present

Other Appointments/Responsibilities

Ashbel Smith Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1998–1/2003

Endowed Positions

N/A

Consultantships

FDA Center for Drug Evaluation and Research, Rockville, Consultant, 1/2003–1/2009

Military or Other Governmental Service

N/A

Institutional Committee Activities

Medical Records Committee, Member, 1/1977–1/1978

Pharmacy Committee, Member, 1/1982–1/1983

Product Standards and Evaluation Committee, Member, 1/1986–1/1987

M. D. Anderson Cancer Center's Surveillance Committee, Alternate Member, 1/1988–1/1989

Division of Medicine Faculty Promotion Committee, Member, 1/1991–1/1994

Surveillance Committee, Vice Chairman, 1/1991–1/1994

Inpatient Service Chief Committee, Member, 1/1992–1/1993

Medical Practice Subcommittee, Member, 1/1993–present

Educational Activities, Coordinator, 1/1993–present

Physician Advisers for the Utilization Management Program, Member, 1/1994–1/1999

Continuing Medical Education Committee, Chairman, 1/1994–1/2002

Clinical Research Committee, Member, 1/1994–1/2003

Surveillance Committee One (IRB I), Chairman, 1/1994–1/2004

Faculty Classification Committee, Member, 1/1995–1/1998

Division of Medicine Fellowship Committee, Member, 1/1995–1/2003

Committee for Graduate Medical Education, Alternate Representative, 1/1997–present

Credentials Committee of the Medical Staff, Alternate Representative, 1/1999–1/2001

Credentials Committee of the Medical Staff, Representative, 1/2001–1/2002

Surveillance Committee Two (IRB II), Chairman, 1/2001–1/2003

Conflict of Interest Committee, Ex-officio Member, 1/2001–1/2004

Credentials Committee of the Medical Staff, Representative, 1/2004–1/2005

Surveillance Committee Three (IRB 3), Member, 2007–2010

Surveillance Committee Five (IRB 5), Chairman, 9/2007–2010

Credentials Committee of the Medical Staff, Member, 9/2007–9/2010

Clinical Effectiveness Committee, Chairman, 9/2007–present

Data Safety Monitoring Board, Member, 9/2009–8/2010

Patent Ethics Review Committee, Vice Chairman, 9/2009–present

Research & Education Information Systems Steering Team, Member, 7/2010–present

CCSG Executive Committee, Member, 7/2010–present

IPCT, Member, 7/2010–present

Executive Research Compliance Committee, Member, 7/2010–present

Institutional Clinical Executive Committee (ICEC), Member, 9/2011–present

Institutional Research Executive Committee (IREC), Member, 2/2012–present

Information Security Compliance Committee, Member, 9/2012–present

HONORS AND AWARDS

Elected fellow in American College of Physician, 1979

One of the Best Medical Oncologist in Breast Cancer in the Nation, Good Housekeeping Magazine, 1990

Honorary Member in Sociedad Venezolana de Mastologia, 1991

Nominated for Faculty Achievement Award in Clinical Research and Clinical Care, 1992

Best Doctor in America, Woodward/White Publisher, Editor Naifeh and Smith, 1994

Distinguished Service Award, Pakistan Society of Clinical Oncology, 1999

Life Time Achievement Award, Pakistan Society of Clinical Oncology, 2001

America's Top Doctors, Medical Oncology, Castle Connolly Medical Ltd, 2002

America's Top Doctors, Medical Oncology, Castle Connolly Medical Ltd, 2003

America's Top Physician, Consumers' Research Council of America, 2003

America's Top Breast Cancer Doctors, Redbook Magazine, 2003

America's Top Doctors, Medical Oncology, Castle Connolly Medical Ltd, 2004

Irwin H. Krakoff Award for Excellence in Clinical Research, Division of Medicine, University of Texas M.D. Anderson Cancer Center, 2006

RESEARCH

Grant Reviewer/Service on Study Sections

Reviewer, NIH, Ad Hoc Member, 2001

Reviewer, FDA, Member, Member of the Oncology Drug Advisory Committee, 2007

Reviewer, FDA, Member, Member of the Oncology Drug Advisory Committee, 2009

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Ali M, Bekheit-Saad S, Soto A, Maroongroge D, **Buzdar A**, Blumenschein G, Hortobagyi G, Tashima C, Shullenberger C. The significance of QRS voltage changes in patients receiving chemotherapy with doxorubicin hydrochloride (adriamycin). *Chest* 72:3, 1977.
2. Waterfield WC, Tashima CK, Hortobagyi GN, Blumenschein GR, **Buzdar AU**, Burgess MA. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. *Cancer* 41:1235-9, 1978.
3. **Buzdar AU**, Legha SS, Tashima CK, Hortobagyi GN, Yap HY, Krutchik AN, Luna MA, Blumenschein GR. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. *Cancer Treat Rep* 62:1005-8, 1978.
4. Krutchik AN, **Buzdar AU**, Blumenschein GR, Sinkovics JG. Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. *Cancer Treat Rep* 62:1565-7, 1978.
5. Krutchik AN, Blumenschein GR, Tashima CK, **Buzdar AU**. Cerebromedullospinal disconnection after intraventricular methotrexate. *South Med J* 71:476-7, 1978.
6. Krutchik AN, **Buzdar AU**, Tashima CK. Cyclophosphamide-induced urticaria. Occurrence in a patient with no cross-sensitivity to chlorambucil. *Arch Intern Med* 138:1725-6, 1978.
7. Krutchik AN, Tashima CK, **Buzdar AU**, Blumenschein GR. Endobronchial metastases in breast carcinoma. *West J Med* 129:177-80, 1978.
8. **Buzdar AU**, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan EA. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. *Cancer* 41:1064-75, 1978.

9. **Buzdar AU**, Tashima CK, Blumenschein GR, Hortobagyi GN, Yap HY, Krutchik AN, Bodey GP, Livingston RB. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. *Cancer* 41:392-5, 1978.
10. Yap HY, Salem P, Hortobagyi GN, Bodey GP, Sr, **Buzdar AU**, Tashima CK, Blumenschein GR. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. *Cancer Treat Rep* 62:405-8, 1978.
11. Samaan NA, deAsis DN, Jr, **Buzdar AU**, Blumenschein GR. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. *Cancer* 41:2084-7, 1978.
12. Hortobagyi GN, Yap HY, Blumenschein GR, Gutterman JU, **Buzdar AU**, Tashima CK, Hersh EM. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guerin. *Cancer Treat Rep* 62:1685-92, 1978.
13. Krutchik AN, **Buzdar AU**, Blumenschein GR, Lukeman JM. Spontaneous regression of breast carcinoma. *Arch Intern Med* 138:1734-5, 1978.
14. **Buzdar AU**, Blumenschein GR, Smith TL, Tashima CK, Hortobagyi GN, Yap HY, Gutterman JU, Hersh EM, Gehan EA. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). *J Surg Oncol* 12:27-40, 1979.
15. Yap HY, Hortobagyi GN, Blumenschein GR, Tashima CK, **Buzdar AU**, Krutchik AN, Benjamin RS, Gutterman JU, Bodey GP, Sr. Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. *J Surg Oncol* 12:333-41, 1979.
16. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, **Buzdar AU**, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. *Cancer* 43:1225-33, 1979.
17. Yap HY, Blumenschein GR, Tashima CK, Hortobagyi GN, **Buzdar AU**, Wiseman CL. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. *Cancer* 44:32-4, 1979.
18. Krutchik AN, **Buzdar AU**, Blumenschein GR, Hortobagyi GN, Tashima CK, Gutterman JU, Yap HY, Hersh EM. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. *J Surg Oncol* 11(4):325-32, 1979.
19. Hortobagyi GN, Gutterman JU, Blumenschein GR, Yap HY, **Buzdar AU**, Tashima CK, Burgess MA, Hersh EM. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. *Cancer* 43:1112-22, 1979.
20. Legha SS, **Buzdar AU**, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bodey GP, Freireich EJ. Complete remissions in metastatic breast cancer treated with combination drug therapy. *Ann Intern Med* 91:847-52, 1979.
21. Ali MK, Soto A, Maroongroge D, Bekheit-Saad S, **Buzdar AU**, Blumenschein GR, Hortobagyi GN, Tashima CK, Wiseman CL, Shullenberger CC. Electrocardiographic changes after adriamycin chemotherapy. *Cancer* 43:465-71, 1979.
22. Hortobagyi GN, Blumenschein GR, Tashima CK, **Buzdar AU**, Burgess MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. *Cancer* 44:398-405, 1979.
23. Hortobagyi GN, DiStefano A, Legha SS, **Buzdar AU**, Blumenschein GR. Hormonal therapy with tamoxifen in male breast cancer. *Cancer Treat Rep* 63:539-41, 1979.
24. **Buzdar AU**, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, Blumenschein GR, Bodey GP. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. *Cancer Treat Rep* 63(1):115-20, 1979.
25. Legha SS, Blumenschein GR, **Buzdar AU**, Hortobagyi GN, Bodey GP. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. *Cancer Treat Rep* 63:1961-4, 1979.
26. Legha SS, **Buzdar AU**, Hortobagyi GN, DiStefano A, Wiseman CL, Yap HY, Blumenschein GR, Bodey GP. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. *Cancer Treat Rep* 63:2053-6, 1979.
27. Yap HY, Benjamin RS, Blumenschein GR, Hortobagyi GN, Tashima CK, **Buzdar AU**, Bodey GP. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. *Cancer Treat Rep* 63(1):77-83, 1979.
28. Krutchik AN, **Buzdar AU**. Pigmentation of the tongue and mucous membranes associated with cancer chemotherapy. *South Med J* 72:1615-6, 1979.

29. **Buzdar AU**, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh EM, Freireich EJ, Gehan EA. Postoperative adjuvant chemotherapy with 5-fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. *Jama* 242:1509-13, 1979.
30. Legha SS, Benjamin RS, **Buzdar AU**, Hortobagyi GN, Blumenschein GR. Rubidazone in metastatic breast cancer. *Cancer Treat Rep* 63(1):135-6, 1979.
31. Legha SS, **Buzdar AU**, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. *Jama* 242:49-52, 1979.
32. Hug V, Hortobagyi GN, **Buzdar AU**, Blumenschein GR, Grose W, Burgess MA, Bodey GP. A phase II study of peptichemio in advanced breast cancer. *Cancer* 45:2524-8, 1980.
33. Blumenschein GR, Hortobagyi GN, Richman SP, Gutterman JU, Tashima CK, **Buzdar AU**, Burgess MA, Livingston RB, Hersh EM. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. *Cancer* 45:742-9, 1980.
34. Hagemester FB, Jr, **Buzdar AU**, Luna MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. *Cancer* 46:162-7, 1980.
35. Hortobagyi GN, Yap HY, Wiseman CL, Blumenschein GR, **Buzdar AU**, Legha SS, Gutterman JU, Hersh EM, Bodey GP. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, *Corynebacterium parvum*, and *Pseudomonas* vaccine. *Cancer Treat Rep* 64(1):157-9, 1980.
36. Krutchik AN, **Buzdar AU**, Akhtar M, Blumenschein GR. Immune-complex glomerulonephritis secondary to nonspecific immunotherapy. *Cancer* 45:495-7, 1980.
37. Gehan EA, Smith TL, **Buzdar AU**, Keating MJ, Freireich EJ. Knowledge acquisition from historical data: application to breast cancer patients. *Bull Cancer* 67(4):437-45, 1980.
38. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, **Buzdar AU**, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. *Ann Intern Med* 93:399-406, 1980.
39. **Buzdar AU**, Legha SS, Luna MA, Tashima CK, Hortobagyi GN, Blumenschein GR. Pulmonary toxicity of mitomycin. *Cancer* 45:236-44, 1980.
40. Legha SS, **Buzdar AU**, Smith TL, Swenerton KD, Hortobagyi GN, Blumenschein GR. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. *Cancer* 46:438-45, 1980.
41. Gehan EA, Smith TL, **Buzdar AU**. Use of prognostic factors in analysis of historical control studies. *Cancer Treat Rep* 64:373-9, 1980.
42. Hortobagyi GN, Smith TL, Swenerton KD, Legha SS, **Buzdar AU**, Blumenschein GR, Gutterman JU, Hersh EM. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. *Cancer* 47(6):1369-76, 3/1981.
43. **Buzdar AU**, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein GR. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. *Cancer* 47(12):2798-802, 6/1981.
44. **Buzdar AU**, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR. Management of inflammatory carcinoma of breast with combined modality approach - an update. *Cancer* 47(11):2537-42, 6/1981.
45. Legha SS, Powell K, **Buzdar AU**, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. *Cancer* 47(12):2803-6, 6/1981.
46. Rodriguez-Kraul R, Hortobagyi GN, **Buzdar AU**, Blumenschein GR. Combination chemotherapy for breast cancer metastatic to bone marrow. *Cancer* 48(2):227-32, 7/1981.
47. Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, **Buzdar AU**, DiStefano A. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. *Cancer Treat Rep* 65(9-10):775-9, 9/1981.
48. Yap HY, Blumenschein GR, Schell FC, **Buzdar AU**, Valdivieso M, Bodey GP. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. *Ann Intern Med* 95(6):694-7, 12/1981.

49. Hortobagyi GN, Blumenschein GR, **Buzdar AU**, Yap HY, Schell FC, Barnes BC, Burgess MA. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. *J Surg Oncol* 18(2):163-72, 1981.
50. Samaan NA, **Buzdar AU**, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R. Estrogen receptor: a prognostic factor in breast cancer. *Cancer* 47:554-60, 1981.
51. Ross MB, **Buzdar AU**, Blumenschein GR. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. *Cancer* 49(3):413-7, 2/1982.
52. **Buzdar AU**, Legha SS, Blumenschein GR, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Fraschini G, Bodey GP. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. *Cancer* 49(9):1767-70, 5/1982.
53. **Buzdar AU**, Powell KC, Blumenschein GR. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. *Cancer Res* 42(8 Suppl):3448s-3450s, 8/1982.
54. **Buzdar AU**, Legha SS, Hortobagyi GN, Powell KC, Blumenschein GR, Bodey GP. AMSA and peptichemio in the treatment of advanced metastatic breast cancer: a phase II study. *Am J Clin Oncol* 5(4):383-7, 8/1982.
55. Yap HY, Blumenschein GR, Hortobagyi GN, **Buzdar AU**, Schell FC, Bodey GP. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. *Am J Clin Oncol* 5(5):511-4, 10/1982.
56. **Buzdar AU**, Powell KC, Legha SS, Blumenschein GR. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. *Cancer* 50(9):1708-12, 11/1982.
57. **Buzdar AU**, Smith TL, Powell KC, Blumenschein GR, Gehan EA. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. *Breast Cancer Res Treat* 2(2):163-9, 1982.
58. Ross MB, **Buzdar AU**, Hortobagyi GN, Lukeman JM. Spontaneous regression of breast carcinoma: follow-up report and literature review. *J Surg Oncol* 19(1):22-4, 1982.
59. Kantarjian H, Yap HY, Hortobagyi G, **Buzdar A**, Blumenschein G. Hormonal therapy for metastatic male breast cancer. *Arch Intern Med* 143(2):237-40, 2/1983.
60. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, **Buzdar AU**, Yap HY, Schell F. Multimodal treatment of locoregionally advanced breast cancer. *Cancer* 51(5):763-8, 3/1983.
61. Hortobagyi GN, Yap HY, Blumenschein GR, **Buzdar AU**, Barnes BC, Legha SS, Wiseman CL. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. *Cancer* 51(5):769-72, 3/1983.
62. Mughal AW, Hortobagyi GN, Fritsche HA, **Buzdar AU**, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. *Jama* 249(14):1881-6, 4/1983.
63. DeMartini AL, **Buzdar AU**, Blumenschein GR. Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer. *J Surg Oncol* 23(1):32-4, 5/1983.
64. Hortobagyi GN, Spanos W, Montague ED, **Buzdar AU**, Yap HY, Blumenschein GR. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. *Int J Radiat Oncol Biol Phys* 9(5):643-50, 5/1983.
65. Hall SM, **Buzdar AU**, Blumenschein GR. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. *Cancer* 52(1):180-4, 7/1983.
66. Ali MK, **Buzdar AU**, Ewer MS, Cheng RS, Haynie TP. Noninvasive cardiac evaluation of patients receiving adriamycin-containing adjuvant chemotherapy (FAC) for stage II or III breast cancer. *J Surg Oncol* 23(3):212-6, 7/1983.
67. Harkins LA, Yap HY, **Buzdar AU**, Blumenschein GR. Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients. *Cancer* 52(7):1308-11, 10/1983.
68. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, **Buzdar AU**, Blumenschein GR. Multivariate analysis of prognostic factors in metastatic breast cancer. *J Clin Oncol* 1(12):776-86, 12/1983.
69. Mughal AW, Hortobagyi GN, Fritsche HA, **Buzdar AU**, Yap HY, Blumenschein GR. Mesures repetees de l' antigene carcinoembryonnaire plasmatique dans le traitement des cancers du sein metastases. *JAMA (ed. Francaise)* 7:619-620, 1983.
70. **Buzdar AU**, Blumenschein GR, Smith TL, Powell KC, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Ames FC, Martin RG, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin,

- and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. *Cancer* 53(3):384-9, 2/1984.
71. **Buzdar AU**, Blumenschein GR, Montague ED, Hortobagyi GN, Yap HY, Pinnamaneni K, Marcus CE, Smith TL. Combined modality approach in breast cancer with isolated or multiple metastases. *Am J Clin Oncol* 7(1):45-50, 2/1984.
 72. Chawla SP, **Buzdar AU**, Hortobagyi GN, Blumenschein GR. Tumor-associated fever in breast cancer. *Cancer* 53(7):1596-9, 4/1984.
 73. Pinnamaneni K, Yap HY, **Buzdar AU**, Distefano A, Blumenschein GR. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. *Cancer* 53(9):1841-4, 5/1984.
 74. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, **Buzdar AU**. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. *Cancer* 53(9):1836-40, 5/1984.
 75. Finnerty NA, **Buzdar AU**, Blumenschein GR. Radiation-induced breast cancer. *Arch Intern Med* 144(6):1217-9, 6/1984.
 76. Aboud A, **Buzdar AU**, Yap HY, Hortobagyi GN, Blumenschein GR. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. *J Surg Oncol* 26(3):205-7, 7/1984.
 77. Smith L, **Buzdar AU**, Rusch V, Blocker SH, McKenna RJ. Post-mastectomy angiosarcoma: case report and review of the literature. *Tex Med* 80(7):43-4, 7/1984.
 78. Tannir N, Yap HY, Hortobagyi GH, Hug V, **Buzdar AU**, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. *Cancer Treat Rep* 68(7-8):1039-41, 7/1984.
 79. Moon TE, Jones SE, Bonadonna G, Powles TJ, Rivkin S, **Buzdar A**, Montague E. Using a database of protocol studies to evaluate therapy: a breast cancer example. *Stat Med* 3(4):333-9, 10/1984.
 80. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, **Buzdar AU**, Martin RG. The management of locally advanced breast cancer: a combined modality approach. *Eur J Cancer Clin Oncol* 20(11):1353-61, 11/1984.
 81. Lippman ME, **Buzdar AU**, Tormey DC, McGuire WL (moderator). Combining endocrine and chemotherapy - any true benefits? *Breast Cancer Res Treat* 4:251-259, 1984.
 82. Yau JC, Yap YY, **Buzdar AU**, Hortobagyi GN, Bodey GP, Blumenschein GR. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. *Cancer* 55(2):337-40, 1/1985.
 83. Ross MB, **Buzdar AU**, Smith TL, Eckles N, Hortobagyi GN, Blumenschein GR, Freireich EJ, Gehan EA. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. *Cancer* 55(2):341-6, 1/1985.
 84. Fastenberg NA, Martin RG, **Buzdar AU**, Hortobagyi GN, Montague ED, Blumenschein GR, Jessup JM. Management of inflammatory carcinoma of the breast. A combined modality approach. *Am J Clin Oncol* 8(2):134-41, 4/1985.
 85. **Buzdar AU**, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. *Cancer* 55(12):2761-5, 6/1985.
 86. Fraschini G, Yap HY, Hortobagyi GN, **Buzdar A**, Blumenschein G. Five-day continuous-infusion vinblastine in the treatment of breast cancer. *Cancer* 56(2):225-9, 7/1985.
 87. Mann GB, Hortobagyi GN, **Buzdar AU**, Yap HY, Valdivieso M. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. *Cancer* 56(6):1320-4, 9/1985.
 88. Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, **Buzdar AU**, Nagel GA, Henderson IC. Aminoglutethimide-induced hematologic toxicity: worldwide experience. *Cancer Treat Rep* 69(9):1003-4, 9/1985.
 89. Pasterz RB, **Buzdar AU**, Hortobagyi GN, Blumenschein GR. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. *Cancer* 56(10):2381-4, 11/1985.
 90. Mondesir J-M, Bidart J-M, Goodman A, Alberici GF, Caille P, Troalen F, Rouesse J, Bohuon C, Gralla RJ, Einzig AI, **Buzdar AU**. Drug-induced antibodies during 2-N-methyl-9-

- hydroxyellipticinium Acetate (NSC-264137) treatment: Schedule dependency and relationship to hemolysis. *J Clin Oncol* 3:735-740, 1985.
91. Feldman LD, **Buzdar AU**, Blumenschein GR. High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. *Oncology* 42(5):273-4, 1985.
 92. Hortobagyi GN, **Buzdar AU**, Frye D, Yap HY, Hug V, Pinnamaneni K, Fraschini G, Halvorson HC, Blumenschein GR. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. *Breast Cancer Res Treat* 5(3):321-6, 1985.
 93. Feldman LD, Hortobagyi GN, **Buzdar AU**, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. *Cancer Res* 46(5):2578-81, 5/1986.
 94. Herring MK, **Buzdar AU**, Smith TL, Hortobagyi GN, Blumenschein GR. Second neoplasms after adjuvant chemotherapy for operable breast cancer. *Am J Clin Oncol* 9(3):269-75, 6/1986.
 95. Polyzos A, **Buzdar AU**. Complete remission with combination chemotherapy in metastatic breast carcinoma. *Am J Clin Oncol* 9(4):361-3, 8/1986.
 96. Janjan NA, McNeese MD, **Buzdar AU**, Montague ED, Oswald MJ. Management of locoregional recurrent breast cancer. *Cancer* 58(7):1552-6, 10/1986.
 97. Theriault RL, Hortobagyi GN, **Buzdar AU**, Levy HB, Hersh EM. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. *Cancer Treat Rep* 70(11):1341-2, 11/1986.
 98. Scheid V, **Buzdar AU**, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. *Cancer* 58(12):2589-93, 12/1986.
 99. Kramer A, **Buzdar AU**. Inflammatory breast carcinoma. *Am J Clin Oncol* 9(6):541-3, 12/1986.
 100. Larroquette CA, Hortobagyi GN, **Buzdar AU**, Holmes FA. Subclinical hepatic toxicity during combination chemotherapy for breast cancer. *Jama* 256(21):2988-90, 12/1986.
 101. Holmes FA, Esparza L, Yap HY, **Buzdar AU**, Blumenschein GR, Hortobagyi GN. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. *Cancer Chemother Pharmacol* 18(2):157-61, 1986.
 102. Casimir MT, **Buzdar AU**, Blumenschein GR, Hortobagyi GN, Bodey GP. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. *Oncology* 43(4):205-7, 1986.
 103. Lee RW, **Buzdar AU**, Blumenschein GR, Hortobagyi GN. Trioxifene mesylate in the treatment of advanced breast cancer. *Cancer* 57(1):40-3, 1986.
 104. Hortobagyi GN, **Buzdar AU**, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY, Blumenschein GR. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. *J Clin Oncol* 5(2):178-84, 2/1987.
 105. Hortobagyi GN, Bodey GP, **Buzdar AU**, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY, Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. *J Clin Oncol* 5(3):354-64, 3/1987.
 106. Ventura GJ, **Buzdar AU**, Kau S, Lichtiger B, Hortobagyi GN. Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer. *Cancer Treat Rep* 71(4):411-3, 4/1987.
 107. Zinser JW, Hortobagyi GN, **Buzdar AU**, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. *J Clin Oncol* 5(5):773-82, 5/1987.
 108. Holmes FA, Yap HY, Esparza L, **Buzdar AU**, Blumenschein GR, Hug V, Hortobagyi GN. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. *Cancer* 59(12):1992-9, 6/1987.
 109. Ro J, **Buzdar AU**, Esparza L, Hortobagyi GN. Phase II study of peplomycin in advanced breast carcinoma. *Cancer Treat Rep* 71(7-8):777-8, 7/1987.
 110. Fraschini G, Yap HY, Mann G, **Buzdar AU**, Blumenschein GR, Hortobagyi GN. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. *Cancer* 60(8):1724-8, 10/1987.
 111. Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, **Buzdar A**, Montague E, Powles T. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. *Am J Clin Oncol* 10(5):387-95, 10/1987.

112. Moon TE, Jones SE, Bonadonna G, Valagussa P, Powles T, **Buzdar A**, Montague E. Development and use of a natural history data base of breast cancer studies. *Am J Clin Oncol* 10(5):396-403, 10/1987.
113. Hortobagyi GN, **Buzdar AU**, Frye D, Hug V, Fraschini G, Ames FC, Montague E, Gutterman JU, Martin RG. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. *Cancer* 60(11):2596-604, 12/1987.
114. Hortobagyi GN, Frye D, Holmes FA, Hug V, Fraschini G, **Buzdar AU**. Phase II study of iproplatin in metastatic breast carcinoma. *Cancer Treat Rep* 71(12):1193-6, 12/1987.
115. Fraschini G, Charnsangavej C, Carrasco CH, **Buzdar AU**, Jabboury KW, Hortobagyi GN. Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. *Am J Clin Oncol* 11(1):34-8, 2/1988.
116. Berte E, **Buzdar AU**, Smith TL, Hortobagyi GN. Bilateral primary breast cancer in patients treated with adjuvant therapy. *Am J Clin Oncol* 11(2):114-8, 4/1988.
117. Skinner WL, **Buzdar AU**, Libshitz HI. Massive osteolysis of the right clavicle developing after radiation therapy. *Jama* 260(3):375-6, 7/1988.
118. Fraschini G, Holmes FA, **Buzdar AU**, Hug V, Hortobagyi GN. Cisplatin in combination with continuous infusion vinblastine for refractory breast cancer. *Am J Clin Oncol* 11(4):448-50, 8/1988.
119. Hortobagyi GN, **Buzdar AU**. Management of locally advanced breast cancer. *Am J Clin Oncol* 11(5):597-601, 10/1988.
120. **Buzdar AU**, Hortobagyi GN, Smith TL, Kau S, Marcus C, Holmes FA, Hug V, Fraschini G, Ames FC, Martin RG. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. *Cancer* 62(10):2098-104, 11/1988.
121. Theriault RL, Hortobagyi GN, Kau SW, Holmes FA, Hug V, Fraschini G, Jabboury K, **Buzdar AU**. Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. *Cancer* 62(10):2105-10, 11/1988.
122. Hortobagyi GN, Ames FC, **Buzdar AU**, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. *Cancer* 62(12):2507-16, 12/1988.
123. **Buzdar AU**, Yap HY, Esparza L, Holmes F, Fraschini G, Hug V, Hortobagyi GN. A comparative randomized trial of doxorubicin and cyclophosphamide in combination with fluorouracil (FAC) or etoposide (EAC) in metastatic breast cancer. *Intl J Exp & Clin Chemother* 1:48-55, 1988.
124. Early Breast Cancer Trialists' Collaborative Group Henderson IC, Mouridsen H, Abe O, Abeloff M, Ahmann D, Andersen K, Baum M, Bianco AR, Boccardo F, Bonadonna G, Buyse M, **Buzdar A**, Carbone P, Carpenter J, Chlebowski R, Collins, Cooper R, Crowley J, Cuzick J, Day N, DeLozier T, de Schryver A, Dubois J, Durrant K, Fisher B, Forbes J, Forrest P, Gelber R, Gelman R, Glick J, Godwin J, Goldhirsch A, Gray R, Hayward J, Hill C, Howell A, Hubay C, Jakesz R, Kaufmann M, Kissin M, Larsson L-G, Lippman M, Margreiter R, Mauriac L, McCardle C, Morrison M, Naja A, Nissen-Meyer R, Nomura Y, Oates GD, Osborne K, Palshof T, Peek U, Peto R, Pritchard K, Redmond C, Repelaer van Driel O, Ribeiro G, Rubens R, Rutqvist L, Ryden S, Scanlon E, Scheurlen H, Semiglazov V, Senanayake F, Senn HJ, Simon R, Smith C, Soderberg M, Spittle M, Stewart H, Swindell R, Tormey D, Valagussa P, van Dongen J, Wallgren A, Wittes R, Wolmark N, Wood W. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An Overview of 61 Randomized Trials among 28,896 Women. *N Engl J Med* 319(26):1681-1692, 1988.
125. **Buzdar AU**, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. *Oncology* 45(5):344-5, 1988.
126. Theriault RL, Hortobagyi GN, Fritsche HA, Frye D, Martinez R, **Buzdar AU**. The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. *Cancer* 63(5):828-35, 3/1989.
127. Chu PS, **Buzdar AU**, Hortobagyi GN. Trilostane with hydrocortisone in treatment of metastatic breast cancer. *Breast Cancer Res Treat* 13(2):117-21, 3/1989.
128. **Buzdar AU**, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. *Am J Clin Oncol* 12(2):123-8, 4/1989.

129. Merkel DE, Fuqua SA, Tandon AK, Hill SM, **Buzdar AU**, McGuire WL. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. *J Clin Oncol* 7(8):1129-36, 8/1989.
130. Hortobagyi GN, Hug V, **Buzdar AU**, Kau SW, Holmes FA, Fritsche HA. Sequential cyclic combined hormonal therapy for metastatic breast cancer. *Cancer* 64(5):1002-6, 9/1989.
131. Thoms WW, Jr, McNeese MD, Fletcher GH, **Buzdar AU**, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. *Int J Radiat Oncol Biol Phys* 17(4):739-45, 10/1989.
132. Patel HZ, 2nd, **Buzdar AU**, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. *Cancer* 64(8):1583-5, 10/1989.
133. Ang PT, **Buzdar AU**, Smith TL, Kau S, Hortobagyi GN. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. *J Clin Oncol* 7(11):1677-84, 11/1989.
134. Hortobagyi GN, Frye D, **Buzdar AU**, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. *Cancer* 63(1):37-45, 1989.
135. Ro J, Fraschini G, Frye D, **Buzdar A**, Hortobagyi G. Reutilization of doxorubicin in patients with progressive metastatic breast cancer. *Intl J Exp Clin Chemother* 2:234-238, 1989.
136. McCready DR, Hortobagyi GN, Kau SW, Smith TL, **Buzdar AU**, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. *Arch Surg* 124(1):21-5, 1989.
137. **Buzdar AU**, McNeese MD, Hortobagyi GN, Smith TL, Kau S, Fraschini G, Hug V, Ellerbroek N, Holmes FA, Ames F, et al. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? *Cancer* 65(3):394-9, 2/1990.
138. Sutton R, **Buzdar AU**, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. *Cancer* 65(4):847-50, 2/1990.
139. Holmes FA, Fritsche HA, Loewy JW, Geitner AM, Sutton RC, **Buzdar AU**, Hortobagyi GN. Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. *J Clin Oncol* 8(6):1025-35, 6/1990.
140. Dunphy FR, Spitzer G, **Buzdar AU**, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath S, Holmes F, Wallerstein RO, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. *J Clin Oncol* 8(7):1207-16, 7/1990.
141. Wallerstein R, Jr, Spitzer G, Dunphy F, Huan S, Hortobagyi G, Yau J, **Buzdar A**, Holmes F, Theriault R, Ewer M, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. *J Clin Oncol* 8(11):1782-8, 11/1990.
142. Theriault RL, **Buzdar AU**. Acute superior vena caval thrombosis after central venous catheter removal: successful treatment with thrombolytic therapy. *Med Pediatr Oncol* 18(1):77-80, 1990.
143. **Buzdar AU**. Current status of endocrine treatment of carcinoma of the breast. *Semin Surg Oncol* 6(2):77-82, 1990.
144. **Buzdar AU**, Hortobagyi GN, Esparza LT, Holmes FA, Ro JS, Fraschini G, Lichtiger B. Elliptinium acetate in metastatic breast cancer--a phase II study. *Oncology* 47(2):101-4, 1990.
145. Koh EH, **Buzdar AU**, Ames FC, Singletary SE, McNeese MD, Frye D, Holmes FA, Fraschini G, Hug V, Theriault RL, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience. *Cancer Chemother Pharmacol* 27(2):94-100, 1990.
146. Vanek N, Hortobagyi GN, **Buzdar AU**. Radiotherapy enhances the toxicity of aminoglutethimide. *Med Pediatr Oncol* 18(2):162-4, 1990.
147. Ziegler LD, **Buzdar AU**. Current status of adjuvant therapy of early breast cancer. *Am J Clin Oncol* 14(2):101-10, 4/1991.
148. Ziegler LD, **Buzdar AU**. Recent advances in the treatment of breast cancer. *Am J Med Sci* 301(5):337-52, 5/1991.
149. Lamki LM, **Buzdar AU**, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN, Murray JL. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. *J Nucl Med* 32(7):1326-32, 7/1991.

150. Macheledt JE, **Buzdar AU**, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. *Breast Cancer Res Treat* 18(3):165-70, 8/1991.
151. Fraschini G, Holmes FA, Esparza L, Theriault RL, **Buzdar AU**, Hortobagyi GN. Phase I-II study of high-dose etoposide in patients with refractory breast cancer. *Invest New Drugs* 9(4):365-7, 11/1991.
152. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, **Buzdar AU**, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. *J Natl Cancer Inst* 83(24):1797-805, 12/1991.
153. Walters RS, Frye D, **Buzdar AU**, Holmes FA, Hortobagyi GN. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. *Cancer* 69(2):476-81, 1/1992.
154. **Buzdar AU**, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. *Cancer* 69(2):448-52, 1/1992.
155. Jaiyesimi IA, **Buzdar AU**. Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes. *Am J Clin Oncol* 15(2):180-3, 4/1992.
156. Jaiyesimi IA, **Buzdar AU**, Hortobagyi G. Inflammatory breast cancer: a review. *J Clin Oncol* 10(6):1014-24, 6/1992.
157. **Buzdar AU**, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. *J Clin Oncol* 10(10):1540-6, 10/1992.
158. Jaiyesimi IA, **Buzdar AU**, Sahin AA, Ross MA. Carcinoma of the male breast. *Ann Intern Med* 117(9):771-7, 11/1992.
159. Theriault RL, Stallings CB, **Buzdar AU**. Pregnancy and breast cancer: clinical and legal issues. *Am J Clin Oncol* 15(6):535-9, 12/1992.
160. Simmons JR, **Buzdar AU**, Ota DM, Marts K, Hortobagyi GN. Complications associated with indwelling catheters. *Med and Pediat Oncol* 20:22-25, 1992.
161. Early Breast Cancer Trialists' Collaborative Group - **Buzdar AU**, Smith T, et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. *The Lancet* 339(8784):1-15, 71-85, 1992.
162. Hortobagyi GN, **Buzdar AU**. Ten-year survival after chemotherapy for high risk primary and metastatic breast carcinoma. *Cancer Invest* 10:12-14, 1992.
163. Cohen PR, **Buzdar AU**. Metastatic breast carcinoma mimicking an acute paronychia of the great toe: case report and review of subungual metastases. *Am J Clin Oncol* 16(1):86-91, 2/1993.
164. **Buzdar AU**, Kau SW, Smith TL, Ames F, Singletary E, Strom E, McNeese M, Hortobagyi GN. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. *Cancer* 71(11):3680-4, 6/1993.
165. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, **Buzdar AU**, Hortobagyi GN. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. *Cancer* 73(8):2157-67, 4/1994.
166. **Buzdar AU**, Esparza L, Natale R, Cody R, Calzone K, Benson AB, 3rd, Sheehan T, Berry W. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study. *Am J Clin Oncol* 17(5):417-21, 10/1994.
167. Hortobagyi GN, Holmes FA, Theriault RL, **Buzdar AU**. Use of Taxol (paclitaxel) in breast cancer. *Oncology* 51 Suppl 1:29-32, 10/1994.
168. **Buzdar AU**, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, et al. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. *J Clin Oncol* 12(1):50-4, 1994.
169. Holmes FA, **Buzdar AU**, Kau S-W, Fraschini G, Ames FC, McNeese MD, Hortobagyi GN. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED): The M. D. Anderson experience. *Breast Dis* 7:7-20, 1994.
170. Yang DJ, Li C, Kuang LR, Price JE, **Buzdar AU**, Tansey W, Cherif A, Gretzer M, Kim EE, Wallace S. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. *Life Sci* 55(1):53-67, 1994.

171. Singletary SE, Ames FC, **Buzdar AU**. Management of inflammatory breast cancer. *World J Surg* 18(1):87-92, 1994.
172. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, **Buzdar AU**. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. *Ann Intern Med* 120(1):18-25, 1994.
173. **Buzdar AU**, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. Phase I trial of droloxifene in patients with metastatic breast cancer. *Cancer Chemother Pharmacol* 33(4):313-6, 1994.
174. Dhingra K, Valero V, Gutierrez L, Theriault R, Booser D, Holmes F, **Buzdar A**, Fraschini G, Hortobagyi G. Phase II study of deoxyspergualin in metastatic breast cancer. *Invest New Drugs* 12(3):235-41, 1994.
175. Jaiyesimi IA, **Buzdar AU**, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. *J Clin Oncol* 13(2):513-29, 2/1995.
176. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, **Buzdar A**, Valero V, et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. *Cancer Res* 55(14):3060-7, 7/1995.
177. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, **Buzdar A**, Hortobagyi GN. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. *Clin Cancer Res* 1(7):691-7, 7/1995.
178. Ibrahim NK, **Buzdar AU**. Aromatase inhibitors: current status. *Am J Clin Oncol* 18(5):407-17, 10/1995.
179. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, **Buzdar AU**, Hortobagyi GN. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. *J Clin Oncol* 13(12):2886-94, 12/1995.
180. Mora EM, Singletary SE, **Buzdar AU**, Johnston DA. Aggressive Therapy For Locoregional Recurrence After Mastectomy In Stage II and III Breast Cancer Patients. *Ann Surg Oncol* 3(2):162-168, 1995.
181. Early Breast Cancer Trialists' Collaborator Group. Effects of Radiotherapy and Surgery in Early Breast Cancer. An Overview of the Randomized Trials. *N Engl J Med* 333(22):1444-1455, 1995.
182. Ibrahim NK, Frye DK, **Buzdar AU**, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. *Arch Intern Med* 156(8):882-8, 4/1996.
183. Multi-Institutional Trialist Collaborative Study Group, **Buzdar AU**, Smith R, et al. Fardazole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. *Cancer* 77(12):2503-2513, 6/1996.
184. **Buzdar A**, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. *J Clin Oncol* 14(7):2000-11, 7/1996.
185. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, **Buzdar AU**. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. *J Clin Oncol* 14(8):2197-205, 8/1996.
186. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, Cherif A, Delpassand E, **Buzdar A**, Podoloff DA. Positron emission tomography using [¹⁸F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. *Cancer Biother Radiopharm* 11(4):235-45, 8/1996.
187. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, **Buzdar AU**, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. *J Clin Oncol* 14(10):2713-21, 10/1996.
188. Diamandidou E, **Buzdar AU**, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide

- combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. *J Clin Oncol* 14(10):2722-30, 10/1996.
189. Fleming RY, Asmar L, **Buzdar AU**, McNeese MD, Ames FC, Ross MI, Singletary SE. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. *Ann Surg Oncol* 4(6):452-61, 9/1997.
 190. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, **Buzdar AU**, Podoloff DA. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. *Clin Imaging* 21(5):332-6, 9/1997.
 191. Herrada J, Iyer RB, Atkinson EN, Sneige N, **Buzdar AU**, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. *Clin Cancer Res* 3(9):1565-9, 9/1997.
 192. Rahman ZU, Frye DK, **Buzdar AU**, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. *J Clin Oncol* 15(10):3171-7, 10/1997.
 193. Roseman BJ, **Buzdar AU**, Singletary SE. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. *J Surg Oncol* 66(3):215-20, 11/1997.
 194. Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, **Buzdar AU**, Frye DK, Dhingra K. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. *Cancer* 80(12):2240-9, 12/1997.
 195. **Buzdar AU**, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A, for the Arimidex Study Group. A Phase III Trial Comparing Anastrozole (1 and 10 Milligrams), a Potent and Selective Aromatase Inhibitor, with Megestrol Acetate in Postmenopausal Women with Advanced Breast Carcinoma. *Cancer* 79:730-739, 1997.
 196. Ueno NT, **Buzdar AU**, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. *Cancer Chemother Pharmacol* 40(4):321-9, 1997.
 197. **Buzdar AU**, Hortobagyi G. Update on endocrine therapy for breast cancer. *Clin Cancer Res* 4(3):527-34, 3/1998.
 198. Diaz-Canton EA, Valero V, Rahman Z, Rodriguez-Monge E, Frye D, Smith T, **Buzdar AU**, Hortobagyi GN. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. *Ann Oncol* 9(4):413-8, 4/1998.
 199. Chang S, Parker SL, Pham T, **Buzdar AU**, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. *Cancer* 82(12):2366-72, 6/1998.
 200. Kuerer HM, Newman LA, **Buzdar AU**, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Hortobagyi GN, Singletary SE. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. *Cancer J Sci Am* 4(4):230-6, 7/1998.
 201. **Buzdar AU**, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. *Cancer* 83(6):1142-52, 9/1998.
 202. Chang S, **Buzdar AU**, Hursting SD. Inflammatory breast cancer and body mass index. *J Clin Oncol* 16(12):3731-5, 12/1998.
 203. Kuerer HM, Newman LA, **Buzdar AU**, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. *Am J Surg* 176(6):502-9, 12/1998.
 204. Kuerer HM, Newman LA, Fornage BD, Dhingra K, Hunt KK, **Buzdar AU**, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Singletary SE. Role of axillary lymph node dissection after tumor

- downstaging with induction chemotherapy for locally advanced breast cancer. *Ann Surg Oncol* 5(8):673-80, 12/1998.
205. Hortobagyi GN, **Buzdar AU**. Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management. *Cancer Invest* 16(6):385-90, 1998.
 206. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. *Lancet* 352:930-942, 1998.
 207. **Buzdar AU**, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. *J Clin Oncol* 16(1):348-53, 1998.
 208. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. *Lancet* 351:1451-1467, 1998.
 209. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, **Buzdar AU**, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. *J Clin Oncol* 17(2):460-9, 2/1999.
 210. Blum JL, Jones SE, **Buzdar AU**, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. *J Clin Oncol* 17(2):485-93, 2/1999.
 211. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, **Buzdar AU**, Hortobagyi GN. Management of breast cancer during pregnancy using a standardized protocol. *J Clin Oncol* 17(3):855-61, 3/1999.
 212. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Frascini G, **Buzdar AU**, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. *Ann Oncol* 10(4):403-11, 4/1999.
 213. Knoche AJ, Michaud LB, **Buzdar AU**. Efficacy of Anastrozole in a Consecutive Series of Advanced Breast Cancer Patients Treated with Multiple Prior Chemotherapies and Endocrine Agents: M. D. Anderson Cancer Center Experience. *Breast J* 5(3):176-181, 5/1999.
 214. Valero V, **Buzdar AU**, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. *J Clin Oncol* 17(5):1425-34, 5/1999.
 215. Buchholz TA, Hunt KK, Amosson CM, Tucker SL, Strom EA, McNeese MD, **Buzdar AU**, Singletary SE, Hortobagyi GN. Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. *Cancer J Sci Am* 5(3):159-64, 5/1999.
 216. **Buzdar AU**. Role of aromatase inhibitors in advanced breast cancer. *Endocr Relat Cancer* 6(2):219-25, 6/1999.
 217. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, **Buzdar AU**, Murray JL, 3rd, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. *Cancer* 86(7):1251-7, 10/1999.
 218. **Buzdar AU**, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. *J Clin Oncol* 17(11):3412-7, 11/1999.
 219. Robertson JF, Howell A, **Buzdar A**, von Euler M, Lee D. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. *Breast Cancer Res Treat* 58(2):157-62, 11/1999.
 220. Lenert JT, Vlastos G, Mirza NQ, Winchester DJ, Binkley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Strom E, **Buzdar AU**, Hortobagyi GN, Singletary SE. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. *Ann Surg Oncol* 6(8):762-7, 12/1999.
 221. Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Frascini G, Frye DK, **Buzdar AU**. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. *Cancer Chemother Pharmacol* 43(6):471-8, 1999.

222. Rivera E, Frascini G, Esparza-Guerra L, Asmar L, Booser DJ, **Buzdar AU**, Theriault RL, Carrasco CH, Hortobagyi GN. Frontline arterial infusion chemotherapy for hepatic metastases in breast cancer patients. *Cancer Therapeutics* 2:44-49, 1999.
223. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, **Buzdar AU**, Hortobagyi GN. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. *Cancer* 85(1):104-11, 1999.
224. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, **Buzdar AU**, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. *Lancet* 355(9200):281-3, 1/2000.
225. Pivot X, Asmar L, **Buzdar AU**, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. *Br J Cancer* 82(3):529-34, 2/2000.
226. Gale RP, Park RE, Dubois R, Bitran JD, **Buzdar A**, Hortobagyi G, Jones SE, Lazar GS, Spitzer G, Swain SM, Vaughn CB, Vogel CE, Martino S. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. *Clin Transplant* 14(1):32-41, 2/2000.
227. Kushwaha AC, Whitman GJ, Stelling CB, Cristofanilli M, **Buzdar AU**. Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. *AJR Am J Roentgenol* 174(2):535-8, 2/2000.
228. Hortobagyi GN, **Buzdar AU**, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. *J Natl Cancer Inst* 92(3):225-33, 2/2000.
229. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW, Ross MI, **Buzdar AU**, Singletary SE. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. *Cancer* 88(6):1417-24, 3/2000.
230. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Pastorini F, **Buzdar A**. A retrospective study of first indicators of breast cancer recurrence. *Oncology* 58(3):185-90, 4/2000.
231. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, **Buzdar AU**, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. *Am J Clin Oncol* 23(2):117-21, 4/2000.
232. Hoff PM, Valero V, **Buzdar AU**, Singletary SE, Theriault RL, Booser D, Asmar L, Frye D, McNeese MD, Hortobagyi GN. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. *Cancer* 88(9):2054-60, 5/2000.
233. Vlastos G, Fornage BD, Mirza NQ, Bedi D, Lenert JT, Winchester DJ, Tolley SM, Ames FC, Ross MI, Feig BW, Hunt KK, **Buzdar AU**, Singletary SE. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. *Am J Surg* 179(6):446-52, 6/2000.
234. Liao Z, Strom EA, **Buzdar AU**, Singletary SE, Hunt K, Allen PK, McNeese MD. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. *Int J Radiat Oncol Biol Phys* 47(5):1191-200, 7/2000.
235. Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Feig BW, Hortobagyi GN, **Buzdar AU**, Singletary SE. Response to Induction Chemotherapy in Black and White Patients with Locally Advanced Breast Cancer. *Breast J* 6(4):242-246, 7/2000.
236. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, Hortobagyi G, **Buzdar AU**, Theriault R, Singletary SE, McNeese MD. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. *J Clin Oncol* 18(15):2817-27, 8/2000.
237. Vlastos G, Rubio IT, Mirza NQ, Newman LA, Aurora R, Alderfer J, **Buzdar AU**, Singletary SE. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. *Ann Surg Oncol* 7(8):581-7, 9/2000.
238. **Buzdar AU**. Tamoxifen's clinical applications: old and new. *Arch Fam Med* 9(9):906-12, 9/2000.
239. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, **Buzdar AU**, Hortobagyi GN, Hunt KK. Sentinel

- lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. *J Clin Oncol* 18(20):3480-6, 10/2000.
240. Nabholz JM, **Buzdar A**, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. *J Clin Oncol* 18(22):3758-67, 11/2000.
 241. Chang S, Alderfer JR, Asmar L, **Buzdar AU**. Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. *Breast Cancer Res Treat* 64(2):157-63, 11/2000.
 242. Ibrahim NK, **Buzdar AU**, Asmar L, Theriault RL, Hortobagyi GN. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. *Ann Oncol* 11(12):1597-601, 12/2000.
 243. Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, **Buzdar AU**, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. *Cancer* 89(11):2195-201, 12/2000.
 244. Brito RA, Valero V, **Buzdar AU**, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. *J Clin Oncol* 19(3):628-33, 2/2001.
 245. Ibrahim NK, **Buzdar AU**, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. *Cancer* 91(4):664-71, 2/2001.
 246. Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary SE, **Buzdar AU**, Hunt KK. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. *J Clin Oncol* 19(8):2240-6, 4/2001.
 247. Munster PN, **Buzdar A**, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. *J Clin Oncol* 19(7):2002-9, 4/2001.
 248. Kuerer HM, **Buzdar AU**, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. *J Surg Oncol* 77(2):139-47, 6/2001.
 249. Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, Hunt KK, Ross MI, Buchholz TA, **Buzdar AU**, Singletary SE. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. *Ann Surg Oncol* 8(5):425-31, 6/2001.
 250. **Buzdar A**, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholz J, Xiang X, Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. *J Clin Oncol* 19(14):3357-66, 7/2001.
 251. **Buzdar A**, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. *Clin Cancer Res* 7(9):2620-35, 9/2001.
 252. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, **Buzdar AU**, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. *Cancer J* 7(5):413-20, 9/2001.
 253. Cristofanilli M, **Buzdar AU**, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. *Cancer* 92(7):1775-82, 10/2001.
 254. Bonnetterre J, **Buzdar A**, Nabholz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. *Cancer* 92(9):2247-58, 11/2001.
 255. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, **Buzdar AU**, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. *Cancer* 92(10):2523-8, 11/2001.
 256. Kuerer HM, Singletary SE, **Buzdar AU**, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. *Am J Surg* 182(6):601-8, 12/2001.

257. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Puztai L, **Buzdar AU**, Bacus SS. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. *Pathol Oncol Res* 7(3):171-7, 2001.
258. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, **Buzdar AU**, Booser DJ, Holmes FA, Murray JL, 3rd, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. *Cancer Invest* 19(5):459-66, 2001.
259. Newman LA, **Buzdar AU**, Singletary SE, Kuerer HM, Buchholz T, Ames FC, Ross MI, Hunt KK. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. *Ann Surg Oncol* 9(3):228-34, 4/2002.
260. **Buzdar AU**, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. *Clin Cancer Res* 8(5):1073-9, 5/2002.
261. **Buzdar A**, Hayes D, El-Khoudary A, Yan S, Lonning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. *Breast Cancer Res Treat* 73(2):161-75, 5/2002.
262. Giordano SH, Valero V, **Buzdar AU**, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. *Am J Clin Oncol* 25(3):235-7, 6/2002.
263. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, **Buzdar AU**, Valero V, Sneige N, Tucker SL. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. *Int J Radiat Oncol Biol Phys* 53(4):880-8, 7/2002.
264. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, **Buzdar A**. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. *J Clin Oncol* 20(16):3386-95, 8/2002.
265. Huang E, McNeese MD, Strom EA, Perkins GH, Katz A, Hortobagyi GN, Valero V, Kuerer HM, Singletary SE, Hunt KK, **Buzdar AU**, Buchholz TA. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. *Int J Radiat Oncol Biol Phys* 53(5):1225-33, 8/2002.
266. Giordano SH, **Buzdar AU**, Hortobagyi GN. Breast cancer in men. *Ann Intern Med* 137(8):678-87, 10/2002.
267. **Buzdar AU**, Robertson JF, Eiermann W, Nabholz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. *Cancer* 95(9):2006-16, 11/2002.
268. The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 359:2131-2139, 2002.
269. Buchholz TA, Tucker SL, Katz A, McNeese MD, Strom EA, Perkins GH, **Buzdar AU**, Kuerer HM, Hunt KK, Singletary SE, Sahin AA, Thames HD, Meric F, Masullo L, Hortobagyi GN. Factors predictive for local-regional recurrence after neoadjuvant chemotherapy and mastectomy: implications for radiation treatment. *The American Journal of Oncology Review* 1(1):13-16, 2002.
270. Rivera E, Holmes FA, **Buzdar AU**, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. *Breast J* 8(1):2-9, 2002.
271. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, **Buzdar AU**, Hortobagyi GN. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. *J Clin Oncol* 20(1):17-23, 2002.

272. Hess KR, Puztai L, **Buzdar AU**, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. *Breast Cancer Res Treat* 78(1):105-18, 3/2003.
273. **Buzdar A**, O'Shaughnessy JA, Booser DJ, Pippin JE, Jr, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. *J Clin Oncol* 21(6):1007-14, 3/2003.
274. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, **Buzdar AU**, Hortobagyi GN, Puztai L. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. *Cancer* 97(7):1758-65, 4/2003.
275. Allred DC, Baum M, **Buzdar AU**, Carlson RW, Dowsett M, Elledge RM, Gradishar WJ, Grana G, Howell A, Mamounas EP. A roundtable discussion of aromatase inhibitors as therapy for breast cancer. *Breast J* 9(3):213-22, 5/2003.
276. Assikis V, **Buzdar A**, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. *Cancer* 97(11):2716-23, 6/2003.
277. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, **Buzdar AU**, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Puztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. *Cancer* 97(12):2960-71, 6/2003.
278. Nabholz JM, Bonnetterre J, **Buzdar A**, Robertson JF, Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. *Eur J Cancer* 39(12):1684-9, 8/2003.
279. **Buzdar AU**. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. *J Steroid Biochem Mol Biol* 86(3-5):399-403, 9/2003.
280. **Buzdar AU**. Breast cancer in men. *Oncology (Williston Park)* 17(10):1361-4; discussion 1364, 1369-72, 10/2003.
281. Woodward WA, Strom EA, McNeese MD, Perkins GH, Outlaw EL, Hortobagyi GN, **Buzdar AU**, Buchholz TA. Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. *Int J Radiat Oncol Biol Phys* 57(2):327-35, 10/2003.
282. Woodward WA, Strom EA, Tucker SL, Katz A, McNeese MD, Perkins GH, **Buzdar AU**, Hortobagyi GN, Hunt KK, Sahin A, Meric F, Sneige N, Buchholz TA. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. *Int J Radiat Oncol Biol Phys* 57(2):336-44, 10/2003.
283. **Buzdar AU**. Role of anastrozole in adjuvant therapy for postmenopausal patients. *Semin Oncol* 30(5 Suppl 16):21-9, 10/2003.
284. Baum M, **Buzdar A**, Cuzick J, Forbes J, Houghton J, Howell A, Sahnoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. *Cancer* 98(9):1802-10, 11/2003.
285. Simons WR, Jones D, **Buzdar A**. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. *Clin Ther* 25(11):2972-87, 11/2003.
286. **Buzdar AU**. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. *Oncologist* 8(4):335-41, 2003.
287. Blakely LJ, **Buzdar AU**, Lozada JA, Shullaih SA, Hoy E, Smith TL, Hortobagyi GN. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. *Cancer* 100(3):465-9, 2/2004.
288. Cristofanilli M, Gonzalez-Angulo AM, **Buzdar AU**, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. *Clin Breast Cancer* 4(6):415-9, 2/2004.

289. Esteva FJ, Sahin AA, Smith TL, Yang Y, Puzstai L, Nahta R, Buchholz TA, **Buzdar AU**, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. *Cancer* 100(3):499-506, 2/2004.
290. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Puzstai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, **Buzdar AU**, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. *Cancer* 100(7):1365-73, 4/2004.
291. **Buzdar AU**. Preoperative chemotherapy for breast cancer. *Clin Adv Hematol Oncol* 2:212-5, 4/2004.
292. Garg AK, Strom EA, McNeese MD, **Buzdar AU**, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. *Int J Radiat Oncol Biol Phys* 59(1):138-45, 5/2004.
293. **Buzdar AU**, Vergote I, Sainsbury R. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. *Breast J* 10(3):211-7, 5/2004.
294. Thomas E, Holmes FA, Smith TL, **Buzdar AU**, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. *J Clin Oncol* 22(12):2294-302, 6/2004.
295. Giordano SH, Cohen DS, **Buzdar AU**, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. *Cancer* 101(1):51-7, 7/2004.
296. Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, Broglio KR, Puzstai L, **Buzdar AU**, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. *Cancer* 101(2):258-63, 7/2004.
297. Blakely LJ, **Buzdar A**, Chang HY, Frye D, Theriault R, Valero V, Rivera E, Booser D, Kuritani J, Tsuda M. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. *Clin Cancer Res* 10(16):5425-31, 8/2004.
298. Wefel JS, Lenzi R, Theriault R, **Buzdar AU**, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. *Cancer* 101(3):466-75, 8/2004.
299. Buchholz TA, Huang EH, Berry D, Puzstai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, **Buzdar AU**, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. *Int J Radiat Oncol Biol Phys* 59(5):1337-42, 8/2004.
300. Jones KL, **Buzdar AU**. A review of adjuvant hormonal therapy in breast cancer. *Endocr Relat Cancer* 11(3):391-406, 9/2004.
301. Gonzalez-Angulo AM, Sneige N, **Buzdar AU**, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN, Cristofanilli M. p53 expression as a prognostic marker in inflammatory breast cancer. *Clin Cancer Res* 10:6215-21, 9/2004.
302. Resetkova E, Gonzalez-Angulo AM, Sneige N, McDonnell TJ, **Buzdar AU**, Kau SW, Yamamura Y, Reuben JM, Hortobagyi GN, Cristofanilli M. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. *Cancer* 101:913-7, 9/2004.
303. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, **Buzdar AU**, Kau SW, Broglio K, Smith TL, Hortobagyi GN. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. *Cancer* 101:1760-6, 10/2004.
304. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, **Buzdar AU**, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. *Cancer* 101(7):1508-13, 10/2004.
305. Morandi P, Rouzier R, Altundag K, **Buzdar AU**, Theriault RL, Hortobagyi G. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. *Cancer* 101(7):1482-9, 10/2004.

306. Yu TK, Whitman GJ, Thames HD, **Buzdar AU**, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. *J Natl Cancer Inst* 96:1676-81, 11/2004.
307. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, **Buzdar AU**, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves local-regional control and survival for selected patients with local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. *J Clin Oncol* 22:4691-9, 12/2004.
308. Giordano SH, **Buzdar AU**, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? *Cancer* 100(1):44-52, 2004.
309. **Buzdar AU**. Paclitaxel in early breast cancer: a viewpoint by Aman U. Buzdar. *Drugs* 64:1848-9, 2004.
310. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, **Buzdar AU**, Kuerer H, Buchholz TA, Hortobagyi GN. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. *J Clin Oncol* 23:41-8, 1/2005.
311. Come SE, **Buzdar AU**, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lonning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. *Clin Cancer Res* 11(2 Pt 2):861s-4s, 1/2005.
312. Howell A, Cuzick J, Baum M, **Buzdar AU**, Dowsett M, Forbes JF, Hocht-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. *Lancet* 365:60-2, 1/2005.
313. **Buzdar AU**. TAS-108: a novel steroidal antiestrogen. *Clin Cancer Res* 11(2 Pt 2):906s-8s, 1/2005.
314. Howell A, **Buzdar A**. Are aromatase inhibitors superior to antiestrogens? *J Steroid Biochem Mol Biol* 93:237-47, 2/2005.
315. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, **Buzdar AU**, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. *Int J Radiat Oncol Biol Phys* 62:351-7, 6/2005.
316. **Buzdar AU**, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Puztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol* 23:3676-85, 6/2005.
317. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault RL, Booser D, **Buzdar AU**, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. *Cancer* 103:2466-72, 6/2005.
318. Montero AJ, Rouzier R, Lluch A, Theriault RL, **Buzdar AU**, Delaloge S, Bermejo B, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. *Cancer* 104:229-35, 7/2005.
319. Hanrahan EO, Broglio KR, **Buzdar AU**, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. *Cancer* 104:1158-71, 9/2005.
320. Green MC, **Buzdar AU**, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Puztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. *J Clin Oncol* 23:5983-92, 9/2005.

321. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, **Buzdar AU**, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. *J Clin Oncol* 23:7098-104, 10/2005.
322. Yamaya H, Yoshida K, Kuritani J, Yonezawa J, Tsuda M, Shindo T, Nagayama S, **Buzdar AU**. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose. *J Clin Pharm Ther* 30:459-70, 10/2005.
323. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, **Buzdar AU**, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. *J Clin Oncol* 23:8331-9, 11/2005.
324. **Buzdar AU**, Cuzick J. Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer. *J Clin Oncol* 23:8544-6, 11/2005.
325. Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, **Buzdar AU**, Hortobagyi GN. Adjuvant systemic therapy for male breast carcinoma. *Cancer* 104:2359-64, 12/2005.
326. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, **Buzdar AU**, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. *J Clin Oncol* 23:9304-11, 12/2005.
327. **Buzdar A**, Macahilig C. How rapidly do oncologists respond to clinical trial data? *Oncologist* 10(1):15-21, 2005.
328. Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asao T, **Buzdar AU**, Terada T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. *Clin Cancer Res* 11(1):315-22, 2005.
329. **Buzdar AU**. TAS-108: a novel steroidal antiestrogen. *Clinical Cancer Research* 11(2):906s-908s, 2005.
330. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, **Buzdar AU**, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. *Ann Surg* 243:257-64, 2/2006. PMID: PMC1448900.
331. **Buzdar AU**, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. *Clin Cancer Res* 12:1037s-1048s, 2/2006.
332. Yamaya H, Saeki M, Yoshida K, Shibata J, Yano S, Sato Y, Takao A, Shindo T, **Buzdar AU**, Nagayama S. Distribution of (7 α)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[¹⁴C]2-hydroxy-1,2,3-propanetricarboxylate ([¹⁴C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(alpha)anthracene-induced mammary tumor. *Drug Metab Dispos* 34:331-8, 2/2006.
333. Come SE, **Buzdar AU**, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. *Clin Cancer Res* 12:997s-1000s, 2/2006.
334. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, **Buzdar AU**, Valero V. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. *Cancer* 106:1000-6, 3/2006.
335. Guarneri V, Broglio K, Kau SW, Cristofanilli M, **Buzdar AU**, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. *J Clin Oncol* 24:1037-44, 3/2006.
336. Cataliotti L, **Buzdar AU**, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. *Cancer* 106:2095-103, 5/2006.

337. **Buzdar AU**. Anastrozole for breast cancer: recent advances and ongoing challenges. *Expert Rev Anticancer Ther* 6:839-48, 6/2006.
338. Hanrahan EO, Broglio K, Frye D, **Buzdar AU**, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary carcinoma: follow-up at 12 years. *Cancer* 106:2327-36, 6/2006.
339. Buchholz TA, Strom EA, Oswald MJ, Perkins GH, Oh J, Domain D, Yu TK, Woodward WA, Tereffe W, Singletary SE, Thomas E, **Buzdar AU**, Hortobagyi GN, McNeese MD. Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. *Int J Radiat Oncol Biol Phys* 65:1155-60, 7/2006.
340. The Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, **Buzdar A**, Howell A, Cuzick J, Wale C, Distler W, Hocht-Boes G, Houghton J, Locker GY, Nabholz JM. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. *Lancet* 7:633-42, 8/2006.
341. **Buzdar AU**, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. *Curr Med Res Opin* 22:1575-85, 8/2006.
342. **Buzdar AU**, Guastalla JP, Nabholz JM, Cuzick J, Atac Trialists' Group. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. *Cancer* 107:472-80, 8/2006.
343. **Buzdar AU**, Robertson JF. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. *Ann Pharmacother* 40:1572-83, 9/2006.
344. Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, **Buzdar AU**, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. *Ann Surg* 244:464-70, 9/2006. PMID: PMC1856540.
345. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, **Buzdar AU**, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. *J Clin Oncol* 24:4236-44, 9/2006.
346. Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, **Buzdar AU**, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. *Cancer* 107:1248-54, 9/2006.
347. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, **Buzdar AU**, Green MC, Symmans WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. *Ann Surg Oncol* 13:1443-9, 11/2006.
348. **Buzdar AU**. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. *Breast Dis* 24:107-17, 2006.
349. **Buzdar AU**, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. *Clin Cancer Res* 13:228-33, 1/2007.
350. Gonzalez RJ, **Buzdar AU**, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). *Breast J* 13:72-5, 1/2007.
351. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, **Buzdar AU**, Pusztai L, Cristofanilli M. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. *Cancer* 109:496-501, 2/2007.

352. **Buzdar AU**. Adjuvant chemotherapy for high-risk operable breast cancer. *J Clin Oncol* 25(13):1642-4, 5/2007.
353. Mazouni C, Kau SW, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson K, Hess K, Gonzalez-Angulo A, Hortobagyi G, **Buzdar A**, Puzstai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. *Ann Oncol*, 5/2007. e-Pub 2/2007.
354. **Buzdar AU**. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer. *J Clin Oncol* 25(15):2147-8, 5/2007.
355. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, **Buzdar AU**, Hortobágyi GN. Trends for inflammatory breast cancer: is survival improving? *Oncologist* 12(8):904-12, 8/2007.
356. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, **Buzdar AU**. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. *Cancer* 110(6):1195-200, 9/2007.
357. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, **Buzdar AU**, Singletary SE, Hortobagyi GN, Puzstai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. *J Clin Oncol* 25(28):4414-22, 10/2007.
358. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, **Buzdar AU**. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. *J Clin Oncol* 25(31):4967-73, 11/2007.
359. Kaufmann M, von Minckwitz G, Bear HD, **Buzdar A**, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. *Ann Oncol*. e-Pub 11/2007.
360. Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, **Buzdar AU**, Hortobagyi GN, Symmans WF, Puzstai L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. *Breast Cancer Res* 9(6):R87, 12/2007. PMID: PMC2246190.
361. Come SE, **Buzdar AU**, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference. *Cancer* 112(S3)(3 Suppl):673-8, 12/2007.
362. **Buzdar AU**, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. *Cancer* 112(S3):700-9, 12/2007.
363. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, **Buzdar AU**, Hortobagyi GN, Hunt KK. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. *J Clin Oncol* 26(2):246-52, 1/2008.
364. Boughey JC, **Buzdar AU**, Hunt KK. Recent advances in the hormonal treatment of breast cancer. *Curr Probl Surg* 45(1):13-55, 1/2008.
365. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, **Buzdar A**. Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. *J Clin Oncol*. e-Pub 1/2008.
366. Galow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, **Buzdar AU**, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. *J Clin Oncol* 26(5):814-9, 2/2008.
367. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, **Buzdar A**, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. *J Clin Oncol* 26(10):1664-70, 4/2008.

368. Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, **Buzdar AU**, Puzstai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. *Br J Cancer* 99(1):68-71, 7/2008.
369. Peintinger F, **Buzdar AU**, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Puzstai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. *Ann Oncol* 19(12):2020-5, 7/2008.
370. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, **Buzdar AU**, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy. *J Natl Cancer Inst*, 8/2008.
371. Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, **Buzdar AU**. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. *Lancet Oncol*, 8/2008.
372. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, **Buzdar AU**, Hortobagyi GN, Hunt KK. Staging of breast cancer in the neoadjuvant setting. *Cancer Res* 68(16):6477-81, 8/2008.
373. Litton JK, Gonzalez-Angulo AM, Warneke CL, **Buzdar AU**, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. *J Clin Oncol* 26(25):4072-7, 9/2008.
374. Dawood S, Broglio K, Gonzalez-Angulo AM, **Buzdar AU**, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. *J Clin Oncol* 26(30):4891-8, 10/2008.
375. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, **Buzdar AU**, Hortobagyi GN. Using Response to Primary Chemotherapy to Select Postoperative Therapy: Long-Term Results from a Prospective Phase II Trial in Locally Advanced Primary Breast Cancer. *Clin Breast Cancer* 8(6):516-21, 12/2008.
376. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, **Buzdar A**, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. *J Cancer Res Clin Oncol* 135(1):141-8, 1/2009.
377. Reyes-Gibby CC, Morrow PK, **Buzdar A**, Shete S. Chemotherapy-Induced Peripheral Neuropathy as a Predictor of Neuropathic Pain in Breast Cancer Patients Previously Treated with Paclitaxel. *J Pain*, 7/2009.
378. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, **Buzdar A**, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. *Breast* 18 Suppl 2:S1-11, 8/2009.
379. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, **Buzdar AU**, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes. *Clin Cancer Res*, 11/2009.
380. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, **Buzdar A**, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. *J Clin Oncol*, 11/2009. e-Pub 11/2009.
381. Wang L, Ellsworth KA, Moon I, Pellemounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, **Buzdar A**, Weinshilboum RM, Ingle JN. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. *Cancer Res* 70(1):319-28, 1/2010. PMID: PMC2804935.
382. Dawood S, Broglio K, **Buzdar AU**, Hortobagyi GN, Giordano SH. Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review. *J Clin Oncol* 28(1):92-8, 1/2010. PMID: PMC2799236.
383. Robidoux A, **Buzdar AU**, Quinaux E, Jacobs S, Rastogi P, Fourchette V, Younan RJ, Pajon ER, Shalaby IA, Desai AM, Fehrenbacher L, Geyer CE, Mamounas EP, Wolmark N. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-

- fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. *Clin Breast Cancer* 10(1):81-6, 2/2010.
384. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, **Buzdar AU**, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. *Cancer* 116(4):814-21, 2/2010.
 385. Ingle JN, **Buzdar AU**, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer. *Cancer Res. e-Pub* 3/2010.
 386. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, **Buzdar A**, Howell A, Bugarini R, Baehner FL, Shak S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. *J Clin Oncol* 28(11):1829-34, 4/2010.
 387. Dominici LS, Negrón Gonzalez VM, **Buzdar AU**, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. *Cancer* 116(12):2884-9, 6/2010.
 388. Wefel JS, Saleeba AK, **Buzdar AU**, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. *Cancer* 116(14):3348-3356, 7/2010.
 389. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, **Buzdar AU**, Martin PM, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. *Proteomics. e-Pub* 9/2010.
 390. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. *J Natl Cancer Inst Monogr* 41:162-77, 2010.
 391. Kuerer HM, **Buzdar AU**, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. *Cancer* 117(1):39-47, 1/2011. PMID: PMC2997136.
 392. Cuzick J, Sestak I, Baum M, **Buzdar A**, Howell A, Dowsett M, Forbes JF, for the ATAC/LATTE investigators. 10-year analysis of the ATAC trial: wrong conclusion? - Authors' reply. *Lancet Oncol* 12(3):217, 3/2011.
 393. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, **Buzdar AU**, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy can Predict Patient Prognosis and Facilitate Treatment Planning. *Ann Surg* 253(3):572-9, 3/2011.
 394. **Buzdar AU**. Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream. *Lancet Oncol* 12(4):316-8, 4/2011.
 395. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, **Buzdar AU**, Martin PM, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. *Proteomics Clin Appl* 5(3-4):193, 4/2011.
 396. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, **Buzdar AU**, Hortobagyi GN, Hunt KK. Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. *J Clin Oncol* 29(15):1956-62, 5/2011. PMID: PMC3107758.
 397. Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, **Buzdar AU**, Forbes J, Pineda S, Cuzick J. Predictive algorithms for adjuvant therapy: TransATAC. *Steroids* 76(8):777-80, 7/2011.
 398. Albert JM, **Buzdar AU**, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. *Breast Cancer Res Treat* 128(2):421-7, 7/2011.

399. Ferrajoli A, **Buzdar AU**, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. *Cancer* 117(14):3268-75, 7/2011.
400. Ring A, Sestak I, Baum M, Howell A, **Buzdar A**, Dowsett M, Forbes JF, Cuzick J. Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. *J Clin Oncol* 29(32):4266-72, 11/2011.
401. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabolgo L, Mallon E, Green AR, Ellis IO, Howell A, **Buzdar AU**, Forbes JF. Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. *J Clin Oncol* 29(32):4273-8, 11/2011.
402. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, **Buzdar AU**, Crow JR, Kuerer HM, Hunt KK. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current american joint committee on cancer staging system. *J Clin Oncol* 29(35):4654-61, 12/2011. PMID: PMC3236648.
403. Arun BK, Dhingra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, **Buzdar AU**, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results. *Oncologist* 16(11):1527-34, 2011.
404. Ewer MS, Yang M, **Buzdar AU**. Screening for Cardiac Risk Before Anthracycline Administration: What Are The Real Benefits? *Clin Breast Cancer* 12(1):1-3, 2/2012. e-Pub 11/2011.
405. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, **Buzdar AU**, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of Anastrozole in Women at increased risk for second primary breast cancer. *Cancer Prev Res (Phila)* 5(2):276-82, 2/2012. e-Pub 11/2011.
406. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, **Buzdar AU**. Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer. *J Clin Oncol* 30(9):930-5, 3/2012. e-Pub 2/2012.
407. **Buzdar AU**, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V, Cheporov S, Gotovkin E, Hoersch S, Rittweger K, Miles DW, O'Shaughnessy J, Tjulandin S, NO16853 trial group. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. *Ann Oncol* 23(3):589-97, 3/2012. e-Pub 6/2011.
408. Kelly CM, **Buzdar AU**. Aromatase inhibitors in premenopausal breast cancer. *Lancet Oncol* 13(4):320-1, 4/2012. e-Pub 1/2012.
409. Bayraktar S, Gonzalez-Angulo AM, Lei X, **Buzdar AU**, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. *Cancer* 118(9):2385-93, 5/2012. e-Pub 9/2011. PMID: PMC3274632.
410. Spinks T, Albright HW, Feeley TW, Walters R, Burke TW, Aloia T, Bruera E, **Buzdar A**, Foxhall L, Hui D, Summers B, Rodriguez A, Dubois R, Shine KI. Ensuring quality cancer care: A follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in america. *Cancer* 118(10):2571-82, 5/2012. e-Pub 11/2011. PMID: PMC3272132.
411. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, **Buzdar AU**, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. *Cancer* 118(10):2603-14, 5/2012. e-Pub 10/2011.
412. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, 1bBuzdar A11b, Gelmon K, Gnant M, Bonnetterre J, Toi M, Hudis C, Robertson JF. The sequential use of endocrine treatment for advanced breast cancer: where are we? *Ann Oncol* 23(6):1378-86, 6/2012. e-Pub 2/2012.
413. **Buzdar A**, Vogel C, Schwartzberg L, Garin A, Perez A, Ingle J, Houghton M, Zergebel C, Kimball B. Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. *Cancer* 118(13):3244-53, 7/2012.

414. Lyman GH, Burstein HJ, **Buzdar AU**, D'Agostino R, Ellis PA. Making Genuine Progress Against Metastatic Breast Cancer. *J Clin Oncol.* e-Pub 8/2012.

Invited Articles

1. **Buzdar AU**, Blumenschein GR, Krutchik AN, Tashima CK, Hortobagyi GN, Gutterman JU, Hersh EM. Combined modality approach for inflammatory breast cancer: Prolongation of disease-free interval and survival. *The Cancer Bull* 31:95-96, 1979.
2. Ali MK, Bekheit-Saad S, Ewer MS, Soto A, **Buzdar AU**, Blumenschein GR, Tashima CK, Wiseman CL, Hortobagyi GN, Maroongroge DP. Noninvasive evaluation of myocardial function in patients receiving adriamycin chemotherapy. *Cancer Bulletin* 31:93-94, 1979.
3. Legha SS, Swenerton KD, **Buzdar AU**, Hortobagyi GN, Smith TL, Bodey GP, Blumenschein GR. Patterns of relapse after complete remission in metastatic breast cancer treatment with chemoimmunotherapy. *The Cancer Bull* 31:108, 1979.
4. Frascini G, DiStefano A, Yap HY, Barnes B, **Buzdar AU**, Hortobagyi G, Blumenschein GR. Chemotherapy with dibromodulcitol (DBD), adriamycin (ADR), cyclophosphamide (DYT) for metastatic breast carcinoma. *Proc XII International Congress of Chemotherapy, Florence, Italy:1485-1487, 7/1981.*
5. Bodey GP, Yap HY, Blumenschein GR, Hortobagyi GN, **Buzdar AU**. A randomized comparative study of vinblastine, vindesine, and vincristine in patients with refractory metastatic breast cancer. *Drug Exp Clin* 8:559-564, 1982.
6. **Buzdar AU**, Blumenschein GR, Hortobagyi GN, Legha SS, Yap HY, Campos LT, Hersh EM. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin (adriamycin) and cyclophosphamide, with or without BCG immunotherapy in stage II or III breast cancer. *Immunotherapy of Human Cancer. Elsevier North Holland, Inc., Terry/Rosenberg, eds:175-181, 1982.*
7. **Buzdar AU**. Adjuvant therapy of breast cancer. *Tex Med* 80:37-8, 1984.
8. **Buzdar AU**, Blumenschein GR. Breast cancer. *Cancer Treat Rev* 11:315-9, 1984.
9. Hortobagyi GN, Smith TL, Blumenschein GR, Legha SS, Yap HY, **Buzdar AU**. Clinical prognostic factors of response. *Current Controversy in Breast Cancer:255-259, 1984.*
10. **Buzdar AU**. Endocrine therapies for breast cancer. The management of breast cancer through endocrine therapies. *Excerpta Medica. (ed.) Joseph C. Allegra:29-37, 1984.*
11. Holmes FA, **Buzdar AU**. Isolated lesions in a patient with a history of recurrent breast cancer - A management dilemma. *The Cancer Bull* 36(6):292-294, 1984.
12. Holmes FA, Yap HY, Esparza L, **Buzdar AU**, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. *Semin Oncol* 11(3):28-31, 1984.
13. Hortobagyi GN, Fritsche HA Jr, Mughal AW, **Buzdar AU**, Yap HY, Blumenschein GR. Role of carcinoembryonic antigen for followup of breast cancer patients. *Current Controversy in Breast Cancer:461-465, 1984.*
14. **Buzdar AU**, Blumenschein GR. Summaries of the papers presented at the 13th International Congress of Chemotherapy (SE 12.1.10 and SE 12.0.10/A) on breast cancer. *Cancer Treat Rev* 11:315-319, 1984.
15. Blumenschein GR, Yap HY, Issell BF, Hortobagyi GN, **Buzdar AU**. The role of VP-16 (Etoposide) in the treatment of metastatic breast cancer. *Etoposide (VP-16-213) Current Status & New Developments (eds.) Brain F. Issell, Franco M. Muggia, and Stephen K. Carter; Academic Press:253-260, 1984.*
16. **Buzdar AU**, Smith TL, Blumenschein GR, Hortobagyi GN. Pre-and post-operative combination chemotherapy in breast cancer - M. D. Anderson experience. *Proc of International Symposium of Senology, Evaluation of the risk of breast cancer primary chemotherapy, Liege-Belgium:287-295, 11/1985.*
17. **Buzdar AU**. Natural history of stage IV breast cancer. Autologous bone marrow transplantation. *Proc of the 1st International Symposium. (eds.) K.A. Dicke, G. Spitzer and R. Zander:185-188, 1985.*
18. Spitzer G, **Buzdar A**, Hortobagyi G, Horwitz L, Jagannath S, Smith K, Dicke K. High-dose chemotherapy intensification and autologous bone marrow transplantation with emphasis on breast carcinoma. *Proceedings of the Third International Symposium, Autologous Bone Marrow Transplantation III:455-463, 12/1986.*

19. Hortobagyi GN, **Buzdar AU**, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1:105-9, 1986.
20. Hortobagyi GN, **Buzdar AU**, Blumenschein GR, Yap HY, Hersh EM. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand 58 (Pt A):357-63, 1986.
21. Hortobagyi GN, **Buzdar AU**. Progress in inflammatory breast cancer: Cause for cautious optimism. J Clin Oncol 4(12):1727-1729, 1986.
22. **Buzdar AU**, Hortobagyi GN, Marcus CE, Smith TL, Martin R, Gehan EA. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr 1:81-5, 1986.
23. **Buzdar A**, Hortobagyi G, Frye D, Ames F, Singletary S, McNeese M, Montague E. Inflammatory carcinoma of the breast: Preliminary results of combined modality approach. Proceedings of the 15th International Congress of Chemotherapy, Istanbul, Turkey:438-439, 7/1987.
24. Feinberg BA, Ewer MS, Batizy S, **Buzdar AU**. Clostridium perfringens infection of the pericardium: A rare form of septic pericarditis. Cancer Bull 39(2):116-117, 1987.
25. **Buzdar AU**. Endocrine-dependent breast cancer-critical assessment of recent advances. The Cancer Bulletin 39(5):272, 1987.
26. **Buzdar AU**. Future directions of adjuvant and preventive therapy of breast cancer. Reviews on Endocrine-related Cancer 27:11-15, 1987.
27. **Buzdar AU**. Chemotherapeutic approaches to advanced breast cancer. Semin Oncol 15(3):65-70, 1988.
28. **Buzdar AU**, Hortobagyi GN. Treatment of early and advanced breast cancer. Syllabus American College of Physicians 1989-1990 Postgraduate Courses Course (#906), 10/1989.
29. **Buzdar AU**. Recent Advances in the treatment of early and advanced breast cancer. Oncol. (Life Sci. Adv.) 8:43-58, 1989.
30. **Buzdar AU**. Combined chemohormonal therapy for metastatic breast cancer. Cancer Chemotherapy: Challenges for the Future 5:257-264, 1990.
31. Hortobagyi GN, Dunphy F, **Buzdar AU**, Spitzer G. Dose intensity studies in breast cancer-- autologous bone marrow transplantation. Prog Clin Biol Res 354B:195-209, 1990.
32. **Buzdar A**, Hortobagyi G, Kau S, Patel H, Hug V, Holmes F, Fraschini G, Singletary S, Ames F. Evaluation of risk and benefits of doxorubicin-containing (FAC) adjuvant chemotherapy in breast cancer - M. D. Anderson Cancer Center experience. Proceedings of the 16th International Congress of Chemotherapy, June 1989, Israel:781.1-781.2, 1990.
33. Hortobagyi GN, Theriault RL, Frye D, Walters RS, Fraschini G, Tashima CK, Ro JS, Salewski E, **Buzdar AU**. Pirarubicin in combination chemotherapy for metastatic breast cancer. Am J Clin Oncol 13(Suppl 1):S54-6, 1990.
34. **Buzdar AU**. Adjuvant therapy and update of prognostic factors in breast cancer. Breast and Endocrine Second Annual Cancer Update, 12/1991.
35. **Buzdar AU**, Hortobagyi GN, McNeese N, Frye D, Holmes F, Fraschini G, Theriault R, Singletary E. Combined modality approach in treatment of inflammatory carcinoma of the breast - M. D. Anderson Cancer Center experience. Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, (eds.) P Banzet, JF Holland, D Khayat, M Weil, (Publ) Springer-Verlag France, Paris:146-148, 1991.
36. Hortobagyi GN, Singletary SE, **Buzdar AU**, McNeese MD, Ross MI, Holmes FA, Strom E, Theriault RL, Sneige N. Primary chemotherapy for breast cancer - M. D. Anderson experience. Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, (eds.) P Banzet, JF Holland, D Khayat, M Weil, (Publ) Springer-Verlag France, Paris:146-148, 1991.
37. **Buzdar AU**. Adjuvant therapy for breast cancer. Advances in Oncology 8(5):10-14, 1992.
38. Valero V, **Buzdar A**, Hortobagyi G. Factores Pronosticos en el Cancer de Mama. Proc Seminario Internacional Ultrasonido de la Mama y Mastografia. Mexico City , J Jellins, M Rickard, H Madjar, (eds.), International Breast Ultrasound School, Baden, Switzerland:106-110, 8/1993.
39. Valero V, **Buzdar A**, Hortobagyi G. Quimioterapia y hormonoterapia en el cancer de mama metastasico. Proc Seminario Internacional Ultrasonido de la Mama y Mastografia. Mexico City, J Jellins, M Rickard, H Madjar, [eds.], International Breast Ultrasound School, Baden, Switzerland:119-123, 8/1993.

40. **Buzdar AU**, Winchester DP, Balch CM. Evaluation of patients after primary therapy for early breast cancer. *The Cancer Bull* 45(6):528-531, 1993.
41. Hortobagyi GN, **Buzdar AU**. Present status of anthracyclines in the adjuvant treatment of breast cancer. *Drugs* 45(Suppl 2):10-9; discussion 18-9, 1993.
42. **Buzdar AU**, Hortobagyi GN. Recent developments and new directions in adjuvant therapy for breast cancer. *The Cancer Bull* 45(6):523-527, 1993.
43. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, **Buzdar AU**, Frye D, Gibbs HR, Hortobagyi GN. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. *J Natl Cancer Inst Monogr* 16:161-9, 1993.
44. Ibrahim NK, Forman AD, Podoloff DA, **Buzdar AU**. Brachial plexopathy and porencephaly in a patient with breast cancer. *Case Report, Cancer Bull* 46:185-188, 1994.
45. **Buzdar AU**. Breast Cancer. *Diagnostic Strategies Therapeutic Tactics. Consultant* 34(4):606-612, 1994.
46. Valero V, Theriault R, Esparza L, Fraschini G, Holmes F, Walters R, **Buzdar AU**, Raber M, Pazdur R, Bellet R, Bayssas M, Hortobagyi Gn. Phase II Study of Taxotere in Patients with Anthracycline-Resistant Metastatic Breast Cancer. *Recent Advances in Chemotherapy: Proc 18th International Congress of Chemotherapy. American Society for Microbiology. Einhorn J, Nord CE, Norrby SR (Eds.):844-845, 1994.*
47. **Buzdar AU**, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. *Surg Oncol Clin N Am* 4(4):715-34, 10/1995.
48. Ibrahim NK, **Buzdar AU**, Hortobagyi GN. Breast Cancer in the elderly. *The Cancer Bulletin* 47:212-217, 1995.
49. Hortobagyi GN, **Buzdar AU**. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. *CA Cancer J Clin* 45:199-226, 1995.
50. **Buzdar AU**, Hortobagyi GN, Holmes FA, McNeese M, Theriault RL, Singletary SE. M.D. Anderson Cancer Center Adjuvant Therapy Trials in Stage II or III Breast Cancer. Autologous Marrow and Blood Transplantation. *Proc of the Seventh International Symposium, KA Dicke, A Keating (Eds.):169-174, 1995.*
51. **Buzdar AU**, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. *Semin Oncol* 22:101-4, 1995.
52. Hortobagyi GN, **Buzdar AU**, Strom EA, Ames FC, Singletary SE. Primary chemotherapy for early and advanced breast cancer. *Cancer Lett* 90:103-9, 1995.
53. **Buzdar AU**, Plourde PV, Hortobagyi GN. Aromatase inhibitors in metastatic breast cancer. *Semin Oncol* 23(4):28-32, 1996.
54. Browne V, **Buzdar AU**, Hortobagyi GN. Current Status of Adjuvant Therapy of Breast Cancer. (Editorial) *The Cancer Journal* 9(4):174-176, 1996.
55. Valero V, **Buzdar AU**, Hortobagyi GN. Inflammatory Breast Cancer: Clinical Features and the Role of Multimodality Therapy. *The Breast Journal* 2(5):345-352, 1996.
56. Valero VV, **Buzdar AU**, Hortobagyi GN. Locally Advanced Breast Cancer. *Oncologist* 1:8-17, 1996.
57. **Buzdar AU**, Hortobagyi GN, Frye D, Valero V. Second-line chemotherapy for metastatic breast cancer including quality of life issues. *The Breast* 5:312-317, 1996.
58. **Buzdar AU**, Hortobagyi GN, Singletary SE, Holmes FA, Theriault RL, Walters R, Dhingra K, Booser D, Morris A, Asmar L, Wright-Browne V, Diamandidou E, Witjaksono MA, Strom E, McNeese M, Ames F. : Impact of FAC-Adjuvant Therapy on Mortality of Early Breast Cancer: Long Term Results of the M.D. Anderson Cancer Center Studies. *Adjuvant Therapy of Cancer VIII, Sydney E. Salmon (Ed.), Lippincott-Raven Publishers:93-100, 1997.*
59. **Buzdar AU**, Jonat W, Howell A, Plourde PV. ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. *J Steroid Biochem Mol Biol* 61:145-9, 1997.
60. Hortobagyi GN, Holmes FA, Theriault RL, Rahman Z, **Buzdar AU**. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. *Semin Oncol* 24(4):S11-13-S11-19, 1997.
61. Michaud LB, **Buzdar AU**. Commentary, Case 1. *Cancer Case Presentations: The Tumor Board* 1:4-6, 1997.

62. Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, **Buzdar AU**. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. *Semin Oncol* 24(5):S17-65-S17-68, 1997.
63. **Buzdar AU**, Hortobagyi GN, Asmar L, Theriault RL, Rahman Z, McNeese M, Singletary S, Ames F. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. *Semin Oncol* 24(5):S17-31-S17-34, 1997.
64. **Buzdar AU**, Hortobagyi GN. Should community oncologists give high-dose chemotherapy requiring G-CSF? *Oncol Rounds* 6(3):48, 1997.
65. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, **Buzdar AU**. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. *Semin Oncol* 24(1) (Suppl. 3):S30-3, 1997.
66. Puzstai L, Hortobagyi GN, Hung M-C, **Buzdar AU**. Advances and Future Directions in Breast Cancer Therapy. *Proc 22nd Congress of the International Association for Breast Cancer Research*. Athens, Greece, Ioannidou-Mouzaka L, Agnantis NJ, Lopez DM (eds.) Monduzzi Editore, International Proceedings Division, Bologna, Italy:79-83, 9/1998.
67. Rahman ZU, **Buzdar AU**, Singletary E, Hortobagyi GN. Selection of systemic therapy: Is axillary lymph node status important? *Sem Br Disease* 1:157-166, 1998.
68. **Buzdar A**. The place of chemotherapy in the treatment of early breast cancer. *British J Cancer* 78 Suppl 4:16-20, 1998.
69. Michaud LB, **Buzdar AU**. Therapeutic interventions in breast cancer: An update. *Medscape Oncol* 1(4), 1998.
70. **Buzdar AU**, Hortobagyi GN. Prospective evaluation of taxol vs. combination chemotherapy with fluorouracil, doxorubicin, cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer. *Cancer Inv, Abstracts*:57-58, 1999.
71. **Buzdar AU** Hortobagyi GN. Recent advances in adjuvant therapy of breast cancer. *Semin Oncol* 26:21-7, 1999.
72. **Buzdar AU**. Recent Advances in Endocrine Therapy. *Breast Cancer: Perspectives on Data and Developments*:35-38, 1999.
73. Hortobagyi GN, Hung MC, **Buzdar AU**. Recent developments in breast cancer therapy. *Semin Oncol* 26:11-20, 1999.
74. Michaud LB **Buzdar AU**. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. *Drug Saf* 21:297-309, 1999.
75. Bland KI, **Buzdar AU**. Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer. *Ann Surg Oncol* 6 (Suppl. 8):12S-13S, 1999.
76. **Buzdar AU**. Sequence of hormonal treatments in breast cancer. *Sem Br Disease* 2:167-679, 1999.
77. **Buzdar AU**. Tamoxifen for the prevention of breast cancer: An overview of randomized trials. *J Clin Outcomes Mgmt* 6:S18-S24, 1999.
78. **Buzdar A**. An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer. *Eur J Cancer* 36(Suppl 4):S82-4, 2000.
79. **Buzdar AU**. Article Reviewed: Endocrine Therapy for Breast Cancer. *Oncology* 14(4):493, 2000.
80. Michaud LB, **Buzdar AU**. Complete Estrogen Blockade for the Treatment of Metastatic and Early Stage Breast Cancer. *Drugs & Aging* 16(4):261-271, 2000.
81. **Buzdar AU**, Huml M. Drug: Anastrozole. *Outline of Oncology Therapeutics*:92, 2000.
82. Michaud LB, **Buzdar AU**. Endocrine Therapy of Metastatic Breast Cancer. *Seminars in Breast Disease: Hormonal Aspects of Breast Cancer* 3(2):100-111, 2000.
83. **Buzdar A**. Exemestane in advanced breast cancer. *Anticancer Drugs* 11:609-16, 2000.
84. **Buzdar AU**. Aromatase inhibitors in breast cancer. *Breast Cancer Online* 4, 4/2001.
85. **Buzdar AU**. A summary of second-line randomized studies of aromatase inhibitors. *Journal of Steroid Biochemistry and Molecular Biology* 79:109-14, 2001.
86. **Buzdar AU**. Anastrozole (Arimidex)—an aromatase inhibitor for the adjuvant setting? *British Journal of Cancer* 85(Suppl 2):6-10, 2001.
87. Johnson PE, **Buzdar A**. Are differences in the available aromatase inhibitors and inactivators significant? *Clin Cancer Res* 7(12):4360s-4368s; discussion 4411s-4412s, 2001.

88. **Buzdar AU**. Article Reviewed: Nonsteroidal and steroidal aromatase inhibitors in breast cancer. *Oncologist* 15(8):978-979, 2001.
89. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, **Buzdar AU**, Hortobagyi GN. Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. *The Oncologist* 6:133-146, 2001.
90. Michaud LB, Jones KL, **Buzdar AU**. Combination endocrine therapy in the management of breast cancer. *Oncologist* 6:538-46, 2001.
91. **Buzdar AU**. Endocrine therapy in the treatment of metastatic breast cancer. *Semin Oncol* 28(3):291-304, 2001.
92. **Buzdar AU**, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS. Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. *Clin Cancer Res* 7(12):4335s-4337s; discussion 4411s-4412s, 2001.
93. **Buzdar AU**. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. *Expert Rev Anticancer Ther* 2(6):623-9, 2002.
94. Assikis VJ, **Buzdar A**. Aromatase inhibitors: Indications for breast cancer therapy. *Am J Cancer* 1(2):93-100, 2002.
95. **Buzdar AU**. New generation aromatase inhibitors--from the advanced to the adjuvant setting. *Breast Cancer Research and Treatment* 75(Suppl 1):S13-7; discussion S33-5, 2002.
96. Valero V, **Buzdar AU**, McNeese M, Singletary E, Hortobagyi GN. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. *Clin Breast Cancer* 3(Suppl 2):S63-8, 2002.
97. **Buzdar AU**. Recent advances in adjuvant therapy of breast cancer. *Breast Cancer: Management and Treatment* 1(1):1-8, 2002.
98. Assikis VJ, **Buzdar A**. Recent advances in aromatase inhibitor therapy for breast cancer. *Seminars in Oncology* 29(3, Suppl. 11):120-8, 2002.
99. **Buzdar AU**. Advanced in endocrine therapy for early and advanced breast cancer. *Journal of the Hong Kong College of Radiologists* 6(3):165-172, 2003.
100. **Buzdar A**. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. *Clinical Breast Cancer* 4(Suppl 1):S42-8, 2003.
101. **Buzdar AU**. Aromatase inhibitors in breast cancer therapy. *Clinical Breast Cancer* 4(Suppl 2):S84-8, 2003.
102. **Buzdar AU**. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. *Clinical Cancer Research* 9:468S-72S, 2003.
103. Come SE, **Buzdar AU**, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. *Clinical Cancer Research* 9:443S-6S, 2003.
104. **Buzdar AU**, Hortobagyi GN. Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer. *Cancer Treat Rev* 29(5):449-52, 2003.
105. Cristofanilli M, **Buzdar AU**, Hortobagyi GN. Update on the management of inflammatory breast cancer. *Oncologist* 8:141-8, 2003.
106. **Buzdar AU**. Current developments in hormonal therapy of breast cancer. *Clinical Breast Cancer* 5(Suppl 1):S4-5, 2004.
107. **Buzdar AU**. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. *Clinical Cancer Research* 10(Suppl 1):355S-61S, 2004.
108. **Buzdar AU**. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. *Drugs of Today (Barc)* 40(9):751-64, 2004.
109. **Buzdar AU**. Hormonal therapy in early and advanced breast cancer. *Breast J* 10(Suppl 1):S19-21, 2004.
110. **Buzdar AU**. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement. *Clinical Cancer Research* 10:327s-330s, 2004.
111. **Buzdar AU**. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update. *Clinical Breast Cancer* 5(Suppl 1):S6-S12, 2004.

112. **Buzdar AU**. The current state of preoperative (neoadjuvant) hormonal therapy for breast cancer. *Breast Diseases: A Year Book Quarterly* 15(3):219-222, 2004.
113. Jones KL, **Buzdar AU**. Trastuzumab in the treatment of early stage breast cancer. *Breast Diseases: A Year Book Quarterly* 17(1):19-22, 2006.
114. **Buzdar AU**. Update on the management of inflammatory breast cancer. *Clin Adv Hematol Oncol* 4(5):344-5, 2006.
115. Cristofanilli M, Valero V, **Buzdar AU**, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. *Cancer* 110(7):1436-44, 10/2007.
116. **Buzdar AU**. Preoperative chemotherapy treatment of breast cancer-A review. *Cancer* 110(11):2394-407, 10/2007. e-Pub 10/2007.
117. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, **Buzdar AU**, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. *Lancet Oncology* 9(1):45-53, 1/2008.
118. Boughey JC, **Buzdar AU**, Hunt KK. In brief. *Curr Probl Surg* 45(1):6-11, 1/2008.
119. **Buzdar AU**. Clinical experience with epothilones in patients with breast cancer. *Clin Breast Cancer Suppl* 2:S71-8, 3/2008.
120. **Buzdar AU**. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer. *Drugs Today (Barc)* 44(9):679-92, 9/2008.
121. **Buzdar AU**. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. *Ann Oncol*. e-Pub 1/2009.
122. **Buzdar AU**. Medical oncology: Endocrine-therapy-related symptoms and breast cancer. *Nat Rev Clin Oncol* 6(6):309-10, 6/2009.
123. Jones KL, **Buzdar AU**. Evolving novel anti-HER2 strategies. *Lancet Oncol* 10(12):1179-87, 12/2009.
124. Kelly CM, **Buzdar AU**. Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trial. *Expert Opin Pharmacother* 11(3):489-92, 2/2010.
125. Kelly CM, **Buzdar AU**. Anastrozole. *Expert Opin Drug Saf* 9(6):995-1003, 11/2010.

Editorials

1. Hortobagyi GN **Buzdar AU**. Progress in inflammatory breast cancer: cause for cautious optimism. *J Clin Oncol* 4(12):1727-9, 1986.
2. Cold S, et al. The Influence of chemotherapy on survival after recurrence in breast cancer: A population-based study of patients treated in the 1950s, 1960s, and 1970s. (Editorial: **Buzdar AU**). *Breast Diseases: A Year Book* 5(2):71-73, 1994.
3. **Buzdar, Aman U**. Cancer in the Elderly: The University of Texas M. D. Anderson Cancer Center. (Editors: Aman U. Buzdar and Michael S. Ewer). *The Cancer Bulletin*, May-June 47(3), 1995.
4. Schwartz GF, Birchansky CA, Kormarnicky LT, Mansfield CM, Cantor RI, Biermann WA, Fellin FM, McFarlane FJ. Induction Chemotherapy followed by breast conservation for locally advanced carcinoma of the breast (*Cancer* 73:362-369, 1994). (Editorial: **Aman U. Buzdar**). *Breast Diseases: A Year Book* 5(4):84-85, 1995.
5. Coombes RC, for the International Collaborative Cancer Group (Charing Cross Hosp, London). Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil Versus Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy in Premenopausal Women with Axillary Node-positive Operable Breast Cancer: Results of a Randomized Trial (*J Clin Oncol* 14:35-45, 1996). (Editorial: **Aman U. Buzdar**). *Breast Diseases: A Year Book Quarterly* 7(4):397-399, 1996.
6. **Buzdar AU**, Brown V, Hortobagyi GN. Current Status of Adjuvant Therapy of Breast Cancer. *Cancer J* 9(4):174-176, 1996.
7. Miller AA, Lipton A, Henderson IC, et al. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. *Cancer* 78:789-793, 1996. (Editorial: **Aman U. Buzdar**). *Breast Diseases: A Year Book Quarterly* 8(2):169-170, 1997.
8. Willsher PC, Robertson JFR, Chan SY, et al. Locally advanced breast cancer: Early results of a randomised trial of multimodal therapy versus initial hormone therapy. *Eur J Cancer* 33:45-49, 1997. (Editorial: **Aman U. Buzdar**). *Breast Diseases: A Year Book Quarterly* 8(3):265, 1997.

9. **Buzdar AU**, Michaud LL. The Goss/Tye Article Reviewed. *Oncology* 11:1707-1708, 1997.
10. Dombrowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. *J Clin Oncol* 16:453-461, 1998. (Editorial: **Aman U. Buzdar**). *Breast Diseases: A Year Book Quarterly* 9(3):311, 1998.
11. **Buzdar AU**. Tamoxifen in breast cancer. *Breast Diseases: A Year Book Quarterly* 10(1):28-29, 1999.
12. **Buzdar AU**, Hortobagyi GN. Review of Article "Update on Adjuvant Chemotherapy for Early Breast Cancer" by McCarthy NJ and Swain SM. *Oncology* 14(9):1280-1283, 2000.
13. **Buzdar AU**. Aromatase inhibitors versus tamoxifen: Which is the better choice? . *Breast Diseases: a Year Book Quarterly* 12(2):148-150, 2001.
14. **Buzdar AU**. Anastrozole: a viewpoint. *Drugs* 62(17):2491-2492, 2002.
15. **Buzdar AU**. Commentary of article "Letrozole improved disease-free survival in postmenopausal women after tamoxifen treatment for breast cancer" by Goss PE, Ingle JN, Martino S, et al. *Evidence-Based Obstetrics and Gynecology* 6:91-92, 2004.
16. Theriault RL, **Buzdar AU**. Review of Article "Pregnancy and Breast Cancer: Epidemiology, Treatment, and Safety Issues" by Partridge A and Schapira L. *Oncology* 19(6):698-700, 2005.
17. **Buzdar AU**. Review of Article: "Optimizing Adjuvant Chemotherapy in Early-Stage Breast Cancer" by Perez E and Muss HB. *Oncology* 19(14):1773-4, 2005.
18. **Buzdar AU**. Dietary modification and risk of breast cancer. *JAMA* 295(6):691-2, 2006.
19. **Buzdar AU**. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. *J Clin Oncol* 24:2409-11, 2006.

Other Articles

1. **Buzdar AU**. Diseases of the Breast. *The Cancer Bulletin* 39(1):67, 1987.
2. **Buzdar AU**. *Oncology-Primary Care of Cancer: Recommendations for Screening, Diagnosis, and Management.* (ed.) E.A. Mortimer, Case Western Reserve University School of Medicine (collab.). *Annals of Internal Medicine* 108(2):317-318, 1988.

Abstracts (past 5 years)

1. **Buzdar AU**, Cuzick J. Is overall survival an appropriate endpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up. 2008 American Society of Clinical Oncology, Annual Meeting, *J Clin Oncol* 26(May 20 Suppl) (#552), 5/2008.
2. **Buzdar AU**, Green MC, Broglio KR, Valero V, Ibrahim NK, Hunt KK, Hortobagyi GN. Prospective randomized trial evaluating weekly paclitaxel (WP) versus docetaxel in combination with capecitabine (DC) in operable breast cancer. *American Society of Clinical Oncology* (#542), 5/2009.
3. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andre F, **Buzdar AU**, Martin P, Kobayashi R, Pusztai L. Evaluation of changes in plasma protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using MALDI-TOF/MS procedure. 2009 American Society of Clinical Oncology Breast Cancer Symposium (#177), 10/2009.
4. **Buzdar AU**, Ballman KV, Meric-Bernstam F, Boughey JC, Leitch AM, Unzeitig G, Ellis MJ, Ewer MS, Beitsch PD, Hunt KK. Initial safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2 positive operable breast cancer (ACOSOG Z1041). 2009 American Society of Clinical Oncology Breast Cancer Symposium (#271), 10/2009.
5. Green MC, **Buzdar AU**, Valero V, Frye D, Christmas J, Carter C, Cohen D, Hortobagyi GN. Rates of adverse events with low-dose dexamethasone (dex) as premedication of weekly paclitaxel (Pac) utilized as adjuvant/neoadjuvant therapy for operable breast cancer. 2009 American Society of Clinical Oncology Breast Cancer Symposium (#307), 10/2009.
6. **Buzdar AU**, Valero V, Ibrahim NK, Theriault RL, Pusztai L, Hunt KK, Esteva FJ, Ewer MS, Hortobagyi GN. Seventy-two month update of randomized trial of preoperative therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy with or without concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer. 2009 American Society of Clinical Oncology Breast Cancer Symposium (#221), 10/2009.

7. **Buzdar AU**, McCall L, Suman V, Beitsch PD, Ewer M, Meric-Bernstam F, Leitch AM, Boughey JC, Ellis ME, Unzeitig G, Royce M, Hunt KK. A randomized phase III trial comparing a neoadjuvant regimen of FEC-75 followed by paclitaxel plus trastuzumab with a neoadjuvant regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER-2 positive operable breast cancer, ACOSOG Z1041. 2010 American Society of Clinical Oncology Annual Meeting, 6/2010.
8. **Buzdar A**, Hunt K, Buchholz TA, Taylor SH, Hortobagyo GN, Hess KR. Improving survival of patients with breast cancer over the past 6 decades: The University of Texas M.D. Anderson Cancer Center experience. 2010 Breast Cancer Symposium (#176), 10/2010.

Book Chapters

1. Hortobagyi GN, Gutterman JU, Blumenschein GR, **Buzdar AU**, Hersh EM. Levamisole in the treatment of breast cancer. In: Immune Modulation and Control of Neoplasia by Adjuvant Therapy, M.A. Chirigos. Raven Press, 131-140, 1976.
2. **Buzdar AU**, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Wheeler W, Gehan E, Freireich E, Hersh EM. Adjuvant chemoimmunotherapy following regional therapy in breast cancer. In: Adjuvant Therapy of Cancer. North-Amsterdam: North-Holland Publishing Co, 139-146, 1977.
3. Blumenschein GR, **Buzdar AU**, Tashima CK, Hortobagyi GN. Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer. In: Adjuvant Therapy of Cancer. North-Holland Publishing Co., 147-152, 1977.
4. Hortobagyi GN, Gutterman JU, Blumenschein GR, **Buzdar AU**, Hersh EM. Chemoimmunotherapy of advanced breast cancer with BCG. In: Recent Results in Cancer Research. 62. Springer-Verlag, 143-150, 1977.
5. Blumenschein GR, **Buzdar AU**, Hortobagyi GN, Gutterman JU, Tashima CK. Non-specific active immunotherapy in combination with chemotherapy for the treatment of metastatic breast cancer. In: Neoplasm Immunity: Solid Tumor Therapy. Franklin Inst. Press, 169-177, 1977.
6. Hortobagyi GN, Gutterman JU, Blumenschein GR, **Buzdar AU**, Burgess MA, Richman SP, Tashima CK, Schwartz M, Hersh EM. Chemoimmunotherapy of advanced breast cancer with BCG. In: Progress in Cancer Research and Therapy, vol. 6, Immunotherapy of Cancer: Present Status of Trials in Man. Raven Press, 655-668, 1978.
7. Hortobagyi GN, Gutterman JU, Blumenschein GR, **Buzdar AU**, Tashima CK, Richman SP, Wiseman CL, Yap HY, Hersh EM. Immunotherapy and chemoimmunotherapy of human breast cancer. In: Immunotherapy of Human Cancer. Raven Press, 321-345, 1978.
8. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, **Buzdar AU**, Hersh EM. Levamisole in treatment of breast cancer. In: Immune Modulation and Control of Neoplasia by Adjuvant Therapy. Raven Press, 131-140, 1978.
9. Blumenschein GR, **Buzdar AU**, Hortobagyi GN, Tashima CK. Adjuvant chemoimmunotherapy following regional therapy for initial solitary metastases of breast cancer (stage IV NED). In: Adjuvant Therapy of Cancer II. Grune & Stratton, 303-310, 1979.
10. **Buzdar AU**, Gutterman JU, Blumenschein GR, Tashima CK, Hortobagyi GN, Yap HY, Hersh EM, Gehan EA. Adjuvant therapy of stage II, III breast cancer. In: Recent Results in Cancer Research. Springer-Verlag, 123-128, 1979.
11. **Buzdar AU**, Blumenschein GR, Gutterman JU, Hortobagyi GN, Campos LT, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan EA. Adjuvant therapy with 5-fluorouracil, adriamycin, cyclophosphamide and BCG (FAC-BCG) for stage II or III breast cancer. In: Adjuvant Therapy of Cancer II. Grune & Stratton, 277-284, 1979.
12. Blumenschein GR, Hortobagyi GN, **Buzdar AU**, DiStefano A, Gutterman J, Hersh EM. Review of multiple non-specific immunotherapeutic agents in combination with FAC chemotherapy of stage IV breast cancer. In: Tumor Regression. North Holland, Inc, 369-378, 1980.
13. Blumenschein GR, **Buzdar AU**, Hortobagyi GN, Yap HY. Adjuvant chemo-immunotherapy to regionally treated stage IV breast cancer patients - a five year follow-up. In: Adjuvant Therapy of Cancer III, 427-434, 1981.
14. **Buzdar AU**, Smith TL, Blumenschein GR, Hortobagyi GN, Hersh EM, Gehan E. Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) for stage II or III breast cancer: 5 year results. In: Adjuvant Therapy of Cancer III, 419-426, 1981.

15. Fraschini G, DiStefano A, Yap HY, Barnes BC, **Buzdar AU**, Hortobagyi GN, Blumenschein GR. Chemotherapy with dibromodulcitol, Adriamycin, cyclophosphamide for metastatic breast cancer. In: Current Chemotherapy and Immunotherapy; Proceedings of the XII International Congress of Chemotherapy, Washington, D.C., American Association of Microbiology, 1485-1487, 1981.
16. Blumenschein GR, Yap HY, Hortobagyi GN, **Buzdar AU**, Legha SS. Interaction between vinca alkaloids in breast carcinoma. In: Proc. of the 12th Intl. Congress of Chemotherapy, Florence, Italy, July 19-24, 19-24, 1981.
17. **Buzdar AU**, Powell KC, Legha SS, Hortobagyi GN, Blumenschein GR. Trioxifene mesylate in the treatment of advanced breast cancer - A phase I-II study. In: In Current Chemotherapy and Immunotherapy; Proc. 12th Intl. Congress of chemotherapy, Florence, Italy, July 19-24, Washington, D.C., American Association of Microbiology, 1472-1473, 1981.
18. Bodey G, Yap HY, Blumenschein GR, Hortobagyi GN, **Buzdar AU**. A randomized comparative study of vinblastine, vindesine and vincristine in patients with refractory metastatic breast cancer. In: Drugs Under Experimental and Clinical Research. 8(5), 559-563, 1982.
19. **Buzdar AU**, Blumenschein GR, Hortobagyi GN, Legha SS, Yap HY, Campos LT, Hersh EM. Adjuvant chemotherapy with 5-fluorouracil, adriamycin and cyclophosphamide, with or without BCG immunotherapy in stage II or III breast cancer. In: Proc. II International Conference on Immunotherapy of Cancer. Cancer Sec. IV, 175-181, 1982.
20. Hortobagyi GN, Blumenschein GR, **Buzdar AU**, Yap HY. Combination chemotherapy for metastatic breast cancer. In: Proc. of the Symposium on Chemotherapy for metastatic breast cancer. (part 2). Adria Laboratories, Inc., 12-16, 1982.
21. Blumenschein GR, Hortobagyi GN, **Buzdar AU**, Yap HY. Poor prognosis breast cancer - is cure possible? In: Education distribution by the CICA Satellite Committee, presented at CANCER 1981 Cancer 2001: In Proceedings II International Conference on Immunology of Cancer, Cancer (Sect. IV), 175-181, 1982.
22. **Buzdar AU**, Ross M, Smith T, Blumenschein G, Hortobagyi G, Eckles N, Gehan E, Freireich E. Improved survival in metastatic breast cancer treated with combination chemotherapy - an experience of past 3 decades. In: Proc 13th International Congress of Chemotherapy, Vienna, Austria, August 28-Sept. 2, 244/1, 1983.
23. Hortobagyi GN, **Buzdar AU**, Blumenschein GR, Yap HY, Hersh EM. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. In: Proc of IABS Symposium on BCG & Tuberculins, Budapest, September 6 to 9, 1983.
24. Blumenschein GR, **Buzdar AU**, Yap HY, Hortobagyi GN. Seven year follow-up of stage IV patients entering complete remission from FAC. In: Proc. 13th International Congress of Chemotherapy, Vienna, Austria, August 28-Sept. 2, 244/9, 1983.
25. **Buzdar AU**, Smith TL, Blumenschein GR, Hortobagyi GN, Yap HY, Hersh EM, Gehan EA. Adjuvant therapy for stage II or III breast cancer: U.T. M. D. Anderson Hospital Experience. In: Current Controversies in Breast Cancer, 169-182, 1984.
26. **Buzdar AU**, Smith TL, Blumenschein GR, Hortobagyi GN, Marcus CE, Hersh E, Martin RG, Gehan EA, Freireich EJ. Breast cancer adjuvant therapy trials of M. D. Anderson Hospital: Results of two studies. In: Adjuvant Therapy of Cancer IV, Proc. of Fourth International Conference, 217-225, 1984.
27. Hortobagyi GN, Smith TL, Blumenschein GR, Legha SS, Yap HY, **Buzdar AU**. Clinical prognostic factors of response. In: Current Controversies in Breast Cancer. University of Texas Press, 255-259, 1984.
28. Blumenschein GR, Pinnamaneni K, **Buzdar AU**, Hortobagyi GN, Yap HY, Montague ED, Ames FC. Combined regional and systemic therapy in breast cancer patients with an isolated metastasis with or without prior chemotherapy. In: Adjuvant Therapy of Cancer IV, Proc. of Fourth International Conference on Adjuvant Therapy, 311-320, 1984.
29. Moon TE, Jones SE, Tong T, Serokman R, Bonadonna G, Veronesi U, Powles TJ, **Buzdar AU**, Montague E. Development of a natural history data base of breast cancer studies. In: Adjuvant Therapy of Cancer IV, Proc of Fourth International Conference, 227-233, 1984.
30. Holmes FA, Yap HY, Esparza L, **Buzdar AU**, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. In: New Perspectives in Chemotherapy: Focus on Novantrone, Seminars in Oncology XI. 3 Suppl. 1, 28-31, 1984.

31. Yap HY, **Buzdar AU**, Hortobagyi GN, Blumenschein G, Bodey G. Promising new agents for metastatic breast cancer. In: 26th Annual Clinical Conference - Current Controversies in Breast Cancer. University of Texas Press, 283-290, 1984.
32. Hortobagyi GN, Fritsche HA, Mughal AW, **Buzdar AU**, Yap HY, Blumenschein GR. Role of carcinoembryonic antigen for follow-up of breast cancer patients. In: Current Controversies in Breast Cancer. University of Texas Press, 461-465, 1984.
33. **Buzdar AU**, Smith TL, Marcus C, Hortobagyi G, Blumenschein G. Significance of drug, dose, timing and radiotherapy in adjuvant therapy of breast cancer. In: 2nd International on Adjuvant Chemotherapy of Breast Cancer. Recent Results in Cancer Research. 96, 141-147, 1984.
34. Gehan EA, Smith TL, **Buzdar AU**. Statistical considerations for historical controlled adjuvant studies with application to FAC-BCG study in breast cancer. In: Current Controversies in Breast Cancer, 469-476, 1984.
35. Blumenschein GR, Yap HY, Hortobagyi GN, **Buzdar AU**, Issell, BF. The role of VP-16 (etoposide) in the treatment of metastatic breast cancer. In: Etoposide (VP-16-213): Current Status and New Developments. Academic Press, 253-260, 1984.
36. Jones S, Moon T, Bonadonna G, Valagussa P, Rivkin S, **Buzdar A**, Montague E, Powles T. The use of a natural history data base (NHDB) to compare selected adjuvant trials or women with operable stage II (node positive) breast cancer. In: Adjuvant Therapy of Cancer IV, Proc of Fourth International Conference on Adjuvant Therapy, 1984.
37. **Buzdar A**, Smith T, Blumenschein G, Hortobagyi G. Adjuvant chemotherapy of operable breast cancer with doxorubicin-containing regimen. In: Results of Three Trials at M. D. Anderson Hospital, Proc. of the 14th International Congress of Chemotherapy, Kyoto, 703-704, 1985.
38. Hortobagyi GN, **Buzdar AU**, Ames FC, Blumenschein GR, Montague ED. Induction chemotherapy of breast cancer. In: Primary Chemotherapy in Cancer Medicine. Alan R. Liss, Inc, 105-116, 1985.
39. Hortobagyi GN, **Buzdar AU**, Montague E, Romsdahl M. Neo-adjuvant chemotherapy for primary breast cancer. In: Colloque INSERM/John Libbey Eurotext Ltd. 137, 189-196, 1986.
40. **Buzdar AU**, Hortobagyi GN, Kau SW, Smith TL, Frascini G, Holmes FA, Hug V, Campos LT, Ames FC, Martin RG. Breast cancer adjuvant therapy trials of M. D. Anderson Hospital: Results of three studies. In: Proceedings of the Fifth International Conference, Adjuvant Therapy of Cancer V. Grune & Stratton, 411-418, 1987.
41. **Buzdar AU**. Diseases of the Breast - A book review. In: The Cancer Bulletin. 39 (1), 67, 1987.
42. Hortobagyi GN, Kau S, **Buzdar AU**, Ames F, McNeese M, Frye D, Holmes F, Frascini G, Hug V, Martin R, Montague E. Induction chemotherapy for stage III primary breast cancer. In: Proceedings of the Fifth International Conference, Adjuvant Therapy of Cancer V. Grune & Stratton, 419-428, 1987.
43. Hortobagyi GN, **Buzdar AU**, Ames FC, McNeese MD. Neo-adjuvant chemotherapy in the management of advanced primary carcinoma of the breast. In: Neo-Adjuvant Chemotherapy. 169. Colloque INSERM/John Libbey Eurotext Ltd., 137-142, 1988.
44. **Buzdar AU**. Progestins in Cancer Treatment. In: Endocrine Management of Cancer, 2 Contemporary Therapy. S. Karger, 1-15, 1988.
45. Dunphy FR, Spitzer G, Dicke KA, **Buzdar AU**, Hortobagyi GN. Tandem high-dose chemotherapy as intensification in stage IV breast cancer. In: Bone Marrow Transplantation: Current Controversies, UCLA Symposia on Molecular and Cellular Biology, New Series, V 87. Alan R. Liss, Inc, 245-251, 1988.
46. **Buzdar AU**. What is Best for the Patient? A United States View. In: Cost Versus Benefit in Cancer Care. The MacMillan Press LTD, 19-30, 1988.
47. Dunphy FR, Spitzer G, Ellis JK, Dicke KA, **Buzdar AU**, Hortobagyi GN. Autologous bone marrow transplantation and hematopoietic recovery in solid tumors. In: Autologous Bone Marrow Transplantation, Proceedings of the Fourth International Symposium. The University of Texas M. D. Anderson Cancer Center, 405-410, 1989.
48. **Buzdar A**, Hortobagyi G, Kau S, Patel H, Hug V, Holmes G, Frascini G, Singletary S, Ames F. Evaluation of risk and benefits of doxorubicin-containing (FAC) adjuvant chemotherapy in breast cancer - M. D. Anderson Cancer Center Experience. In: Proceedings of the 16th International Congress of Chemotherapy, June, 781.1-781.2, 1989.

49. Spitzer G, Dunphy FR, Ellis JK, **Buzdar AU**, Hortobagyi GN, Holmes FA, Jabboury KW, Horwitz LJ, Jagannath S, Dicke KA. High-dose intensification for stage IV hormonally-refractory breast cancer. In: Autologous Bone Marrow Transplantation, Proceedings of the Fourth International Symposium. The University of Texas M.D. Anderson Cancer Center, 399-404, 1989.
50. Ang PT, **Buzdar AU**. Breast Cancer. In: Difficult Medical Management. W. B. Saunders Co, 126-131, 1990.
51. Hortobagyi GN, Ames FC, **Buzdar AU**, Kau S, Frye D, McNeese MD, Holmes FA, Fraschini G, Hug V, McBride CM. Combined modality therapy for locally advanced breast cancer: 14 years results. In: Adjuvant Therapy of Cancer VI. W.B. Saunders Co, 254-261, 1990.
52. Hortobagyi GN, Dunphy F, **Buzdar A**, Spitzer G. Dose intensity studies in breast cancer - Autologous bone marrow transplantation. In: Effects of Therapy on Biology and Kinetics of the Residual Tumor, Part B: Clinical Aspects. Wiley-Liss, 195-209, 1990.
53. **Buzdar AU**, Hortobagyi GN, Kau S, Smith TL, Fraschini G, Holmes FA, Hug V, Gutterman JU, McNeese MD, Singletary SE, Ames F. Doxorubicin-containing adjuvant therapy for patients with stage II breast cancer: M. D. Anderson Cancer Center Experience. In: Adjuvant Therapy of Cancer VI. W.B. Saunders Co., 210-215, 1990.
54. Holmes FA, **Buzdar AU**, Kau S, Fraschini G, Hug V, Smith T, Theriault TL, Singletary ES, Ames F, McNeese MD, Hortobagyi GN. Isolated Visceral Recurrences of Breast Cancer: 10 Year Results of a Combined Modality Approach. In: Adjuvant Therapy of Cancer VI. W.B. Saunders Co, 262-266, 1990.
55. Spitzer G, Huan S, Dunphy F, Dicke K, Wallerstein R, Hortobagyi G, **Buzdar A**, Holmes F, Yau J, Deisseroth A. Double high-dose therapy in human solid tumors an emphasis on breast cancer. In: New Strategies in Bone Marrow Transplantation, 437-445, 1991.
56. Hortobagyi GN, **Buzdar AU**. Locally advanced breast cancer: A review including the M.D. Anderson Experience. In: High Risk Breast Cancer Therapy. Springer-Verlag, 382-416, 1991.
57. Spitzer G, Huan S, Dunphy FR, **Buzdar AU**, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath JS, Holmes FA, Wallerstein RO, Dicke KA. Tandem high dose chemotherapy for metastatic breast cancer. In: Autologous Bone Marrow Transplantation V. The U. of Nebraska Medical Center, 323-332, 1991.
58. Giralt S, **Buzdar AU**. Progestins and other pregnane derivatives. In: Antitumor Steroids. Academic Press, Inc, 123-153, 1992.
59. **Buzdar AU**, Frye D, Ho D, Booser D, Valero V, Holmes FA, Plourde P, Hortobagyi GN. Bioavailability of Nolvadex (Tamoxifen Citrate) as Once-Daily and Twice Daily Dosage Regimens in Patients with Breast Cancer. In: Adjuvant Therapy of Cancer VII. J. B. Lippincott Co, 237-239, 1993.
60. **Buzdar AU**, Hortobagyi GN, Kau SW, Holmes FA, Fraschini G, Theriault RL, McNeese M, Ross M, Singletary E. Breast cancer adjuvant therapy at the M. D. Anderson Cancer Center - Results of four prospective studies. In: Adjuvant Therapy of Cancer VII. J. B. Lippincott Co, 220-225, 1993.
61. Hughes P, **Buzdar A**. Early stage breast cancer and adjuvant therapy. In: Medical Oncology: A Comprehensive Review, University of Texas M. D. Anderson Cancer and the journal Oncology, 201-208, 1993.
62. Dunphy F, Spitzer G, Yau J, Huan S, Spinolo J, Jagannath S, Wallerstein R, Dicke K, **Buzdar A**, Hortobagyi G. Long-term follow-up of poor prognosis stage IV breast cancer patients treated with two courses of high-dose chemotherapy and bone marrow support. In: Sixth International Symposium on Autologous Bone Marrow Transplantation VI. 118-123, 1993.
63. Galindo EG, **Buzdar AU**. Avaliação de Pacientes em Seguimento Após Tratamento. In: CÂNCER DA MAMA Diagnóstico e Tratamento. Medsi, 197-204, 1994.
64. **Buzdar AU**, Hortobagyi G, Kau S, Holmes F, Fraschini G, Theriault R, McNeese M, Singletary S. Long-term efficacy and late sequelae of doxorubicin-containing adjuvant therapy for breast cancer: M. D. Anderson Cancer Center Studies. In: Cancer Treatment - An Update. Springer-Verlag, 163-166, 1994.
65. **Buzdar AU**, Hortobagyi GN, Holmes FA, McNeese M, Theriault RL, Singletary SE. M. D. Anderson Cancer Center Adjuvant Therapy Trials in Stage II or III breast cancer. In: Proceedings of the Seventh International Symposium, Arlington, TX, Autologous Marrow and Blood Transplantation VII. Baxter Healthcare Corporation - Hyland Division, 169-173, 1994.

66. Hortobagyi GN, **Buzdar AU**, Frye D, Singletary SE, Holmes FA, Ames F, McNeese MD, Theriault RL. Primary chemotherapy for breast cancer: Response to preoperative chemotherapy as prognostic factor. In: *Cancer Treatment - An update*. Springer-Verlag, 105-109, 1994.
67. Dhingra K, Fritsche H, Murray JL, LoBuglio A, Khazaeli MB, Kelley S, Tepper M, Greene D, Booser D, **Buzdar A**, Raber M, Gutierrez L, Hortobagyi G. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by Deoxyspergualin: A Phase I Study. In: *Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment*, 193-202, 1994.
68. Holmes FA, Valero V, Walters R, Theriault R, Booser D, **Buzdar A**, Gibbs H, Frye D, Young K, Hortobagyi G. Taxol in metastatic breast cancer: the M. D. Anderson Cancer Center Experience. In: *Cancer Treatment -An Update*. Springer-Verlag, 161-171, 1994.
69. **Buzdar AU**, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined mocality treatment of stage III and inflammatory breast cancer. In: *Management Strategies for the Care of Advanced Primary and Metastatic Breast Cancer*. 4(4). W. B. Saunders Co, 715-734, 1995.
70. Friedewald V, **Buzdar AU**. In: *Ask the Doctor: Breast Cancer*. Andrews and McMeel, 1997.
71. Hortobagyi GN, **Buzdar AU**. Locally Advanced Breast Cancer. In: *Textbook of Breast Cancer - A Clinical Guide to Therapy*. Martin Dunitz Publishers, 155-168, 1997.
72. Singletary SE, **Buzdar AU**, Diamandidou E. Advanced breast carcinoma, locoregional recurrences, and distant metastases. In: *Cancer in Women*. Blackwell Science, Inc, 174-194, 1998.
73. Diamandidou E, **Buzdar AU**, Plourde P. Breast Cancer. In: *Drug Development for Women*. John Wiley and Sons Publishers, 337-386, 1998.
74. Hunt KK, **Buzdar AU**. Breast conservation after tumor downstaging with induction chemotherapy. In: *Breast Cancer, M. D. Anderson Solid Tumor Oncology Series*. Springer-Verlag, 196-207, 1998.
75. Singletary SE, **Buzdar AU**. Inflammatory breast cancer. In: *Cancer in Women*. Blackwell Science, Inc, 195-203, 1998.
76. Singletary SE, **Buzdar AU**, Diamandidou E. Advanced breast carcinoma, locoregional recurrences, and distant metastases. In: *Breast Cancer*. Blackwell Science, Inc, 118-138, 1999.
77. **Buzdar AU**, Diamandidou E. Aspetti Clinici. In: *Carcinoma della Mammella*. Poletto Editore, 61-70, 1999.
78. **Buzdar AU**, Hortobagyi GN. Breast Cancer. In: *Cancer Chemotherapy and Biological Response Modifies Annual 18*. Elsevier Sciences B.V., 435-469, 1999.
79. **Buzdar AU**, Cristofanilli M, Hortobagyi G. Carcinoma Infiammatorio. In: *Carcinoma della Mammella*. Potello Editore, 296-306, 1999.
80. **Buzdar AU**, Cristofanilli M, Pro B. Fractture Patologiche. In: *Carcinoma della Mammella*. Potello Editore, 353-355, 1999.
81. Singletary SE, **Buzdar AU**. Inflammatory breast cancer. In: *Breast Cancer*. Blackwell Science, Inc, 139-174, 1999.
82. **Buzdar AU**, Cristofanilli M, Pro B. Manifestazioni Del Sistem Nervoso Centrale. In: *Carcinoma della Mammella*. Potello Editore, 347-352, 1999.
83. **Buzdar AU**, Brunelli CA, Zwelling LA. Protecting human subjects from risk in the performance of clinical research and the informed consent process. In: *Progress in Anti-Cancer Chemotherapy*. Springer-Verlag, 7-20, 1999.
84. **Buzdar AU**, Matei CM. Quimioterapia primaria en cancer mamario. In: *Compendio de Patologia Mamaria*. Academia Mexicana de Cirugia, 207-216, 1999.
85. **Buzdar AU**, Cristofanilli M. Terapia Endocrina. In: *Carcinoma della Mammella*. Potello Editore, 307-320, 1999.
86. Thomas E, **Buzdar AU**, Hortobagyi GN, Asmar L, Frye D, Theriault R, Booser D, McNeese M, Strom E, Ames F, Singletary SE. Treatment of locally advanced and inflammatory breast cancer. In: *Advanced Therapy of Breast Disease*. B.C. Decker, Inc, 267-280, 1999.
87. Hortobagyi GN, **Buzdar AU**. Treatment of metastatic breast cancer. In: *Advanced Therapy of Breast Diseases*. B.C. Decker, Inc, 281-289, 1999.
88. **Buzdar AU**, Hortobagyi GN. Aromatase Inhibitors in the Treatment of Breast Cancer. In: *Breast Cancer Management: Application of Evidence to Patient Care*. Martin Dunitz Ltd, 171-180, 2000.

89. Blumenschein GR, **Buzdar AU**, Hortobagyi GN. FAC+BCG as adjuvant therapy in breast cancer: An 8 year Update. In: *Recent Results of Cancer Research*. 96, 129-132, 2000.
90. **Buzdar AU**, Hortobagyi GN. New Endocrine Agents in Breast Cancer. In: *Textbook of Breast Cancer: A Clinical Guide to Therapy*. Martin Dunitz Ltd, 251-262, 2000.
91. Hortobagyi GN, **Buzdar A**. Preoperative (Neoadjuvant) Chemotherapy for Operable Breast Cancer. In: *Textbook of Breast Cancer: A Clinical Guide to Therapy*. Martin Dunitz Ltd, 119-137, 2000.
92. Michaud LB, **Buzdar AU**. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. In: *Breast Cancer Management*. Adis International, 21-33, 2000.
93. Strom EA, **Buzdar AU**, Hunt KK. Chapter 1: Multidisciplinary Care of the Breast Cancer Patients: Overview and Implementation. In: *Breast Cancer*. Springer-Verlag, 1-19, 2001.
94. **Buzdar AU**. Chapter 13: Endocrine Therapy for Breast Cancer. In: *Breast Cancer*. Springer-Verlag, 366-381, 2001.
95. Jones KL, **Buzdar AU**, Hortobagyi GN. Chapter 15: Aromatase inhibitors in the treatment of breast cancer. In: *Breast Cancer Management: Application of Clinical and Translational Evidence to Patient Care*. Lippincott Williams & Wilkins, 203-222, 2002.
96. Whitman GJ, Iyer RB, Lifshitz OH, **Buzdar AU**. Chapter 10: Sequential magnetic resonance and response of breast cancer to neoadjuvant therapy. In: *Image-Guided Diagnosis and Treatment of Cancer*. Humana Press Inc, 213-228, 2003.
97. Boehnke Michaud L, Wojdylo JR, **Buzdar AU**. Chapter 6: Novel hormonal agents. In: *Breast Cancer Therapy Annual*. Martin Dunitz, 91-106, 2003.
98. **Buzdar AU**, Harvey HA. Chapter 64: Aromatase Inhibitors. In: *Cancer Medicine*. BC Decker Inc, 947-959, 2003.
99. Baum M, **Buzdar A**. Chapter 7: Anastrozole as adjuvant therapy. In: *History and Advancement of Anastrozole in the Treatment of Breast Cancer*. Royal Society of Medicine Press Ltd, 45-51, 2003.
100. Baum M, **Buzdar A**. The current status of aromatase inhibitors in the management of breast cancer. In: *Surg Clin N Am*. 83, 973-994, 2003.
101. Singletary SE, **Buzdar AU**. Breast Cancer: Adjuvant Systemic Therapy. In: *Current Surgical Therapy*. Elsevier Mosby Inc, 641-645, 2004.
102. **Buzdar AU**, Gradishar WJ. Chapter 45: Adjuvant hormonal therapy for early breast cancer in postmenopausal women. In: *Advanced Therapy of Breast Disease*. BC Decker Inc, 459-466, 2004.
103. **Buzdar AU**. Chapter 57: Endocrine therapy for metastatic breast cancer. In: *Advanced Therapy of Breast Disease*. BC Decker Inc, 567-578, 2004.
104. **Buzdar AU**. The third-generation aromatase inhibitors: a clinical overview. In: *Aromatase Inhibitors*. Ed(s) Furr BJA. Birkhauser Verlag, 119-137, 2005.
105. Berry DA, Smith TL, **Buzdar AU**. Breast Cancer. In: *Textbook of Clinical Trials*, 2. John Wiley & Sons, Ltd.: England, 49-62, 2006.
106. Fanale MA, **Buzdar AU**. Chapter 19: Early-stage, locally advanced, and inflammatory breast cancer. In: *MD Anderson Manual of Medical Oncology*. Ed(s) Kantarjian HM, Wolff RA, Koller CA. McGraw-Hill Company, 463-502, 2006.
107. **Buzdar AU**. Chapter 21: Endocrine therapy of early and advanced breast cancer. In: *Breast Cancer*, 2nd Ed. Ed(s) Winchester DJ, Winchester DP, Hudis CA, Norton L. BC Decker Inc., 331-352, 2006.
108. **Buzdar AU**, Harvey HA, Jordan VC. Chapter 54: Estrogen, Antiestrogens, and Aromatase Inhibitors. In: *Cancer Medicine*. Ed(s) Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E. BC Decker Inc., 828-842, 2006.
109. **Buzdar AU**. The third-generation aromatase inhibitors: a clinical overview. In: *Aromatase Inhibitors*, 2. Ed(s) Furr BJA. Birkhauser: Basel, Switzerland, 2008.
110. **Buzdar AU**, Dawood S, Harvey HA, Jordan VC. Antiestrogens, Progestins, and Aromatase Inhibitors. In: *Cancer Medicine*, 8th. Ed(s) Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E. BC Decker: Shelton, Connecticut, 737-749, 2010.

Books (edited and written)

1. Bonifacino A, Halliwell M, **Buzdar AU**. *Carcinoma della Mammella*. Poletto Editore, 1999.

2. Nabholz JM, Tonkin K, Apro MS, **Buzdar AU**. Breast Cancer Management: Application of Evidence to Patient Care. Martin Dunitz Ltd, 2000.
3. Hunt KK, Robb GL, Strom EA, Ueno NT. Breast Cancer. In: M.D. Anderson Cancer Care Series. Springer-Verlag, 2001.
4. Tonkin K, Reese DM, Apro MS, **Buzdar AU**. Breast Cancer Management: Application of Clinical and Translational Evidence to Patient Care. Lippincott Williams & Wilkins, 2002.
5. Fossella FV, Komaki R, Putnam JB. Lung Cancer. In: M.D. Anderson Cancer Care Series. Springer-Verlag, 2002.
6. **Buzdar A**, Baum M. History and Advancement of Anastrozole in the Treatment of Breast Cancer. Royal Society of Medicine Press Ltd, 2003.
7. Ajani JA, Curley SA, Janjan NA, Lynch PM. Ed(s) **Buzdar AU**, Freedman RS. Gastrointestinal Cancer. In: M.D. Anderson Cancer Care Series. Springer-Verlag, 2005.
8. Chan KW, Raney RB, Ed(s) **Buzdar AU**, Freedman RS. Pediatric Oncology. In: M.D. Anderson Cancer Center Care Series. Springer-Verlag, 2005.
9. Eifel PJ, Gershenson DM, Kavanagh JJ, Silva EG. Ed(s) **Buzdar AU**, Freedman RS. Gynecologic Cancer. In: M.D. Anderson Cancer Care Series. Springer Science+Business Media Inc., 2006.
10. **Aman U. Buzdar**. Ed(s) Aman U. Buzdar. Endocrine Therapies in Breast Cancer. Oxford Oncology Library: Oxford, UK, 2007.
11. DeMonte F, Gilbert MR, Mahajan A, McCutcheon IE. Ed(s) **Buzdar AU**, Freedman RS. Tumors of the Brain and Spine. In: M.D. Anderson Cancer Care Series. Springer Science+Media, LLC: New York, 2007.

Letters to the Editor

1. **Buzdar AU**, Eckles N, Tashima CK. Estrogen therapy and metastatic breast cancer. *Jama*, 6/1977.
2. Krutchik AN, **Buzdar AU**, Tashima CK. Azathioprine and breast carcinoma. *Jama* 239:107, 1978.
3. Krutchik AN, **Buzdar AU**. Liver metastases vs. granulomas: A caveat. *Ann Intern Med* 88:844-845, 1978.
4. Krutchik AN, **Buzdar AU**. Liver scanning in breast cancer. *Arch Surg* 113:1110, 1978.
5. Krutchik AN, Tashima CK, **Buzdar AU**, Blumenschein GR. Longitudinal nail banding associated with breast carcinoma unrelated to chemotherapy. *Arch Intern Med* 138:1302-1303, 1978.
6. **Buzdar AU**, Legha SS, Hortobagyi GN, Blumenschein GR. Drug-associated cardiotoxicity. *Jama* 241:1893, 1979.
7. Legha SS, Blumenschein GR, **Buzdar AU**, Hortobagyi GN. Hormone receptors in breast cancer and response to chemotherapy. *N Engl J Med* 300:1053, 1979.
8. DiStefano AD, **Buzdar AU**. Viral-induced remission in chronic lymphocytic leukemia? *Arch Intern Med* 39:946, 1979.
9. Krutchik AN, **Buzdar AU**, Tashima CK, Blumenschein GR. Endobronchial metastases in breast cancer. *Chest* 74:319-320, 1980.
10. **Buzdar AU**, Smith T, Blumenschein GR. Adjuvant chemotherapy for early breast cancer. *Br Med J* 287:1141, 1983.
11. **Buzdar AU**, Frascini G, Blumenschein GR. Hematologic adverse effects of aminoglutethimide. *Ann Intern Med* 100:159, 1984.
12. **Buzdar AU**, Hortobagyi GN. Long-term tamoxifen adjuvant therapy in node positive breast cancer. *Breast Cancer Res Treat* 6:149-150, 1985.
13. **Buzdar AU**, Hortobagyi GN. Adjuvant therapy for breast cancer. *Jama* 255(17):2296, 1986.
14. Hortobagyi GN, **Buzdar AU**. Progress in inflammatory breast cancer: Cause for cautious optimism. *J Clin Oncol* 4:1727-1729, 1986.
15. **Buzdar AU**, Ellerbroek NA, Libshitz HI. Osteolysis of the Clavicle. *Jama* 260(21):3129, 1988.
16. **Buzdar AU**, Hortobagyi GN. Sixteen-Week, Dose-Intense Chemotherapy in Adjuvant Treatment of Breast Cancer. *JNCI* 82(14):1220, 1990.
17. Jaiyesimi IA, **Buzdar AU**, Ross MA. Carcinoma of the male breast. *Ann Int Med* 118(9):749, 1993.
18. Valero V, **Buzdar AU**, Hortobagyi GN. Regarding: Valero V, Buzdar AU, Hortobagyi GN: Locally Advanced Breast Cancer - Author's Response . *The Oncologist* 1:278-279, 1996.

19. **Buzdar AU**, Hortobagyi GN. Tamoxifen and Toremifene in Breast Cancer: Comparison of Safety and Efficacy - Author's Response. *J Clin Oncol* 16:1999-2000, 1998.
20. **Buzdar AU**. Letrozole: Which Dose to be Used? . *J Clin Oncol* 18(8):1802-1803, 2000.
21. Nabholz JM, Bonnetterre J, **Buzdar A**, Robertson JFR, Thurlimann B, Steinberg M, Webster A, von Euler M. Is Anastrozole Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer? . *Journal of Clinical Oncology* 19(9):2578-2582, 2001.
22. Mackey JR, Joy AA, **Buzdar AU**, Brady C, Chaudri-Ross HA. Letrozole in Second-Line Therapy of Advanced Breast Cancer: More Questions Than Answers. *J Clin Oncol* 19:4353-4355, 2001.
23. **Buzdar AU**, Mouridsen H, Chaudri-Ross HA. Superior efficacy of letrozole versus tamoxifen as first-line therapy. *J Clin Oncol* 20(3):876-882, 2002.
24. Baum M, **Buzdar A**, Howell A. ATAC trial did not report interim results. *BMJ* 327(7422):1050, 2003.
25. Cuziek J, **Buzdar A**, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Adjuvant use of anastrozole in breast cancer. *JCO* 22(8):1524-1533, 2004.
26. **Buzdar AU**. Letrozole in breast cancer. *N Engl J Med* 350(7):727-730, 2004.
27. **Buzdar AU**. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. *JCO* 22(15):3199-3200, 2004.
28. **Buzdar AU**, Baum M, Cuzick J. Letrozole or tamoxifen in early breast cancer. *New England Journal of Medicine* 354(14):1528-30, 2006.
29. **Buzdar AU**. St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy. *Ann Oncol* 17(5):878-9, 2006.
30. Cuzick J, Sestak I, Baum M, **Buzdar A**, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. *Lancet Oncol* 11(12):1135-41, 12/2010.

Manuals, Teaching Aids, Other Teaching Publications

1. Segaloff A, Ansfield FJ, **Buzdar AU**, Tall RW. A Round Table Discussion for Bristol. 6/1982.
2. **Buzdar AU**. Adjuvant chemotherapy for stage II and III breast cancer. 1983.
3. **Buzdar AU**. Endocrine therapy in the management of advanced breast cancer. 1983.
4. **Buzdar AU**. Future direction of adjuvant and preventive therapy of breast cancer. 27, 11-15, 1987.
5. **Buzdar AU**. The Reviewed Monograph on Trilostane for American Society of Hospital Pharmacists. 1987.
6. **Buzdar AU**. Pitfalls and Controversies in Diagnosis and Treatment. 28, 4, 35-45, 1988.
7. **Buzdar AU**. Status of Adjuvant Therapy in Breast Cancer. 3, 1, 1-7, 1988.
8. Hortobagyi GN, **Buzdar AU**. 17 Years' experience with anthracycline-containing regimens at the M.D. Anderson Cancer Center. 19-23, 1992.
9. Osborne CK, Bonadonna G, **Buzdar AU**, Davidson NE, Donegan WL, Margolese RG, Pritchard KI. Controversies in the Treatment of Early Breast Cancer. 6-29, 3/1993.
10. Utian WH, Ades TB, **Buzdar AU**, Osuch JR, Petrek JA, Pilgrim CA, Wilcox PM. Overcoming your patients' fear of breast cancer. 11/1994.
11. Ueno NT, **Buzdar AU**, Hortobagyi GN. Inflammatory Breast Cancer. 2, 4, 1-15, 1994.
12. **Buzdar AU**. Monograph on Breast Cancer: Endocrine Therapies. 1996.
13. Brodie AH, **Buzdar AU**, Goss P, Lonning PE, Miller WR. Optimizing Anti-Aromatase Agents in Breast Cancer: An Accredited Program for Physicians. 11/2000.
14. **Buzdar AU**, Elledge RM, Osborne CK. An Update on Aromatase Inhibitors as Therapy for Advanced Breast Cancer. *Discovery International*, 1/2001.
15. Hortobagyi G, Dixon JM, **Buzdar A**, Ganz P, Petrek JA. Conversations with Oncology Leaders: Bridging the gap between research and patient care. 7/2001.
16. **Buzdar AU**. Current Management of Breast Cancer: Metastasis. 10/2001.
17. **Buzdar AU** (Ed). Hormonal agents in the treatment of breast cancer: current status. 11/2002.
18. Come SE, **Buzdar AU** (Guest Editors). Recent advances and future directions in endocrine manipulation of breast cancer. 9, 1, 443s-532s, 2003.

19. Come SE, **Buzdar AU** (Guest Editors). Recent advances and future directions in endocrine manipulation of breast cancer. 10, 1, 327s-410s, 2004.
20. Come SE, **Buzdar AU** (Guest Editors). Recent advances and future directions in endocrine manipulation of breast cancer. 11, 2, 861s-962s, 2005.
21. Come SE, **Buzdar AU** (Guest Editors). Recent advances and future directions in endocrine manipulation of breast cancer. 12(3). Clinical Cancer Research, 997s-1068s, 2006.

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Editorial Board, Year Book of Cancer, 1980–1988

Editorial Board, Revista Mexicana de Mastologia - Asociacion Mexicana De Mastologia, 1990–present

Editorial Board, Mamogramma, 1992–present

Editorial Board, Cancer Bulletin, 1993–1995

Editorial Board, Hippocrates, 2000–2001

Guest Editor, Seminars in Breast Disease, Hormonal Aspects of Breast Cancer, 2000

Editorial Board, American Journal of Cancer, 2001

Guest Co-Editor, Clinical Cancer Research, Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer, 2001

Editorial Board, Clinical Cancer Research, 2001

Associate Editor, Clinical Cancer Research, 2001–present

Editorial Academy, International Journal of Oncology, 2002

Editorial Board, The American Journal of Oncology Review, 2002

Editor, Breast Cancer: Management and Treatment, 2002–present

Guest Co-Editor, Clinical Cancer Research, Proceedings of the Second International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer, 2003

Guest Co-Editor, Clinical Cancer Research, Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer, 2004

Member of Editorial Review Board

N/A

Journal Reviewer

Annals of Internal Medicine

Archives of Internal Medicine

Breast Cancer and Treatment Report

Cancer

Cancer Treatment Report

Clinical and Experimental

Current Therapeutic Research

Journal of Clinical Oncology

New England Journal of Medicine

Other Editorial and Review Activities

Member, Editorial Advisory Board, Cancer, 2006–2009

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching



(b) (6)



Teaching Outside of Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

Supervisor, Physical Diagnosis 10-week Course, UT Medical School at Houston, 2nd year Medical Students, 1/1993-3/1993

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

Workshop on Medroxyprogesterone Acetate in Treatment of Breast Cancer, Milano, Italy, Chairman, 11/1989

9th Asia Pacific Cancer Conference, Choices of Local Treatment, Systemic Therapy for Stage II and III breast cancer - Current Status, and Treatment Approaches for Patients with Metastatic Breast Cancer, Lahore, Pakistan, Chairman, 11/1989

International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer, Cambridge, MA, Co-Chairman, 6/2001

2nd International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer, Cambridge, MA, Co-Chairman, 6/2002

3rd International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer, Cambridge, MA, Co-Chairman, 7/2003

4th International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer, Cambridge, MA, Co-Chairman, 6/2004

7th Milan Breast Cancer Conference, Male Breast Cancer, Milan, Italy, Session Chairman, 6/2005

Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer, 5th International Conference, Cambridge, MA, Co-Chair, 6/2005

Asia Pacific Breast Cancer Summit, Guangzhou, China, Co-Chair, 3/2007

Endocrine and Targeted Manipulation of Breast Cancer, 6th International Conference, Cambridge, MA, Co-Chair, 4/2007

American Society of Breast Disease, 32nd Annual Symposium of the American Society of Breast Disease, San Diego, CA, Board Member, 4/2008

Independent Satellite Symposium, American Society of Clinical Oncology Education, Science, and Career Development Department, Orlando, FL, Co-Chair, 5/2009

Aromatase XI, A Satellite Meeting, Endorsed by The Endocrine Society / Presentation: Summary of AIs use in the Breast Cancer Treatments, Houston, TX, Co-Chair, 6/2012

Presentations at National or International Conferences

Invited

Adjuvant Therapy, International Conference of Adjuvant Therapy, Tucson, AZ, 3/1977

An intensive new adjuvant chemoimmuno-therapy program containing 5-fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC-BCG) for operable breast cancer, American Society of Clinical Oncology, Denver, CO, 5/1977

Adjuvant Chemoimmunotherapy of operable breast cancer -- Updated Report, American Society of Clinical Oncology, Washington, DC, 4/1978

Adjuvant Therapy of Operable Breast Cancer, International Meeting on Breast Cancer, Athens, Greece, 6/1978

Adjuvant therapy with immunotherapy of stage II and III breast cancer, XII International Cancer Congress, Buenos Aires, Argentina, 10/1978

Combination modality approach for inflammatory breast carcinoma -prolongation of disease-free interval and survival, XII International Cancer Congress, Buenos Aires, Argentina, 10/1978

Peptichemio vs. L-PAM, XI International Congress Chemotherapy, Buenos Aires, Argentina, 10/1978

Adjuvant therapy with 5-fluorouracil, adriamycin, cyclophosphamide and BCG (FAC-BCG) for stage II or III breast cancer, 2nd International Cancer Congress, Tucson, AZ, 3/1979

Peptichemio in the treatment for advanced refractory breast cancer - a phase II study, American Association for Cancer Research, New Orleans, LA, 5/1979

Peptichemio vs. L-PAM, 19th Interscience on Antimicro-agents and chemotherapy, Boston, MA, 10/1979

Adjuvant therapy with 5-FU, adriamycin, cyclophosphamide, and BCG for stage II, III breast cancer, IV Asian Cancer Conference, Bombay, India, 12/1979

Trioxifene mesylate in the treatment of advanced breast cancer - a phase I-II, 12th International Congress of Chemotherapy, Florence, Italy, 7/1981

Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen, Aromatase: New Perspectives for Breast Cancer, Key Biscayne, FL, 12/1981

Adjuvant chemotherapy and chemotherapy and additive hormone therapy, National Conference on Breast Cancer, New Orleans, LA, 3/1982

Breast Carcinoma/Basic Approaches to Adjuvant Therapy in Breast Cancer, International Conference on Advances in Adjuvant Therapy of Cancer, London, United Kingdom, 6/1982

Cancer, and Breast Cancer Treatment Regimens, Bristol Myers Panel Discussion, Chicago, IL, 6/1982

Hormone therapy of breast cancer, Bristol Myers Panel Discussion, New Orleans, LA, 6/1982

Treatment of Early Breast Cancer, National Cancer Institute, Lisbon, Portugal, 6/1982

Adjuvant therapy of breast cancer, 13th International Cancer Congress, Seattle, WA, 9/1982

Endocrine Therapy, Endocrine Therapy Symposium, Chicago, IL, 12/1982

Adjuvant chemotherapy for stage II or III Breast Cancer, 3rd Breast Cancer Working Conference EORTC, Amsterdam, Netherlands, 4/1983

Combined modality approach in breast cancer with isolated or multiple metastases, American Radium Society, Savannah, GA, 4/1983

Adjuvant Therapy Breast Cancer Corsi Nazionali Di Clinica, Oncologica Bologna, Bologna, Italy, 5/1983

Improved survival in metastatic breast cancer treated with combination chemotherapy - an experience of past 3 decades, 13th International Congress of chemotherapy, Vienna, Austria, 8/1983

Adjuvant Breast Cancer, 13th International Congress of Chemotherapy, Vienna, Austria, 9/1983

Endocrine Therapy of Breast Cancer, New Perspectives for Hormonal Treatment of Breast Cancer Conference, Chicago, IL, 10/1983

New Perspectives for Hormonal Treatment of Breast Cancer, Mini Symposium, St. Louis, MI, 10/1983

Bisantrene in Treatment of Breast Cancer, Investigator's Meeting, Pearl River, NY, 12/1983

Breast Cancer Adjuvant Therapy Trials, Fourth International Conference on the Adjuvant Therapy of Cancer, Tucson, AZ, 3/1984

Staging of Breast Cancer Estrogen Receptors-Endocrine Therapy, Providence St. Margaret Health Center, Kansas City, KS, 3/1984

Phase I trial of elliptinium acetate in advanced cancer, American Society of Clinical Oncology and American Association for Cancer Research, Toronto, Canada, 5/1984

Value of staging procedures for detection of recurrent disease in breast cancer patients and its impact on survival, American Society of Clinical Oncology and American Association for Cancer Research, Toronto, Canada, 5/1984

Adjuvant of Breast Cancer, Phoenix Oncology Society, Phoenix, AZ, 10/1984

Treatment of Advanced Stage III Breast Cancer and Adjuvant Treatment, Breast Cancer 1984: Surgical and Medical Management, Huntsville, AL, 10/1984

Adjuvant chemotherapy for cancer of the breast and management of metastatic disease, Breast Cancer Newer Trends in the Management, St. Joseph, MO, 11/1984

Prosorba, IMRE Annual Meeting & Review, Reno, NV, 1/1985

The Current Status of Novantrone, Symposium, Scottsdale, AZ, 3/1985

Adjuvant chemotherapy of operable breast cancer with doxorubicin-containing regimens - results of three trials, 14th International Congress of Chemotherapy, Kyoto, Japan, 6/1985

Adjuvant chemotherapy for Breast Cancer, NIH Consensus Development Conference, Bethesda, MD, 9/1985

Evaluation of the risk of breast cancer primary chemotherapy, Pre- and post-operative combination chemotherapy in breast cancer, Symposium, Liege, Belgium, 11/1985

Role of Protein A in Breast Cancer, IMRE Meeting, Honolulu, HI, 4/1986

Phase II study of Trilostane, American Society of Clinical Oncology and American Association for Clinical Research Annual Meetings, Los Angeles, CA, 5/1986

A comparative randomized trial of doxorubicin, cyclophosphamide in combination with fluorouracil (FAC) or etoposide (EAC) in metastatic breast cancer, 14th International Cancer Congress, Budapest, Hungary, 8/1986

Breast Cancer Adjuvant Therapy Trials of M. D. Anderson Hospital: Results of Three Studies, 5th International Conference on the Adjuvant Therapy of Cancer, Tucson, AZ, 3/1987

Is Chemotherapy Effective in Reducing the Local Failure Rate in Operable Breast Cancer Patients, American Society of Clinical Oncology and American Association for Cancer Research Annual Meetings, Atlanta, GA, 5/1987

Treatment of operable Breast Cancer with Emphasis on Adjuvant Therapy, and Treatment of Advanced Breast Cancer, Hospital De Maternidad and in the Instituto Del Cancer De El Salvador, San Salvador, El Salvador, 6/1987

Combined modality approach in inflammatory carcinoma of the breast - preliminary results of a prospective study, 15th International Congress of Chemotherapy, Istanbul, Turkey, 7/1987

Concepto Actual de la Qt. Neoadjuvant en Cancer Mamario, XIV Jornadas Nacionales de Cancerologia, Morelia, Mexico, 10/1987

Chemotherapeutic Approaches to Advanced Breast Cancer, Perspectives on Cancer Treatment, Madrid, Spain, 11/1987

Adjuvant Therapy of Node-Positive & Node-Negative Breast Cancer, 5th Annual International Breast Seminar, Miami, FL, 3/1988

Elliptinium Acetate in Treatment of Advanced Breast Cancer - A Phase II Study, American Society of Clinical Oncology and American Association for Cancer Research Annual Meetings, New Orleans, LA, 5/1988

Role of Systemic Therapy in patients with Operable Breast Cancer, Early Breast Cancer, Midland, MI, 9/1988

Phase I-II Study of Monoclonal Antibody (monab B72.3) in Patients with Breast Cancer, Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA, 1/1989

Combined modality approach in treatment of inflammatory carcinoma-results of a prospective study, American Society of Clinical Oncology/American Association for Clinical Research, San Francisco, CA, 5/1989

Evaluation of the risks and benefits of doxorubicin-containing adjuvant chemotherapy - M. D. Anderson Cancer Center Experience, 16th International Congress of Chemotherapy, Jerusalem, Israel, 6/1989

Adjuvant Therapy in Breast Cancer, and Controversies in Breast Cancer, III Medical Biennial Meeting, San Angel, Mexico, 3/1990

Inferior Disease-free Survival of Following <6 Cycles of FAC Adjuvant Chemotherapy for Operable Breast Cancer, American Society of Clinical Oncology and American Association for Cancer Research Annual Meetings, Washington, DC, 5/1990

Endocrine Management of Metastatic Disease, Sixth International Congress on Breast Disease, Boston, MA, 6/1990

Adjuvant therapy N0, Combined modality approach of advanced primary breast cancer, and Prognostic factors in T1N0 breast cancer, Second National Symposium on Cancer, Panama City, Panama, 7/1990

Supportive care of the Chemotherapy Patient, CCOP Lectures Series, Long Beach, CA, 11/1990

Combined modality approach in Treatment of Inflammatory Carcinoma of the Breast - M. D. Anderson Experience, Third International Congress on Neo-adjuvant Chemotherapy, Paris, France, 2/1991

Terapeutica Adjuvante, 10 Simposio Internacional Sobre Cancer Inicial de MaMa, Clube de MaMa, Rio de Janeiro, Brazil, 7/1991

Tratamiento actual integrado en cancer avanzado, II Venezuelan Congress, Caracas, Venezuela, 10/1991

Cancer Breast - Treatment, 3rd International Conference of Pakistan Association of Pathologists, Lahore, Pakistan, 11/1991

Hormonal therapy of advanced breast cancer, Adjuvant therapy of advanced Breast Cancer, King Edward Medical College Alumni Association, Lahore, Pakistan, 12/1991

Adjuvant Therapy for Breast Cancer: The M. D. Anderson Experience, Controversies in the Treatment of Early Breast Cancer and the Treatment of Gynecological Cancer., St. Louis, MO, 3/1992

Adjuvant chemotherapy for breast cancer with fluorouracil, adriamycin, cyclophosphamide (FAC) with or without BCG and with or without post-operative irradiation (XRT) - A prospective randomized study, American Society of Clinical Oncology and American Association for Cancer Research Annual Meeting, St. Louis, MI, 4/1992

Sequence of chemotherapy and irradiation and its impact on local control in management of operable breast cancer, American Radium Society, Orlando, FL, 4/1992

A phase I trial of droloxifene in 30 patients with metastatic breast cancer, American Society of Clinical Oncology and American Association for Cancer Research Annual Meetings, San Diego, CA, 5/1992

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy, 7th International Congress on Senology, Rhodes, Greece, 5/1992

Participation and Discussion in the First Expert Meeting on Aromatase Inhibitors in Breast Cancer, Sponsored by Janssen Pharmaceuticals, Dordrecht, Netherlands, 9/1992

Systemic therapy of early breast-plenary lecture, Inflammatory breast cancer - M. D. Anderson Cancer Center Experience, and Treatment of Advanced Breast Cancer - Recent Developments, First Conference Internacional de Cancer, Rio de Janeiro, Brazil, 9/1992

Current status of adjuvant therapy; Prognostic factor in early breast cancer; Management of locally advanced breast cancer and inflammatory cancer; and New drugs for treatment of breast cancer, VIII Congreso Latinoamericano De Mastologia, Montevideo, Uruguay, 11/1992

Natural History of Male Breast Cancer, FDA Advisory Committee Rockville, regarding approval of indication of tamoxifen for treatment of male breast cancer, Bethesda, MD, 11/1992

Treatment of Stage III Breast Cancer, 2nd International Oncology Conference, Karachi, Pakistan, 11/1992

Adjuvant Therapy of Breast, 2nd Annual Oncology Care Conference, Lansing, MI, 3/1993

Bioavailability of 20 mg tamoxifen citrate (Nolvadex(R)-D) Once a day to 10 mg administered twice daily in patients with breast cancer - results of a prospective randomized trial, 7th International Conference on the Adjuvant Therapy of Cancer, Tucson, AZ, 3/1993

Cancer Adjuvant Therapy Trials of MD Anderson Cancer Center - Results of Four Prospective Studies, 7th International Conference on the Adjuvant Therapy of Cancer, Tucson, AZ, 3/1993

Controversies and Challenges of Breast Cancer, 2nd Annual Oncology Nursing Meeting, Lansing, MI, 3/1993

Long-term efficacy and toxicities of doxorubicin-containing adjuvant therapy in breast cancer - M. D. Anderson Cancer Center Studies, Fourth International Congress on Anti-cancer Chemotherapy, Paris, France, 3/1993

Neoadjuvant and adjuvant therapy of breast cancer, Neoadjuvant and Adjuvant Therapy for Selected Malignancies, New Brunswick, NJ, 4/1993

Bioavailability of 20 mg tamoxifen citrate (Nolvadex(R)) once a day to 10 mg administered twice daily in patients with breast cancer, American Society of Clinical Oncology, Orlando, FL, 5/1993

Increased risk of second primary breast cancer after radiotherapy for treatment of breast cancer, American Association for Cancer Research Annual Meeting, Orlando, FL, 5/1993

Evaluation and clinical application of prognostic factors in breast cancer, International Symposium on New Developments in Breast Cancer, Wilsede, Germany, 6/1993

Early Diagnosis and Role of Screening Mammography, ACT - AAPI - MCI Symposium on Recent Advances in Oncology, New Delhi, India, 12/1993

Experience at M. D. Anderson Cancer Center, ACT - AAPI - MCI Symposium on Recent Advances in Oncology, New Delhi, India, 12/1993

Role of Adjuvant Chemotherapy, ACT - AAPI - MCI Symposium on Recent Advances in Oncology, New Delhi, India, 12/1993

Taxol in the Treatment of Cancer, The Louisville Oncology Symposium, Louisville, KY, 3/1994

Role of doxorubicin-containing chemotherapy in early breast cancer. The M. D. Anderson experience, International Oncology Meeting under the patronage of the AIO, The Role of Continuous infusion in the treatment of solid tumors, 4/1994

Secondary therapies in advanced breast cancer, International Oncology Meeting under the patronage of the AIO, The Role of Continuous Infusion in the Treatment of Solid Tumors, 4/1994

Adjuvant treatment of breast cancer, 8th International Congress on Senology, Rio de Janeiro, Brazil, 5/1994

Induction chemotherapy, 9th International Congress on Senology, Rio de Janeiro, Brazil, 5/1994

Locally advanced breast cancer, 8th International Congress on Senology, Rio de Janeiro, Brazil, 5/1994

Systemic treatment of breast cancer, 8th International Congress on Senology, Rio De Janeiro, Brazil, 5/1994

Study T 301 - A Randomized Double-Blind, placebo controlled, phase II trial comparing sandostatin LAR, Joint Sandoz U.S.A. and Canada Investigators Meeting, Montreal, Quebec, Canada, 6/1994

Adjuvant Therapy of Breast cancer - Current Status, Combined Modality Approach Stage III Disease, XIII Congresso Brasileiro De Cancerologia, Rio de Janeiro, Brazil, 9/1994

Stage I Disease - Who to treat; with what?, XIII Congresso Brasileiro De Cancerologia, Rio de Janeiro, Brazil, 9/1994

Treatment of Breast Cancer, Use of Taxanes, Fifth Alabama Cancer Congress, Perdido Beach, AL, 10/1994

Doxorubicin-containing adjuvant therapies-M. D. Anderson Cancer Center - 20 Years Experience, Fifth International Congress on Anti-Cancer Chemotherapy, Baxter Satellite Symposium Advances in Cancer, Paris, France, 1/1995

Randomized phase III study of the new selective aromatase inhibitor arimidex (A) (ZD1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer, Zeneca Satellite Symposium, Nottingham, London, United Kingdom, 9/1995

Navelbine in Treatment of Metastatic Breast Cancer: US Experience, IX Congresso Brasileiro De Oncologia Clinica, Belo Horizonte, Brazil, 10/1995

Avances en Oncologia clinica y Experimental, La Fundacion Clinca Medica Sur, A.C., Mexico, 11/1995

Adjuvant Therapy in Breast Cancer, 8th International Conference on the Adjuvant Therapy of Cancer, Scottsdale, AZ, 3/1996

Clinical phase III studies of new aromatase inhibitors with emphasis on Arimidex, and some data on Fadrozole phase III studies, 4th International Aromatase Conference, Tahoe City, CA, 6/1996

Arimidex®: An overview of the efficacy and tolerability of Arimidex® compared with Megestrol Acetate in postmenopausal women with advanced breast cancer, Canadian National Symposium, Toronto, Ontario, Canada, 9/1996

Impact of patient characteristics on treatment outcomes: anthracycline resistance, 7th EORTC Breast Cancer Working Conference, Bordeaux, France, 9/1996

Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer, Complexities in Breast Cancer Management, Fred Hutchinson Cancer Research Center, Seattle, WA, 10/1996

Is there any place for hormonotherapy and chemotherapy combination?, 10th International Meeting European Society of Gynaecological Oncology, Coimbra, Portugal, 4/1997

Significant improved survival with Arimidex® (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials, 33rd Annual Meeting of the American Society of Clinical Oncology, Denver, CO, 5/1997

Newer chemotherapies in breast cancer and Neoadjuvant therapies and hormonal therapy, 10th Annual Oncology Update Conference: Breast Cancer, Bismarck, ND, 9/1997

Endocrine Therapy in Breast Cancer Treatment, Breast Cancer in the 21st Century, Novi, MI, 10/1997

Adjuvant chemotherapy in patients with breast cancer, Satellite Symposium: Strategies on Treatment of Breast Cancer, Berlin, Germany, 11/1997

Anthracyclines – still up-to-date in state-of-the-art treatment of breast cancer?, 17th Annual Meeting of the German Society for Senology, Berlin, Germany, 11/1997

Aromatase inhibitor in management of breast cancer, SOMPS Symposium, Paris, France, 2/1998

Axillary lymph node dissection in breast cancer, 8th International Congress on Anti-Cancer Treatment, Paris, France, 2/1998

Protection of human subject from risk of clinical research and informed consent, 8th International Congress on Anti-Cancer Treatment, Paris, France, 2/1998

The place of chemotherapy in the treatment of early breast cancer, 6th International Conference of Adjuvant Therapy of Primary Breast Cancer, St. Gallen, Switzerland, 2/1998

Alternative Options and Complementary Treatments, 10th International Congress on Senology, Oporto, Portugal, 6/1998

Genetic Screening, 10th International Congress on Senology, Oporto, Portugal, 6/1998

Role of aromatase inhibitors in advanced disease, International Symposium Aromatase and Its Inhibitors: New biology and Clinical Perspectives, Prague, Czech Republic, 9/1998

Tamoxifen for the Prevention of Breast Cancer...An Overview of Randomized Trials, Safeguarding the Health of Women at High Risk for Breast Cancer, Managed care Consensus Panel, Atlanta, GA, 1/1999

Recent Advances in Early and Advanced Breast Cancer, 9th International Congress on Anti-Cancer Treatment, Paris, France, 2/1999

Neoadjuvant therapy in stage III and inflammatory carcinoma, 16th Annual Miami Breast Cancer Conference, Miami, FL, 3/1999

New directions in hormonal therapy: Update on aromatase inhibitors, 16th Annual Miami Breast Cancer Conference, Miami, FL, 3/1999

Prospective, randomized study of taxol versus FAC as neoadjuvant therapy in patients with operable breast cancer, 3rd Pan-European Interactive Forum: New Strategies on the Management of Breast Cancer, Marrakech, Morocco, 3/1999

Reevaluation of high dose chemotherapy; patients most likely to benefit, 16th Annual Miami Breast Cancer Conference, Miami, FL, 3/1999

Endocrine Therapy Update – Early and Advanced Disease, Genesis Medical Center Grand Rounds, Davenport, IA, 4/1999

Endocrine Therapy for Metastatic Breast Cancer, The 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, 5/1999

Oncology Workshop, Breast Cancer Prevention: Incorporating New Data into Clinical Practice, New Haven, CT, 7/1999

Recent advances in early and advanced breast cancer, The 2nd Biennial Meeting of Asian Breast Cancer Society, Tianjin, China, 9/1999

Update in Adjuvant Treatment of Breast Cancer, Advances in Comprehensive Breast Cancer Management, Louisville, KY, 9/1999

Breast Cancer, 11th Brazilian Congress of Clinical Oncology, Florianopolis, Brazil, 10/1999

Reducing the Incidence of Breast Cancer in Women with High Risk, 10th Annual Hematology-Oncology Symposium, Avon, CT, 10/1999

Taxol vs FAC in Trial of Neoadjuvant Therapy in Early Breast Cancer, Chemotherapy Foundation Symposium XVII, New York City, NY, 11/1999

Non-steroidal treatments for breast cancer (aromatase-inhibitors), 2nd Biennial International Meeting of the Flemish Gynaecological Oncology Group: The Oestrogen Receptor and its Selective Modulators in Gynaecological Oncology, Brussels, Belgium, 12/1999

What is the optimal duration of chemotherapy in advanced breast cancer?, 10th International Congress on Anti-Cancer Treatment, Paris, France, 2/2000

Anastrozole (Arimidex) Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer (ABC) in Postmenopausal (PM) Women Combined Analysis from Two Identically Designed Multicenter Trials, 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 5/2000

Anastrozole versus Tamoxifen in Postmenopausal Women with Advanced Breast Cancer, 8th Annual Meeting of the Japan Breast Cancer Society, Yokohama, Japan, 5/2000

High-Dose Chemotherapy State of the Art, XI International Congress of Senology, Cancun, Mexico, 5/2000

Neoadjuvant Chemotherapy, XI International Congress of Senology, Cancun, Mexico, 5/2000

New Hormonal Compounds, XI International Congress of Senology, Cancun, Mexico, 5/2000

What's New in Endocrine Therapy?, Approaches to Treating Breast Cancer, Columbus, OH, 5/2000

ASCO Roundup 2000, Southern California Academy of Clinical Oncology, Los Angeles, CA, 6/2000

Third-Generation Aromatase Inhibitors, 2nd International BCIRG Conference, Edmonton, Canada, 6/2000

The Role of Arimidex in the First-Line Treatment of Advanced Breast Cancer and Beyond, Arimidex Symposium, Cincinnati, OH, 8/2000

Anastrozole (AN) versus Tamoxifen (TAM) as First-Line Therapy for Advanced Breast Cancer (ABC) in Post-menopausal (PM) Women. Findings Highlight the Importance of Receptor Status Assessment Prior to Treatment Initiation, 25th ESMO Congress, Hamburg, Germany, 10/2000

New Agents for the Management of Metastatic Breast Cancer, International Breast Cancer Symposium, Taipei, Taiwan, 10/2000

New Developments of Endocrine Therapy of Early and Advanced Breast Cancer, International Breast Cancer Symposium, Taipei, Taiwan, 10/2000

Arzoxifene (LY353381) A Novel SERM for the Treatment of Breast Cancer, Aromatase 2000 and 3rd Generation, Port Douglas, Australia, 11/2000

Summary of Second Line Randomized Studies of Aromatase Inhibitors, Aromatase 2000 and 3rd Generation, Port Douglas, Australia, 11/2000

Treatment Strategy for Metastatic Breast Cancer with a New Generation Aromatase Inhibitor, Cancer with Hormonal Agents Meeting, Tokyo, Japan, 11/2000

Current Knowledge of Aromatase Inhibitors Gained from 2nd Line Randomized Studies, Adjuvant Therapy of Primary Breast Cancer, 7th International Conference, St. Gallen, Switzerland, 2/2001

The Role of 'Arimidex' (Anastrozole) in the First-Line Treatment of Advanced Breast Cancer and Beyond, AstraZeneca Singapore, Singapore, 2/2001

Hormonal Therapy in Breast Cancer, 14th Annual National Cancer Symposium, Chicago, IL, 4/2001

Update on Adjuvant Therapy Role of Paclitaxel, CAMO Satellite Symposium, Montreal, Canada, 4/2001

Breast Cancer, 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, 5/2001

Meet the Professor Session: Neoadjuvant Chemotherapy for Breast Cancer, 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, 5/2001

Are differences in the available aromatase inhibitors and inactivators significant?, Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer, Cambridge, MA, 6/2001

Recent Advances in Selective Aromatase Inhibitors in the Treatment of Breast Cancer, Hong Kong College of Radiologists and Hong Kong Society of Radiation Therapy and Oncology, Hong Kong, China, 6/2001

Anti-PTHrP Antibody, Targeted Therapies in the Treatment of Breast Cancer, Colorado Springs, CO, 7/2001

Recent Advances in Aromatase Inhibitor Therapy, Targeted Therapies in the Treatment of Breast Cancer, Colorado Springs, CO, 7/2001

Faslodex – A New Hormonal Therapy, Challenging Cases in Breast Cancer, Boston, MA, 8/2001

Metastatic Breast Cancer, Challenging Cases in Breast Cancer, Boston, MA, 8/2001

Aromatase Inhibitors, Mexican Oncology Symposium, Morelia, Mexico, 10/2001

Optimal Sequencing of Endocrine Therapies for Primary and Metastatic Breast Cancer and Non-Invasive Breast Disease, Lynn Sage Breast Cancer Symposium, Chicago, IL, 10/2001

Endocrine Sequencing in Metastatic Breast Cancer, IMPACT 2002 Breast Cancer Program, Banff, Alberta, Canada, 2/2002

Arimidex for Adjuvant Therapy of Early-Stage Breast Cancer in Postmenopausal Women, Endocrine Therapy and Breast Cancer: An Update for Oncologists, Seattle, WA, 5/2002

Arimidex for Adjuvant Therapy of Early-Stage Breast Cancer in Postmenopausal Women, American Society of Clinical Oncology Annual Meeting, Orlando, FL, 5/2002

Aromatase Inhibitors in Advanced Breast Cancer, Endocrine Therapy and Breast Cancer: An Update for Oncologists, Seattle, WA, 5/2002

Aromatase Inhibitors – Pharmacologic Differences?, International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer, Cambridge, MA, 6/2002

ATAC: What Does It Mean?, NSABP Meeting, Denver, CO, 6/2002

Third-Generation Aromatase Inhibitors, BCIRG Conference, Los Angeles, CA, 6/2002

First Line Hormonal Therapy for Postmenopausal Breast Cancer Patients Should Include an Aromatase Inhibitor – Pro, SAO 15th Annual Meeting, Destin, FL, 7/2002

Recent Advances in Aromatase Inhibitor Therapy, 5th Annual Opinion Leader Summit, Maui, HI, 7/2002

Aromatase Inhibition as Adjuvant Therapy, Future of Breast Cancer, An International Breast Cancer Congress, Paradise Island, Bahamas, 8/2002

Towards a Future of Even Greater Promise, Global Breast Cancer Summit, Cannes, France, 9/2002

Aromatase Inhibitors in the Prevention of Breast Cancer: Implications from the Initial ATAC Adjuvant Therapy Data, American Association for Cancer Research Annual Meeting, Boston, MA, 10/2002

ATAC Outcome Data: Efficacy Analyses, Aromatase 2002: The New Millennium, Kyoto, Japan, 10/2002

The ATAC Trial and Its Implications, 4th Annual Lynn Sage Symposium, Chicago, IL, 11/2002

ATAC Update, 20th Annual Miami Breast Cancer Conference, Miami, FL, 2/2003

Progress in Systemic Therapy in Metastatic Breast Cancer, 5th Annual Palm Beach Cancer Symposium: Emerging Paradigms in Cancer Care, Delray Beach, FL, 3/2003

Blocking Oestrogen-Mediated Growth in Breast Cancer: Current Treatment Options, Novel Approaches to Treatment in Hormone-Sensitive Breast Cancer, The Royal College of Surgeons, London, United Kingdom, 5/2003

Phase I TAS-108, American Association for Cancer Research Annual Meeting, Washington, DC, 7/2003

Counterpoint: Anastrozole is the New Standard of Care for Postmenopausal Early Breast Cancer, 2nd International Breast Cancer Congress, Banff, Alberta, Canada, 8/2003

Hormonal Therapy for Advanced Breast Cancer, 7th Annual Fall Oncology Conference: Focus on Solid Tumors and Supportive Care, Hilton Head, SC, 10/2003

Role of Anastrozole in the Treatment of Postmenopausal Women with Early Breast Cancer, 41st Annual Meeting of the Japan Society of Clinical Oncology, Sapporo, Japan, 10/2003

The Importance of Keeping Breast Cancer Guidelines Up to Date, Global Breast Cancer Summit, Madrid, Spain, 11/2003

Are Aromatase Inhibitors Superior to Tamoxifen After Menopause?, International Meeting of the Endocrine Treatment & Prevention of Breast and Gynaecological Cancers, Brussels, Belgium, 1/2004

Advances in Hormone Therapy for Breast Cancer, The 4th Biennial Meeting of Asian Breast Cancer Society and The 2nd Taipei International Breast Cancer Symposium, Taipei, Taiwan, 2/2004

First Choice Hormonal Therapy for Early Breast Cancer – Anastrozole (Arimidex) or Tamoxifen?, The 4th Biennial Meeting of Asian Breast Cancer Society and The 2nd Taipei International Breast Cancer Symposium, Taipei, Taiwan, 2/2004

New Endocrine Agents, 4th International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer, Cambridge, MA, 6/2004

Significantly Higher Pathological Complete Remission (PCR) Rate Following Neoadjuvant Therapy with Trastuzumab (Herceptin), Paclitaxel and Anthracycline-Containing Chemotherapy: Initial Results of a Randomized Trial in Operable Breast Cancer Patients with, 2004 American Society of Clinical Oncology Annual Meeting, New Orleans, LA, 6/2004

Clinical Update: Optimizing Sequence of HT Therapies in the Adjuvant and Advanced Settings, 7th Annual Targeted Therapies for the Treatment of Breast Cancer Investigator's Meeting, Beaver Creek, CO, 7/2004

Trastuzumab in the Neoadjuvant Setting, 7th Annual Targeted Therapies for the Treatment of Breast Cancer Investigator's Meeting, Beaver Creek, CO, 7/2004

Aromatase Inhibitors: Breast Cancer Therapy, Aromatase 2004, Edinburgh, Scotland, 9/2004

Novel Treatment Strategies with Targeted Therapy in Breast Cancer, Lynn Sage Breast Cancer Symposium, Chicago, IL, 10/2004

Trastuzumab, Controversies in Breast Cancer, Adjuvant and Neoadjuvant Therapy 2004, New York City, NY, 10/2004

Remission Rate Advantage with Neoadjuvant Trastuzumab, Paclitaxel, and Epirubicin-Containing Chemotherapy, Chemotherapy Foundation Symposium XXII: Innovative Cancer Therapy for Tomorrow, New York City, NY, 11/2004

Controversies in Systemic Therapy of Early Breast Cancer: A debate of clinical researchers, Breast Cancer Update, San Antonio, TX, 12/2004

Herceptin primary systemic therapy: important information to guide Herceptin treatment, 9th International Conference Herceptin Satellite Symposium, St. Gallen, Switzerland, 1/2005

Neoadjuvant Herceptin Trials, American College of Surgeons Oncology Group 2005 Meeting, San Antonio, TX, 1/2005

Controversies in Breast Cancer, Southern California Academy of Clinical Oncology 11th Oncology Seminar, Los Angeles, CA, 2/2005

Interdisciplinary Management of Early Breast Cancer: A Case-Based Interactive Tumor Panel Discussion, 58th Annual Cancer Symposium, The Society of Surgical Oncology, Atlanta, GA, 3/2005

Integrating Aromatase Inhibitors into Therapy, American Society of Breast Disease 29th Annual Symposium, Las Vegas, NV, 4/2005

MBC and NAC with Herceptin + Taxol, 5th Biennial Meeting of the Asian Breast Cancer Society, Tokyo, Japan, 4/2005

Update on the Use of Trastuzumab in the Neoadjuvant Setting, New Strategies in Breast Cancer 2005, Philadelphia, PA, 4/2005

ATAC Trial Results, Primary Hormonal Update and Specialists Education Program, Boston, MA, 5/2005

Toxicities of Aromatase Inhibitors: Are all AI's Equal? How Should Toxicities be Managed?, Primary Hormonal Update and Specialists Education Program, Boston, MA, 5/2005

Controversies in Systemic Therapy of Breast Cancer, Breast Cancer Update, New York City, NY, 6/2005

Future Directions: M.D. Anderson phase I and II protocols, 27th Annual Participants' Scientific Meeting, Australian New Zealand Breast Cancer Trials Group, Perth, Australia, 7/2005

Individualizing Breast Cancer Treatment, 4th Annual Future of Breast Cancer, Southampton, Bermuda, 7/2005

M.D. Anderson Neoadjuvant trastuzumab (Herceptin), 27th Annual Participants' Scientific Meeting, Australian New Zealand Breast Cancer Trials Group, Perth, Australia, 7/2005

Your Most Challenging Cases in Breast Cancer, Reality Oncology, San Jose, CA, 8/2005

Breast Cancer - Tumor Biology, 18th Annual Asia-Pacific Cancer Conference, Seoul, Korea, Republic of, 9/2005

Management Strategies for Hormone Receptor Positive Breast Cancer in the Adjuvant Setting, Annenberg Center for Health Sciences, Irvine, CA, 9/2005

Update on NSABP B-41/ACOSOG Z1041, National Surgical Adjuvant Breast and Bowel Project Group Meeting, Baltimore, MD, 9/2005

Breast Cancer Scientific Data, Brazilian Society of Clinical Oncology Congress, Rio de Janeiro, Brazil, 10/2005

Novel Medical Approaches in Preoperative Therapy, 7th Annual Lynn Sage Breast Cancer Symposium, Chicago, IL, 10/2005

update on the Systemic Management of Early Stage Breast Cancer, American College of Surgeons 91st Annual Clinical Congress, San Francisco, CA, 10/2005

Role of Aromatase Inhibitors, Oncology World Congress, New York City, NY, 11/2005

An update on anastrozole (ATAC, ABCSG, ARNO), 5th International Meeting on Endocrine Treatment and Prevention of Breast and Gynaecological Cancer, The Flemish Gynaecological Oncology Group, Brussels, Belgium, 1/2006

Highlights from the 28th Annual SABCS Meeting, American School of Oncology, Chicago, IL, 2/2006

Highlights from the 28th Annual SABCS Meeting, American School of Oncology, San Francisco, CA, 2/2006

Aromatase Inhibitor Overview, 5th European Breast Cancer Conference, Nice, France, 3/2006

Preoperative (neoadjuvant) therapy in breast cancer - Current status and future perspectives, 106th Annual Congress of Japan Surgical Society, Tokyo, Japan, 3/2006

American College of Surgeons Oncology Group Meeting, ACSOG-NIH, Washington, DC, 4/2006

Clinical Trials and Innovation Report, American Society of Breast Disease, Las Vegas, NV, 4/2006

Herceptin use in early stage, high risk breast cancer and neoadjuvant settings, American Society of Breast Disease, Las Vegas, NV, 4/2006

Clinical features of joint symptoms observed in the 'Arimidex,' Tamoxifen, Alone or in Combination (ATAC) trial. American Society of Clinical Oncology, Atlanta, GA, 6/2006

Future of Endocrine Therapy, Biological Basis of Breast Cancer: Implications for Clinical Diagnosis and Treatment, Loews Coronado, San Diego, CA, 7/2006

Early Breast Cancer Trialists' Collaborative Group, Oxford Overview, Oxford, United Kingdom, 9/2006

Innovations in Targeted Therapies: Breast Cancer, Clinical Challenges in Cancer Medicine, 10th Annual Fall Oncology Conference, Hilton Head, SC, 9/2006

Neoadjuvant Therapy - The Houston Experience, Neoadjuvant Therapy in Early Breast Cancer, Biedenkopf Symposium, Frankfurt, Germany, 9/2006

Postmenopausal Women with Early Breast Cancer, Global Breast Cancer Summit Meeting, Barcelona, Spain, 9/2006

Hormone-Sensitive Adjuvant Breast Cancer Treatment: The end of Tamoxifen?, Vi Congreso De Sociedades Oncologicas, San Jose, Costa Rica, 10/2006

Meet the Professors, Breast Cancer Update Think Tank, Miami, FL, 1/2007

- Novel Preoperative Therapy Strategies, Current Trends in Breast Cancer, Seattle, WA, 1/2007
- Preoperative Trastuzumab-Containing Chemotherapy for HER2+ Patients, 24th Annual Miami Breast Cancer Conference, Miami, FL, 2/2007
- Rationally Designed Therapies for Patients with Breast Cancer, 24th Annual Miami Breast Cancer Conference, Miami, FL, 2/2007
- Timing-Duration Cardiac Toxicity Associated with Trastuzumab, 24th Annual Miami Breast Cancer Conference, Miami, FL, 2/2007
- Postmenopausal Women with Early Breast Cancer, Asia Pacific Breast Cancer Summit, Guangzhou, China, 3/2007
- Premenopausal Women with Early Breast Cancer: Overview of Current Situtation, Asia Pacific Breast Cancer Summit, Guangzhou, China, 3/2007
- Preoperative biologic therapy - anti-HER2 agents, Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions, National Institutes of Health, Bethesda, MD, 3/2007
- Oxford Overview Data - Local and Systemic Therapies of Breast Cancer, 31st Annual Symposium American Society of Breast Disease, San Francisco, CA, 4/2007
- Selectivity of Aromatase Inhibitors, 5th Central European Oncology Congress, Opatija, Croatia, 6/2007
- Future of Endocrine Therapy, Second Annual Biological Basis of Breast Cancer Conference: The Science amd Art of Clinical Care, Santa Monica, CA, 7/2007
- Treatment of Early Breast Cancer Discussion, The Best of ASCO 2007, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, 8/2007
- All Postmenopausal Women with Hormone Receptor Positive Early Stage Breast Cancer Should be Treated Initially with Aromatase Inhibitors, Breast Cancer, Third Annual Oncology Congress, San Francisco, CA, 9/2007
- Arimidex, ECCO Annual Meeting, Barcelona, Spain, 9/2007
- Aromatase Inhibitors in Adjuvant Therapy of Postmenopausal Hormone Receptor Positive Breast Cancer, 13th Annual Puerto Rico Breast Cancer Conference, Isla Verde, Puerto Rico, 10/2007
- New Agents to Increase Pathologic Complete Response and the Value of Pathologic Response, Surgical Management Following Neoadjuvant Therapy for Breast Cancer, 93rd Annual Clinical Congress, New Orleans, LA, 10/2007
- ATAC Trial: 100 months of follow up, Strategie Nel Trattamento del Carcinoma Mammario: Conferme e Novita, Venice, Italy, 1/25/2008
- ATAC Trial: 100 months of follow up, Aggiornamenti Sul Tumore Della Mammella: 2 Incontro, Parma, Italy, 1/30/2008
- ATAC:Results from 100 month follow-up, ATAC 100 - Longest Follow-up of Upfront Treatment for HR+ Postmenopausal Early Breast Cancer, AstraZeneca Turkey, Istanbul, Turkey, 3/8/2008
- Defending the Use of Anthracyclines, 2008 Era of Hope Controversy Session, Department of Defense Breast Cancer Research Program, Baltimore, MD, 6/27/2008
- Buzdar AU. Defending the use of anthracyclines, Medical Education Collaborative and the U.S. Army Medical Research and Material Command, Era of Hope 2008, Baltimore, MD, 6/27/2008

Adjuvant systemic treatment for early breast cancer, India Breast Cancer Symposia, Astrazeneca India, Bangalore, India, 7/21/2008

Current status of adjuvant chemotherapy in breast cancer: including the Oxford Overview Data, The First CCH International Breast Cancer Symposium, Breast Cancer Society of Taiwan and Changhua Christian Hospital, Changhua, Taiwan, 8/2/2008

Buzdar AU. Controversies in adjuvant therapy, Symposium Breast and Gynecologic Cancer, Paraguayan Society of Surgical Oncology, Asuncion, Paraguay, 8/8/2008

Buzdar AU. Review of current molecular predictors and profiles, Symposium Breast and Gynecologic Cancer, Paraguayan Society of Surgical Oncology, Asuncion, Paraguay, 8/8/2008

Breast Cancer Symposium, Best of ASCO, American Society of Clinical Oncology, Singapore Society of Oncology, and the Chapter of Medical Oncologists College of Physicians, Singapore, Singapore, 8/15/2008

Buzdar AU. ATAC 100 Update, Caribbean Oncology and Hematology Congress, Nassau, Bahamas, 9/4/2008

Buzdar AU. Adjuvant therapies of breast cancer - current status, Innovative Therapies in Breast Cancer, First Breast Cancer Symposium, Jacksonville, FL, 9/20/2008

Buzdar AU. New Options for Metastatic Breast Cancer, Institute for Medical Education and Research, New York City, NY, 10/16/2008

Buzdar AU. Breast Cancer Meet the Professors, Dr. Neil Love, Research to Practice, Miami, FL, 10/24/2008

Buzdar AU. New Options for Metastatic Breast Cancer, Institute for Medical Education and Research, San Francisco, CA, 10/29/2008

Buzdar AU. Updates on Chemotherapy for Frontline and Refractory Metastatic Breast Cancer, Current Trends in Breast Cancer, Physicians' Education Resource, Richmond, VA, 1/31/2009

Buzdar AU. Adjuvant Treatment Choice in Premenopausal Breast Cancer Patients - What's New?, Astrazeneca, Astrazeneca, Taiwan, China, 4/16/2009

Buzdar AU. Emerging Therapy Combinations for Metastatic Breast Cancer, Independent Satellite Symposium, American Society of Clinical Oncology, Education, Science, and Career Development Department, Orlando, FL, 5/29/2009

Buzdar AU. The Impact of Neoadjuvant Therapies for HER2neu+ Breast Cancers on Surgical Care, ACOSOG, ACOSOG, Weston, FL, 6/20/2009

10th International Congress on The Future of Breast Cancer, Physicians' Education Resource, Coronado, CA, 4/2011

Alliance Breast Committee Meeting, American College of Surgeons Oncology Group, Chicago, IL, 4/26/2011

ACOSOG 2011 Spring Meeting, American College of Surgeons Oncology Group, Chicago, IL, 5/2011

Breast Cancer Clinical Trials Planning Meeting, NCI Breast Cancer Steering Committee (BCSC), Rockville, MD, 5/2011

Breast Cancer GWAS Pharmacogenomics, Mayo-NIH Pharmacogenomics Research Network (PGRN) External Scientific Advisory Committee Meeting, Rochester, MN, 9/2011

Other, Including Scientific Exhibitions

Current Status and Future Directions in Treatment of Early and Advanced Breast Cancer, TEMA Medical Lecture Series, South Africa, 3/1/1998

Novel Preoperative Therapy Strategies, Current Trends in Breast Cancer, Physician's Education Resource, Pasadena, CA, 3/1/2008

ATAC: Results at 100 Months Follow-up, Symposia de ATAC, Astrazeneca, Mexico City, Mexico, 3/13/2008

Buzdar AU. Results of CALGB/CTSU 49907 and TBCRC 001, Best of ASCO, Singapore Society of Oncology, Singapore, Singapore, 8/14/2008

Seminar Invitations from Other Institutions

Treatment of early and advanced breast cancer, University Hospital, Athens, Greece, 6/1982

Treatment of early and advanced breast cancer, Highlights in Cancer, Part II, Moffitt Cancer Center, Tampa, FL, 10/1982

Current Concepts in Breast Cancer, Highlights in Cancer Part I, St. Vincent's Medical Center Cancer Education Program, Jacksonville, FL, 2/1983

Adjuvant Therapy: Who and How much?, Cancer Education Seminar on Breast Cancer, El Paso Radiation Treatment Center and El Paso County Tumor Registry, El Paso, TX, 3/1983

New Perspectives for Hormonal Treatment of Breast Cancer, University of Miami, Miami, FL, 11/1983

New Treatment of Breast Cancer, King Edward Medical College, Lahore, Pakistan, 1/1984

Review Course in Oncology, Armed Force Medical College, Rawalpindi, Pakistan, 1/1984

Diagnosis and Management of Breast Carcinoma, John Peter Smith Hospital, Fort Worth, TX, 4/1984

Adjuvant Therapy of Breast Cancer - M. D. Anderson Hospital Experience, Wayne State University, Detroit, MI, 7/1986

Treatment of Breast Cancer, Norwalk Hospital Grand Rounds, Norwalk, CT, 9/1987

Current Status of Adjuvant Therapy of Operable Breast Cancer, Chula Vista Community Hospital, San Diego, CA, 11/1987

Current Status of Treatment of Early and Advanced Breast Cancer, Hershey Medical School Grand Rounds, Hershey, PA, 11/1987

Treatment of Advanced Breast Cancer, St. Luke Hospital, Jacksonville, FL, 1/1989

Controversies in the Management of Breast Cancer, 11th Annual Cancer Symposium, Northwest Community Hospital, Arlington Heights, IL, 11/1989

Medical aspects: Overview, epidemiology, screening, staging, pathology, and treatment; Chemotherapy as standard therapy; Hormonal and biological options, and Multimodality Treatment: The M. D. Anderson Approach, Opelousas General Hospital presents Primary Breast Cancer: Treatment for the 1990's, Opelousas, LA, 4/1990

Current status of adjuvant therapy in operable breast cancer, University of Hawaii Research Cancer Center, West O'ahu, HI, 8/1990

Supportive care of the Chemotherapy Patient, CCOP Lectures, Cleveland Clinic, Cleveland, OH, 10/1990

BREAST CANCER - Treatment of Stage IIIA, Department of Internal Medicine Grand Rounds, University of Utah School of Medicine, Salt Lake City, UT, 11/1991

Current Status of Treatment of Breast Cancer, Khaber Medical College Peshawer, Peshawer, Pakistan, 10/1992

Current M. D. Anderson Studies with Paclitaxel in the treatment of breast cancer, Fox Chase Cancer Center, Boca Raton, FL, 3/1994

- Treatment of early and advanced breast cancer - Basis for rational treatment approaches, Salick Health Care, Inc, St. Monica, CA, 5/1994
- Status of treatment for both early and advanced breast cancer, Mercy-Baptist Cancer Center, New Orleans, LA, 6/1994
- Current Treatment of Early and Advanced Breast Cancer, Texas Tech Medical School, Lubbock, TX, 10/1994
- Breast Cancer: Controversies in Therapy, The University of Utah School of Medicine, Park City, UT, 4/1995
- Current Status of treatment of early and advanced breast cancer, Beth Israel Medical Center - North Division, New York City, NY, 4/1995
- Breast Cancer, Norwalk Hosiptal Medical Education Fund Program, Norwalk, CT, 1/1997
- Hormonal Treatment for Advanced Breast Cancer, Mary Bird Perkins Cancer Center, Baton Rouge, LA, 2/1997
- Prospective randomized trial of paclitaxel alone versus 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) as an induction chemotherapy in patients with operable breast cancer, Free University Hospital Workshop and Consensus Conference, Fox Chase Cancer Center, Puerto Rico, 3/1997
- Update on treatment of early and advanced breast cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada, 6/1997
- Advanced in endocrine therapy for the treatment of breast cancer, University of Rochester Cancer Center, Rochester, NY, 7/1997
- Emerging Strategies for Hormonal Therapy for Early and Advanced Breast Cancer, Cancer Conference Integris Baptist Medical Center, Oklahoma City, OK, 10/1997
- Advances in Oncology, Institut De Recherches Cliniques De Montreal, Montreal, Canada, 11/1998
- Controversies in Primary Management of Breast Cancer. The Role of Combined Modality Therapy, Sequencing of Therapy, Institut De Recherches Cliniques De Montreal, Montreal, Canada, 11/1998
- Developments in the Hormonal Management of Breast Cancer, Jewish General Hospital, Montreal, Canada, 11/1998
- Manipulation of Hormonal Therapy in the Next Millenium, Charles Lemoyne Hospital, Montreal, Canada, 11/1998
- The Role and Importance of Adjuvant Therapy for Breast Cancer, Chum Pavillion, Notre-Dame, Montreal, Canada, 11/1998
- Endocrine therapy, University of Pittsburgh, Pittsburgh, PA, 2/1999
- Neoadjuvant therapy of breast cancer, University of Pittsburgh, Pittsburgh, PA, 2/1999
- The role of aromatase inhibitors in the treatment of advanced breast carcinoma, Saint Francis Memorial Hospital Grand Rounds, San Francisco, CA, 4/1999
- Adjuvant Treatment in Poor Prognosis Patients – New Protocols with Taxanes and High Dose Chemotherapy, The M.D. Anderson Cancer Center Symposium, Albert Einstein Hospital, Sao Paulo, Brazil, 8/1999
- Incorporation of new drugs in the treatment of advanced breast cancer and advances in hormonal treatment of breast cancer, The M.D. Anderson Cancer Center Symposium, Albert Einstein Hospital, Sao Paulo, Brazil, 8/1999
- Update on Aromatase Inhibitors, Providence Hospital, Southfield, MI, 8/1999

Reducing the Incidence of Breast Cancer in Women with High Risk, St. Joseph Mercy Hospital, Pontiac, MI, 10/1999

Reducing the Incidence of Breast Cancer in Women with High Risk, Holy Cross Hospital, Ft. Lauderdale, FL, 10/1999

Reducing the Incidence of Breast Cancer in Women with High Risk, Kansas University Medical Center, Kansas City, KS, 1/2000

Update on the Role of Endocrine Therapy in the Treatment of Breast Cancer, Memorial Sloan-Kettering Cancer Center, New York City, NY, 4/2000

Update on the Role of Endocrine Therapy in the Treatment of Breast Cancer, Cancer Research Center, Honolulu, HI, 4/2000

ASCO Review, Cleveland Clinic Cancer Center, Cleveland, OH, 6/2000

Chemotherapeutic Management of Breast Cancer, 11th Annual Zalmen A. Arlin Solid Tumor Symposium, Tarrytown, NY, 9/2000

Role of Paclitaxel in Early Breast Cancer, Chemotherapy Foundation Symposium, New York City, NY, 11/2000

Endocrine Therapy of Early and Advanced Breast Cancer: An Update, Cancer Care in the New Millenium, St. Louis, MO, 4/2001

Breast Cancer and Hormone Therapy, Breast Journal Club Meeting, Jacksonville, FL, 10/2001

Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer, Yale University School of Medicine, New Haven, CT, 10/2001

Novel Agents in Breast Cancer, Advances and Controversies in Cancer Management, New York Methodist Hospital, New York City, NY, 3/2002

Estrogen Receptor Downregulators: A New Class of Breast Cancer Therapy for Hormone-Therapy for Hormone-Resistant Disease, Grand Rounds, Columbia University, New York City, NY, 4/2002

Estrogen Receptor Antagonists: Developments in Treatment for Patients with Metastatic Breast Cancer with Disease Progression Following Antiestrogen Therapy, Hematology/Oncology Cancer Center CME Grand Rounds, James P. Wilmot Cancer Center, Rochester, NY, 7/2002

Endocrine Therapy of Early & Advanced Breast Cancer: Recent Developments, Grand Rounds, Tacoma General Hospital, Seattle, WA, 9/2002

Update Endocrine Therapy: Early and Advanced Breast Cancer, 2nd Annual Karmanos Cancer Institute Breast Cancer Symposium, Karmanos Cancer Institute, Dearborn, MI, 9/2002

CrossFire Debate, Breast Cancer Tumor Board, Massachusetts General Hospital, Boston, MA, 5/2003

ATAC Trial and Hormonal Treatment of Breast Cancer, University of Michigan Medical School, Ann Arbor, MI, 6/2003

An Update of the ATAC Trial: Changing Care Standards in the Hormonal Therapy of Early Stage Breast Cancer, 6th Annual Changing Concepts in Breast Cancer, University of Pennsylvania, Philadelphia, PA, 9/2003

ATAC Trial Update, University Hospitals of Cleveland, Cleveland, OH, 9/2003

ATAC Trial Update, Tumor Conference, Cedar Rapids, IA, 10/2003

ATAC Trial Update, Tumor Conference, Des Moines, IA, 10/2003

Recent Advances in Adjuvant Therapy of Breast Cancer, Grand Rounds, John H. Stroger Hospital, Chicago, IL, 10/2003

Current Hormonal Therapies for Postmenopausal Women with Early-Stage Hormone Receptor-Positive Breast, Medical Education Program, William Beaumont Hospital, Royal Oak, MI, 8/2004

Breast Cancer (Update on Hormonal Therapy), Oncology Update 2004, LSU Medical School, New Orleans, LA, 9/2004

Current Update on the Therapy of Early Stage Breast Cancer, Hematology/Oncology Grand Rounds, Loma Linda University, Loma Linda, CA, 9/2004

HER2+ Therapy, Evening of Experts, The University of Texas Southwestern Medical School, Dallas, TX, 1/2005

Current Status of Chemotherapy in Breast Cancer, Westmead Hospital, Sydney, Australia, 7/2005

My experience with breast cancer: Neoadjuvant, chemotherapy and, hormone in post-menopausal women, Hopital Charles-Lemoyne, Hopital Maisonneuve-Rosemont, and Hopital Sacre Coeur, Montreal, Canada, 10/2005

The Evolving Role of HER2-Targeted Therapies in Breast Cancer, Johns Hopkins University School of Medicine, Detroit, MI, 10/2005

The Evolving Role of HER2-Targeted Therapies in Breast Cancer, Grand Rounds, Medical College of Wisconsin, Wilwaukee, WI, 11/2005

M.D. Anderson AI Studies, Mayo-NIH Program, Mayo Clinic, Rochester, MN, 8/2006

The Current Status of Endocrine Therapy in Post-Menopausal Patients with ER+ Early Stage Breast Cancer, Moffitt Cancer Center, Orlando, FL, 11/2006

Optimal Endocrine Treatment in Breast Cancer, Vasteras Breast Cancer Center, Vasteras, Sweden, 1/2007

Treating Breast Cancer: The earlier the better?, NI Breast Meeting, Belfast City Hospital, Northern Ireland Cancer Centre, Belfast, Ireland, 3/2007

Putting the Pieces Together: Breast Cancer Management in 2009, University of Miami Sylvester Cancer Center, Miami, FL, 5/20/2009

Northwestern Breast Fellow Program Site Visit, The Society of Surgical Oncology, Inc., Chicago, IL, 7/25/2011

Endocrine Therapy of Breast Cancer: 2011 Update, 17th Annual Puerto Rico Breast Cancer Conference, Puerto Rico, 10/2011

XV Annual Russian Cancer Congress Moscow, The Russisan Academy of Medical Sciences Russian Cancer Research Center, Clinical Pharmacology and Chemotherapy, Moscow, Russian Federation, 11/2011

Lectureships and Visiting Professorships

Biology and Management of Breast Cancer, McGill University Visiting Professor, Royal Victoria Hospital, Montreal, Canada, 11/1998

Recent Advances in Endocrine Therapy of Early and Advanced Breast Cancer, Visiting Professor Program 2002, M.D. Anderson Cancer Center Orlando, Orlando, FL, 10/2002

2005 Management Strategies for Hormone Receptor Positive Breast Cancer in the Adjuvant Setting, Annenberg Center for Health Sciences at Eisenhower, Salt Lake City, UT, 11/2005

Treatment of Early Breast Cancer, Breast Medical Oncology Multidisciplinary Patient Conference, M. D. Anderson Cancer Center Orlando, Orlando, FL, 11/2007

Other Presentations at State and Local Conferences

Effect of timing of adjuvant chemotherapy on disease-free (D-F) interval in operable breast cancer, 4th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 11/1981

Treatment of Early and Late Breast Cancer, Diagnostic Clinic, Houston, TX, 2/1983

Participated in Luncheon Panel Discussion on Treatment of Operable Breast Cancer, 6th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 11/1983

Risk of Early and Late Cardiotoxicity in Doxorubicin-Treated Breast Cancer Patients, 6th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 11/1983

New Perspectives for Hormonal Treatment of Breast Cancer, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 4/1984

Natural History of Stage IV Breast Cancer, International Symposium on Autologous Bone Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 5/1984

Elliptynium Acetate in Advanced Breast Cancer Refractory to Combination Chemotherapy-Results of Phase I-II Studies, 7th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/1984

Tamoxifen in Combination with Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) for Treatment of Advanced Breast Cancer, Panel Discussion, 7th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/1984

Adjuvant Therapy of Operable Breast Cancer, Treatment of Infections in the Cancer Patient, Dallas, TX, 10/1986

Role of Adjuvant Chemotherapy in Male Breast Cancer, 9th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 11/1986

Adjuvant Therapy of Operable Breast Cancer, Cancer Update 1987, New Perspectives in Cancer Biology Controversies in Management Board Review, Houston, TX, 5/1987

Treatment of Early Breast Cancer, 10th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/1987

Ciprofloxacin: A Major Advance in Antimicrobial Therapy, Symposium, San Antonio, TX, 4/1988

Adjuvant Therapy of Breast Cancer, Update on Breast Cancer, Pasadena, TX, 10/1988

Phase I-II Clinical Study of Monoclonal Antibody B72.3 In Imaging in Patients with Breast Cancer, 11th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 11/1988

Medical Oncology: A Comprehensive Review, Adjuvant Therapy and Chemotherapy of Advanced Disease, American College of Physicians, Houston, TX, 10/1989

Hormonal Therapy of Breast and Prostate Cancer, Bone Metastasis: Path Physiology, Diagnosis and Treatment, Houston, TX, 9/1990

Breast Cancer: Adjuvant Therapy, Medical Oncology: A Comprehensive Board Review, Houston, TX, 10/1991

Adjuvant Chemotherapy and Update of Prognostic Factors, Breast and Endocrine Second Annual Cancer Update, Houston, TX, 12/1991

Current Status of Treatment of Early and Advanced Breast Cancer, 13th Annual Medical Congress Southwest Association of Hispanic American Physicians, El Paso, TX, 11/1992

Chemotherapy of Breast Cancer, Imaging Perspectives - Diagnosis and Treatment of Breast Diseases, Houston, TX, 9/1993

Tumor Conference, Bayshore Medical Center, Pasadena, TX, 6/1994

State of the Art Chemotherapy, Seventh International Symposium on Autologous Bone Marrow Transplantation, Arlington, TX, 8/1994

Screening and Treatment of Breast Cancer, 6th Annual Primary Care for the 90's, Texas Academy of Family Physicians, Houston, TX, 10/1994

Breast Cancer: Adjuvant Therapy, Medical Oncology: A Comprehensive Review, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1995

Case Histories and Questions, Medical Oncology: A Comprehensive Review, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1995

Arimidex: Efficacy and Tolerability of 'Arimidex' (anastrozole) in two Randomized Comparative Studies Versus Megestrol Acetate in Postmenopausal Women in Advanced Breast Cancer, 18th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/1995

Aromatase Inhibitors in the Treatment of Advanced Breast Cancer, 18th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/1995

Issues in Clinical Research, Human Protection Workshop, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 11/1996

Update on Aromatase Inhibitors, Progestins, Antiprogestins, and Antiandrogens, San Antonio Satellite Symposium, San Antonio, TX, 12/1996

Current Management of Cancer: Chemo/Hormonal Options, Spohn Health System Fifth Annual Oncology Conference, Corpus Christi, TX, 4/1997

Clinical Faculty Development, Minority Faculty and Administrators Workshop, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 7/1997

Hormonal Therapy of Breast Cancer, Medical Oncology of Breast Cancer Fellows Program, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 7/1997

Early Stage Breast Cancer, Adjuvant Therapy, and Hormonal Therapy, Medical Oncology: A Comprehensive Review, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1997

Prognostic Factors for Relapse-Free Survival in Breast Cancer, Institutional Grand Rounds, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1997

Nolvadex and Secondary Effects and Arimidex: Update of Survival Benefits, Breast Cancer Speakers Forum, Dallas, TX, 10/1997

Adjuvant Therapy of Breast Cancer and Endocrine Therapy, Medical Oncology: A Comprehensive Review, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 10/1998

Hormonal Therapies, Institutional Grand Rounds, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 10/1998

Locally Advanced and Inflammatory and Metastatic Breast Cancer, Medical Oncology: A Comprehensive Review, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 10/1998

Risks and Benefits, Investigator's Responsibilities, Institutional Grand Rounds, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 3/1999

Hormonal Therapy, UT M.D. Anderson Cancer Center Conference Update in Breast Cancer, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1999

Systemic Therapy Approaches in Breast Cancer, UT M.D. Anderson Associates' Conference Cancer Care - UT M.D. Anderson Approach, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1999

Recent Advances in Endocrine Therapy, Breast Cancer: Perspectives on Data and Development, San Antonio, TX, 12/1999

Update on the Treatment of Breast Cancer with Aromatase Inhibitors, US Oncology Audioconference, Houston, TX, 12/1999

Adjuvant Therapy - M.D. Anderson Trials Contributions, 4th Foundation of Clinical Cancer Research Symposium: Triumphs and Challenges in Oncology, Houston, TX, 3/2000

Adjuvant Therapy, Medical Oncology Board Review Course, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 10/2000

Issues Regarding Use of Residual Tissues for Future Research, Institutional Grand Rounds, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 10/2000

New Generation of Aromatase Inhibitors - From the Advanced to the Adjuvant Setting, 24th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2001

The ATAC Trial in Postmenopausal Women with Early Breast Cancer - Updated Efficacy Results Based on a Median Follow-Up of 47 Months, 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2001

Trials with Aromatase Inhibitors for First-Line Use in the Treatment of Breast Cancer (Results Focusing on ER-positive Patients), 24th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2001

Integrating Recent Data on Hormonal Therapy into Clinical Practice, 27th Annual Symposium of the American Society of Breast Disease, Dallas, TX, 4/2003

Hormonal Therapy of Breast Cancer, Post ASCO Update 2003, Dallas, TX, 8/2003

Pathological Complete Response (PCR) to Chemotherapy is Related to Hormone Receptor Status, 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2003

Endocrine Therapy of Breast Cancer: Recent Advances, Baptist Health System, 15th Annual Cancer Update 2004, San Antonio, TX, 2/2004

Hormonal Treatments in Breast Cancer, First National CURE Patients and Survivor Forum, Dallas, TX, 5/2004

The Evolving Role of Trastuzumab-Based Therapy, Current Trends in Breast Cancer, Houston, TX, 1/2005

Future Trials of Endocrine Agents at M.D. Anderson and Imperial College, M.D. Anderson / Imperial College London Meeting, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 3/2005

Systemic Chemotherapy in Breast Cancer, Oncology Best Practices 2005, Houston, TX, 3/2005

Breast Center Overview, Houston Breast Cancer Consensus Conference, M.D. Anderson Cancer Center, Houston, TX, 12/2005

Current Controversies in Systemic Therapy in Early Breast Cancer: The Great Adjuvant Debate, Breast Cancer Update, San Antonio, TX, 12/2005

Advances in Biologic Therapies and Novel Agents for Breast Cancer, Emerging Trends in Oncology, Physicians Education Resource Conference, Dallas, TX, 6/2006

Adjuvant Therapies for HER2-overexpressing Breast Cancer, Traditional Therapies in Breast Cancer, Dallas, TX, 12/2006

Controversies in Adjuvant Hormonal Therapy and Novel Preoperative Therapy, Current Trends in Breast Cancer, Houston, TX, 1/2007

Update on Adjuvant Therapies for Early Stage Breast Cancer, Oncology Best Practices 2006, Physicians Education Resource, Austin, TX, 6/2007

Adjuvant Endocrine Therapies: A 2006 Perspective, Oncology Best Practices 2006, Physicians Education Resource, Houston, TX, 7/2007

Novel Preoperative Therapy Strategies, Current Trends in Breast Cancer, Physicians Education Resource, Dallas, TX, 2/16/2008

Expanded Access Programs, Ethics and Compliance in Oncology Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, 4/5/2008

Optimal Treatments for Adjuvant Breast Cancer: Who Benefits?, Practical Updates in Oncology, Physicians Education Resource, Dallas, TX, 4/5/2008

Buzdar AU. Treating Breast Cancer, 11th Biennial National Convention, Philippine Association of Medical Technologists-USA, Houston, TX, 8/28/2008

Buzdar AU. Arimidex: An Evidence-Based Choice in Adjuvant Treatment, Latin America Symposium on Breast Cancer, Astrazeneca, San Antonio, TX, 12/13/2008

Buzdar AU. New Developments in Adjuvant and Neoadjuvant Chemotherapy, Current Trends in Breast Cancer, Physicians' Education Resource, Dallas, TX, 1/17/2009

Buzdar AU. Biologic Therapies in Adjuvant and Metastatic Breast Cancer, Institute for Medical Education and Research, San Antonio, TX, 4/29/2009

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held National and International

Oncologic Drugs Advisory Committee (ODAC)
Member, 12/2012–present

American Association for Cancer Research

American College of Physicians

American Federation of Clinical Research

American Medical Association

American Radium Society

American Society of Breast Disease

American Society of Breast Disease

American Society of Clinical Oncology

Harris County Medical Association

New York Academy of Science

Pakistan Medical Association

Senologic International Society

Texas Medical Association

Vice President North America, Senologic International Society

Local/State

N/A

UNIQUE ACTIVITIES

N/A

DATE OF LAST CV UPDATE

9/14/2012